<SEC-DOCUMENT>0001104659-25-100488.txt : 20251020
<SEC-HEADER>0001104659-25-100488.hdr.sgml : 20251020
<ACCEPTANCE-DATETIME>20251017181042
ACCESSION NUMBER:		0001104659-25-100488
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20251016
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251020
DATE AS OF CHANGE:		20251017

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Praxis Precision Medicines, Inc.
		CENTRAL INDEX KEY:			0001689548
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39620
		FILM NUMBER:		251401812

	BUSINESS ADDRESS:	
		STREET 1:		99 HIGH STREET, 30TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		617-300-8460

	MAIL ADDRESS:	
		STREET 1:		99 HIGH STREET, 30TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2528989d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:PRAX="http://praxismedicines.com/20251016">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_PRAX_praxismedicines.com_20251016 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20251016_20251016 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001689548 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000004" name="dei:EntityCentralIndexKey">0001689548</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="prax-20251016.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-10-16">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001689548</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-10-16</xbrli:startDate>
        <xbrli:endDate>2025-10-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_904_edei--DocumentType_c20251016__20251016_z8avGBdlfhzj"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_901_edei--DocumentPeriodEndDate_c20251016__20251016_zaBlKildq891"><ix:nonNumeric contextRef="AsOf2025-10-16" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">October 16, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityRegistrantName_c20251016__20251016_zNkWo7iiS0N"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000011" name="dei:EntityRegistrantName">PRAXIS PRECISION MEDICINES, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding: 1.75pt 1.25pt; font-size: 10pt; text-align: center; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20251016__20251016_zzOReDit8zqe"><ix:nonNumeric contextRef="AsOf2025-10-16" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding: 1.75pt 1.25pt; font-size: 10pt; text-align: center; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityFileNumber_c20251016__20251016_zzXsO242G2Bd"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000013" name="dei:EntityFileNumber">001-39620</ix:nonNumeric></span></b></span></td>
    <td style="padding: 1.75pt 1.25pt; font-size: 10pt; text-align: center; width: 34%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20251016__20251016_zNL9CNDrekWa"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000014" name="dei:EntityTaxIdentificationNumber">47-5195942</ix:nonNumeric></span></b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 1.75pt 1.25pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of incorporation)</b></p></td>
    <td style="padding: 1.75pt 1.25pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>File Number)</b></p></td>
    <td style="padding: 1.75pt 1.25pt">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Praxis Precision Medicines, Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_903_edei--EntityAddressAddressLine1_c20251016__20251016_z60DydymR93l"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000015" name="dei:EntityAddressAddressLine1">99 High Street</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine2_c20251016__20251016_zovf4aZy4293"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000016" name="dei:EntityAddressAddressLine2">30th Floor</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20251016__20251016_zJDp3C991WT4"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000017" name="dei:EntityAddressCityOrTown">Boston</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20251016__20251016_zkAP3ro1pqB5"><ix:nonNumeric contextRef="AsOf2025-10-16" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">Massachusetts</ix:nonNumeric></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20251016__20251016_zTEZv508atee"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000019" name="dei:EntityAddressPostalZipCode">02110</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Address of principal executive offices, including
zip code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_90A_edei--CityAreaCode_c20251016__20251016_zB6HJUWi5b97"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000020" name="dei:CityAreaCode">617</ix:nonNumeric></span>) <span id="xdx_909_edei--LocalPhoneNumber_c20251016__20251016_zJOIuSuqsLyg"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000021" name="dei:LocalPhoneNumber">300-8460</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Registrant&#8217;s telephone number, including
area code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed Since
Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 0 auto; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Check the appropriate box below if the Form&#160;8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 16.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_90A_edei--WrittenCommunications_c20251016__20251016_zuNy6gTATPr1"><ix:nonNumeric contextRef="AsOf2025-10-16" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 16.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_900_edei--SolicitingMaterial_c20251016__20251016_zylNlRvs3pZj"><ix:nonNumeric contextRef="AsOf2025-10-16" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 16.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_902_edei--PreCommencementTenderOffer_c20251016__20251016_zFz1ZtcYtbXc"><ix:nonNumeric contextRef="AsOf2025-10-16" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 16.8pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementIssuerTenderOffer_c20251016__20251016_z1q9jLgLVfa9"><ix:nonNumeric contextRef="AsOf2025-10-16" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="padding: 1.75pt 1.25pt; font-size: 10pt; text-align: center; width: 33%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Title of each class</span></b></span></td>
    <td style="padding: 1.75pt 1.25pt; width: 2%">&#160;</td>
    <td style="padding: 1.75pt 1.25pt; width: 30%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Trade</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">Symbol(s)</span></b></p></td>
    <td style="padding: 1.75pt 1.25pt; width: 2%">&#160;</td>
    <td style="padding: 1.75pt 1.25pt; width: 33%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Name of each exchange</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">on which registered</span></b></p></td></tr>
  <tr>
    <td style="padding: 1.75pt 1.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--Security12bTitle_c20251016__20251016_zOb4wknw6Nt8"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000026" name="dei:Security12bTitle">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></b></span></td>
    <td style="padding: 1.75pt 1.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 1.75pt 1.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--TradingSymbol_c20251016__20251016_zZT3qmD3gLJk"><ix:nonNumeric contextRef="AsOf2025-10-16" id="Fact000027" name="dei:TradingSymbol">PRAX</ix:nonNumeric></span></b></span></td>
    <td style="padding: 1.75pt 1.25pt; vertical-align: bottom">&#160;</td>
    <td style="padding: 1.75pt 1.25pt; vertical-align: top; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--SecurityExchangeName_c20251016__20251016_z4XkbDQlgS45"><ix:nonNumeric contextRef="AsOf2025-10-16" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">The Nasdaq Global Select Market</ix:nonNumeric></span></b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule&#160;12b-2 of the Securities
Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 10pt">Emerging growth company </span><span style="font-family: Wingdings"><span id="xdx_900_edei--EntityEmergingGrowthCompany_c20251016__20251016_zrUoF1Bmhjv5"><ix:nonNumeric contextRef="AsOf2025-10-16" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On October&#160;16, 2025, Praxis Precision Medicines,&#160;Inc.
(the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with TD Securities
(USA) LLC, Piper Sandler&#160;&amp; Co. and Guggenheim Securities, LLC, as representatives of the several underwriters named in
Schedule A thereto (collectively, the &#8220;Underwriters&#8221;), relating to an underwritten offering of 3,025,480 shares (the
&#8220;Shares&#8221;) of the Company&#8217;s common stock, $0.0001 par value per share (the &#8220;Common Stock&#8221;), and, in
lieu of Common Stock to certain investors, pre-funded warrants (the &#8220;Pre-funded Warrants&#8221;) to purchase up to 318,470
shares of Common Stock (the &#8220;Offering&#8221;). The closing of the Offering is expected to take place on October&#160;20, 2025,
subject to the satisfaction of customary closing conditions. All of the Shares and the Pre-funded Warrants are being sold by the
Company. The offering price of the Shares to the public is $157.00 per share, and the offering price of the Pre-funded Warrants to
the public is $156.9999 per underlying share, which equals the price per share of Common Stock being sold in this Offering, minus
$0.0001, the Pre-funded Warrants&#8217; exercise price per share. The Company also granted the Underwriters an option to purchase up
to 501,592 additional shares of Common Stock within 30 days from the date of the Underwriting Agreement. On October&#160;17, 2025,
the Underwriters exercised the option to purchase such additional shares in full. The net proceeds from the Offering are expected
to be approximately $567.0 million, after deducting underwriting discounts and
commissions and estimated offering expenses payable by the Company, and giving effect to the exercise of the Underwriters' option
to purchase additional shares. The Company does not intend to list the Pre-funded Warrants on The Nasdaq Global Select Market
(&#8220;Nasdaq&#8221;) or any other nationally recognized securities exchange or trading system.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The exercise price and the number of shares of Common Stock issuable
upon exercise of the Pre-funded Warrants are subject to appropriate adjustments in the event of certain stock dividends and distributions,
stock splits, stock combinations, reclassifications or similar events affecting the Common Stock. The Pre-funded Warrants are exercisable
from the date of issuance and may be exercised by means of a cashless exercise. Under the Pre-funded Warrants, the Company may not effect
the exercise of the Pre-funded Warrants, and a holder will not be entitled to exercise any portion of the Pre-funded Warrants that, upon
giving effect to such exercise, would result in: (i)&#160;the aggregate number of shares of Common Stock beneficially owned by such holder
(together with its affiliates) exceeding 4.99% (or 9.99%) of the number of shares of Common Stock outstanding immediately after giving
effect to the exercise; or (ii)&#160;the combined voting power of the Company&#8217;s securities beneficially owned by such holder (together
with its affiliates) exceeding 4.99% (or 9.99%) of the combined voting power of all of the Company&#8217;s securities outstanding immediately
after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-funded Warrants,
which percentage may be changed at the holder&#8217;s election to a higher or lower percentage not in excess of 19.99% upon 61 days&#8217;
notice to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, in certain circumstances, upon a Fundamental Transaction
(as defined in the Pre-funded Warrants), a holder of the Pre-funded Warrants will be entitled to receive, upon exercise of the Pre-funded
Warrants, the kind and amount of securities, cash or other property that such holder would have received had it exercised the Pre-funded
Warrants immediately prior to the Fundamental Transaction without regard to any limitations on exercise contained in the Pre-funded Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company intends to use the net proceeds of the Offering, together
with the Company&#8217;s existing cash, cash equivalents and marketable securities, to continue the research and development activities
of its clinical-stage product candidates, and preparation activities for potential commercialization of its late-stage assets as well
as advancement of its earlier stage assets and for working capital and other general corporate purposes. Based on the planned use of proceeds
described above, the Company believes that the net proceeds from this Offering, together with its existing cash, cash equivalents and
marketable securities, will be sufficient to enable the Company to fund its operating expenses and capital expenditure requirements into
2028. This estimate is based on assumptions that may prove to be incorrect, and the Company could utilize available capital resources
sooner than expected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Offering was made pursuant to a shelf registration statement on
Form&#160;S-3&#8239;ASR that was filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on December&#160;23, 2024&#8239;and was immediately
effective upon filing (File No.&#160;333-284016). A prospectus supplement relating to the Offering has been filed with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The representations, warranties and covenants contained in the Underwriting
Agreement and the Pre-funded Warrants were made solely for the benefit of the parties thereto and may be subject to limitations agreed
upon by the contracting parties. Accordingly, the Underwriting Agreement and the Pre-funded Warrants are incorporated herein by reference
only to provide investors with information regarding the terms of the Underwriting Agreement and not to provide investors with any other
factual information regarding the Company or its business, and should be read in conjunction with the disclosures in the Company&#8217;s
periodic reports and other filings with the SEC.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing descriptions of the Underwriting Agreement and the Pre-funded
Warrants are not complete and are qualified in their entireties by reference to the full text of the Underwriting Agreement and the Form&#160;of
Pre-funded Warrant, copies of which are filed as Exhibits 1.1 and 4.1, respectively, to this report and are incorporated by reference
herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the opinion of Latham&#160;&amp; Watkins LLP relating to
the legality of the issuance and sale of the Shares, the Pre-funded Warrants and the shares of common stock issuable upon exercise of
the Pre-funded Warrants is attached as Exhibit&#160;5.1 to this report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Forward-Looking Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Current Report on Form&#160;8-K contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding
the closing of the Offering, the Company&#8217;s intent not to list the Pre-funded Warrants on Nasdaq or any other nationally recognized
securities exchange or trading system, anticipated amount of net proceeds from the Offering, the intended use of such proceeds, and the
sufficiency of the net proceeds from the Offering and existing cash and cash equivalents to fund operating expenses and capital expenditure
requirements. The forward-looking statements included in this Current Report on Form&#160;8-K are subject to a number of risks, uncertainties
and assumptions, including, without limitation, risks and uncertainties associated with market conditions, the satisfaction of customary
closing conditions related to the offering and other risks as described in the Company&#8217;s Annual Report on Form&#160;10-K for the
year ended December&#160;31, 2024, its Quarterly Report on Form&#160;10-Q for the quarter ended June&#160;30, 2025 and other filings with
the SEC. These statements are based only on facts currently known by the Company and speak only as of the
date of this Current Report on Form&#160;8-K. As a result, you are cautioned not to rely on these forward-looking statements and the Company
undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments
or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits. </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(d)&#160;Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><a href="tm2528989d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="tm2528989d1_ex1-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    Agreement, dated October&#160;16, 2025, by and between Praxis Precision Medicines,&#160;Inc. and TD Securities (USA) LLC, Piper Sandler&#160;&amp;
    Co. and Guggenheim Securities, LLC, as representatives of the several underwriters named therein.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><a href="tm2528989d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="tm2528989d1_ex4-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&#160;of
    Pre-funded Warrant. </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><a href="tm2528989d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="tm2528989d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
    of Latham&#160;&amp; Watkins LLP. </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><a href="tm2528989d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="tm2528989d1_ex5-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent
    of Latham&#160;&amp; Watkins LLP (included in Exhibit&#160;5.1). </span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page&#160;Interactive Data File (embedded within the inline XBRL document).</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRAXIS PRECISION
    MEDICINES,&#160;INC.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 51%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 46%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: October 17, 2025</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Marcio Souza</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcio Souza</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2WUy3esjHxCKyCInodckxlnRHZreyT+ov25RoGBiGe8+9QoRiTSvdIMN5WRZwxLZrlEMosUZGc0HvyDbbFPwt8aqtY2Xc8P7AjDyDnplHcqq8MFgf2mKVQryYxHIiZ5DIdDqDw04EXz0jU+sKjdOqAWUqODB1rNEpfo0JR9WTofY1VJ2QrSaTQhLFo/wGGScS9vRQT+KbhaLIRBAOE4g1073zrrx3aL4k5A22vs6O9H+DDweTSo4= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm2528989d1_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 1.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>3,025,480 Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pre-Funded Warrants to Purchase up to 318,470
Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Praxis Precision Medicines,&nbsp;Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>UNDERWRITING AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">October&nbsp;16, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase">TD Securities (USA) LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PIPER SANDLER&nbsp;&amp; CO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">GUGGENHEIM SECURITIES, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Representatives of the several Underwriters</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o <FONT STYLE="text-transform: uppercase">TD Securities (USA) LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1 Vanderbilt Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o PIPER SANDLER&nbsp;&amp; CO.<BR>
350 North 5th Street, Suite&nbsp;1000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Minneapolis, MN 55401</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">c/o GUGGENHEIM SECURITIES, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">330 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>Introductory.</B></FONT>
Praxis Precision Medicines,&nbsp;Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), proposes to issue and sell to the several
underwriters named in <U>Schedule A</U> (the &ldquo;<B>Underwriters</B>&rdquo;) (i)&nbsp;an aggregate of 3,025,480 shares (the &ldquo;<B>Firm
Shares</B>&rdquo;) of its common stock, par value $0.0001 per share (the &ldquo;<B>Common Stock</B>&rdquo;) and (ii)&nbsp;pre-funded warrants
(the &ldquo;<B>Pre-Funded Warrants</B>&rdquo;) to purchase up to 318,470 shares of Common Stock (the &ldquo;<B>Warrant Shares</B>&rdquo;)
at an exercise price of $0.0001 per share in the form attached hereto as <U>Exhibit&nbsp;A</U>. The 3,025,480 Firm Shares and Pre-Funded
Warrants to purchase up to 318,470 shares of Common Stock to be sold by the Company are called the &ldquo;<B>Firm Securities</B>.&rdquo;
In addition, the Company has granted to the Underwriters an option to purchase up to an additional 501,592 shares of Common Stock as provided
in &lrm;Section&nbsp;2 of this Agreement. The additional 501,592 shares of Common Stock to be sold by the Company pursuant to such option
are collectively called the &ldquo;<B>Optional Shares</B>,&rdquo; and together with the Firm Shares, the &ldquo;<B>Shares</B>.&rdquo;
The Firm Securities and, if and to the extent such option is exercised, the Optional Shares are collectively called the &ldquo;<B>Offered
Securities</B>.&rdquo; TD Securities (USA) LLC (&ldquo;<B>TD Cowen</B>&rdquo;), Piper Sandler&nbsp;&amp; Co. (&ldquo;<B>Piper</B>&rdquo;),
and Guggenheim Securities, LLC (&ldquo;<B>Guggenheim</B>&rdquo;) have agreed to act as representatives of the several Underwriters (in
such capacity, the &ldquo;<B>Representatives</B>&rdquo;) in connection with the offering and sale of the Offered Securities. To the extent
there are no additional underwriters listed on <U>Schedule A</U>, the term &ldquo;Representatives&rdquo; as used herein shall mean you,
as Underwriters, and the term &ldquo;Underwriters&rdquo; shall mean either the singular or the plural, as the context requires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has prepared and filed with the U.S.
Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) a shelf registration statement on Form&nbsp;S-3ASR, File No.&nbsp;333-284016,
including a base prospectus (the &ldquo;<B>Base Prospectus</B>&rdquo;) to be used in connection with the public offering and sale of the
Offered Securities. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the
form in which it became effective under the Securities Act of 1933, as amended, and the rules&nbsp;and regulations promulgated thereunder
(collectively, the &ldquo;<B>Securities Act</B>&rdquo;), including all documents incorporated or deemed to be incorporated by reference
therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule&nbsp;430A or Rule&nbsp;430B under
the Securities Act, is called the &ldquo;<B>Registration Statement</B>.&rdquo; The preliminary prospectus supplement dated October&nbsp;16,
2025 describing the Offered Securities and the offering thereof (the &ldquo;<B>Preliminary Prospectus Supplement</B>&rdquo;), together
with the Base Prospectus, is called the &ldquo;<B>Preliminary Prospectus</B>,&rdquo; and the Preliminary Prospectus and any other prospectus
supplement to the Base Prospectus in preliminary form that describes the Offered Securities and the offering thereof and is used prior
to the filing of the Prospectus (as defined below), together with the Base Prospectus, is called a &ldquo;<B>preliminary prospectus</B>.&rdquo;
As used herein, the term &ldquo;<B>Prospectus</B>&rdquo; shall mean the final prospectus supplement to the Base Prospectus that describes
the Offered Securities and the offering thereof (the &ldquo;<B>Final Prospectus Supplement</B>&rdquo;), together with the Base Prospectus,
in the form first used by the Underwriters to confirm sales of the Offered Securities or in the form first made available to the Underwriters
by the Company to meet requests of purchasers pursuant to Rule&nbsp;173 under the Securities Act. References herein to the Preliminary
Prospectus, any preliminary prospectus and the Prospectus shall refer to both the prospectus supplement and the Base Prospectus components
of such prospectus. As used herein, the &ldquo;<B>Applicable Time</B>&rdquo; is 9:30 PM (New York City time) on October&nbsp;16, 2025.
As used herein, &ldquo;<B>free writing prospectus</B>&rdquo; has the meaning set forth in Rule&nbsp;405 under the Securities Act, and
 &ldquo;<B>Time of Sale Prospectus</B>&rdquo; means the Preliminary Prospectus, as amended or supplemented immediately prior to the Applicable
Time, together with the information included on <U>Schedule B-1</U> hereto and the free writing prospectuses, if any, identified in <U>Schedule
B-2</U> hereto. As used herein, <B>&ldquo;Road Show&rdquo;</B> means a &ldquo;road show&rdquo; (as defined in Rule&nbsp;433 under the
Securities Act) relating to the offering of the Offered Securities contemplated hereby that is a &ldquo;written communication&rdquo; (as
defined in Rule&nbsp;405 under the Securities Act).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All references in this Agreement to the Registration
Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus and the Prospectus shall include the documents
incorporated or deemed to be incorporated by reference therein. All references in this Agreement to financial statements and schedules
and other information which are &ldquo;contained,&rdquo; &ldquo;included&rdquo; or &ldquo;stated&rdquo; in, or &ldquo;part of&rdquo; the
Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the
Prospectus, and all other references of like import, shall be deemed to mean and include all such financial statements and schedules and
other information which is or is deemed to be incorporated by reference in the Registration Statement, the Preliminary Prospectus, any
preliminary prospectus, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. All references in this
Agreement to amendments or supplements to the Registration Statement, the Preliminary Prospectus, any preliminary prospectus, the Base
Prospectus, the Time of Sale Prospectus or the Prospectus shall be deemed to mean and include the filing of any document under the Securities
Exchange Act of 1934, as amended, and the rules&nbsp;and regulations promulgated thereunder (collectively, the &ldquo;<B>Exchange Act</B>&rdquo;)
that is or is deemed to be incorporated by reference in the Registration Statement, the Preliminary Prospectus, any preliminary prospectus,
the Base Prospectus, or the Prospectus, as the case may be. All references in this Agreement to the Registration Statement, the Preliminary
Prospectus, any preliminary prospectus, the Base Prospectus or the Prospectus, any amendments or supplements to any of the foregoing,
or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic Data Gathering, Analysis
and Retrieval System (&ldquo;<B>EDGAR</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In the event that the Company has only one subsidiary,
then all references herein to &ldquo;subsidiaries&rdquo; of the Company shall be deemed to refer to such single subsidiary, <U>mutatis
mutandis</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>Section&nbsp;1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Representations
and Warranties.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company hereby represents, warrants and covenants
to each Underwriter, as of the date of this Agreement, as of the First Closing Date (as hereinafter defined) and as of each Option Closing
Date (as hereinafter defined), if any, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Compliance
with Registration Requirements</I>.</B></FONT> The Registration Statement has become effective under the Securities Act. The Company has
complied, to the Commission&rsquo;s satisfaction, with all requests of the Commission for additional or supplemental information, if any.
No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been instituted
or are pending or, to the best knowledge of the Company, are contemplated or threatened by the Commission. At the time the Company&rsquo;s
Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2024 (the &ldquo;<B>Annual Report</B>&rdquo;) was filed with the
Commission, or, if later, at the time the Registration Statement was originally filed with the Commission, the Company met the then-applicable
requirements for use of Form&nbsp;S-3 under the Securities Act. The Company meets the requirements for use of Form&nbsp;S-3 under the
Securities Act specified in FINRA Conduct Rule&nbsp;5110(B)(7)(C)(i). The documents incorporated or deemed to be incorporated by reference
in the Registration Statement, the Time of Sale Prospectus and the Prospectus, at the time they were or hereafter are filed with the Commission,
or became effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements
of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Disclosure</I>.</B></FONT>
Each preliminary prospectus and the Prospectus when filed complied in all material respects with the Securities Act and, if filed by electronic
transmission pursuant to EDGAR, was identical (except as may be permitted by Regulation S-T under the Securities Act) to the copy thereof
delivered to the Underwriters for use in connection with the offer and sale of the Offered Securities. Each of the Registration Statement
and any post-effective amendment thereto, at the time it became or becomes effective, complied and will comply in all material respects
with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time, the Time of Sale Prospectus
did not, and at the First Closing Date (as defined in &lrm;Section&nbsp;2 of this Agreement) and at each applicable Option Closing Date
(as defined in Section&nbsp;2 of this Agreement), will not, contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus,
as of its date, did not, and at the First Closing Date and at each applicable Option Closing Date, will not, contain any untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences
do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto, or the Prospectus
or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information
relating to any Underwriter furnished to the Company in writing by the Representatives expressly for use therein, it being understood
and agreed that the only such information consists of the information described in &lrm;Section&nbsp;9(b)&nbsp;below. There are no contracts
or other documents required to be described in the Time of Sale Prospectus or the Prospectus or to be filed as an exhibit to the Registration
Statement which have not been described or filed as required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Free
Writing Prospectuses; Road Show</I>.</B></FONT> As of the determination date referenced in Rule&nbsp;164(h)&nbsp;under the Securities
Act, the Company was not, is not or will not be (as applicable) an &ldquo;ineligible issuer&rdquo; in connection with the offering of
the Offered Securities pursuant to Rules&nbsp;164, 405 and 433 under the Securities Act. Each free writing prospectus that the Company
is required to file pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act has been, or will be, filed with the Commission in accordance
with the requirements of the Securities Act. Each free writing prospectus that the Company has filed, or is required to file, pursuant
to Rule&nbsp;433(d)&nbsp;under the Securities Act or that was prepared by or on behalf of or used or referred to by the Company complies
or will comply in all material respects with the requirements of Rule&nbsp;433 under the Securities Act, including timely filing with
the Commission, retention and legending, as applicable, and each such free writing prospectus, as of its issue date and at all subsequent
times through the completion of the public offer and sale of the Offered Securities did not, does not and will not include any information
that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Prospectus or any preliminary
prospectus unless such information has been superseded or modified as of such time. Except for the free writing prospectuses, if any,
identified in <U>Schedule B-2</U>, and electronic road shows, if any, furnished to the Representatives before first use, the Company has
not prepared, used or referred to, and will not, without the Representatives&rsquo; prior written consent, prepare, use or refer to, any
free writing prospectus. Each Road Show, when considered together with the Time of Sale Prospectus, did not, as of the Applicable Time,
contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Distribution
of Offering Material By the Company</I>.</B></FONT> Prior to the later of (i)&nbsp;the expiration or termination of the option granted
to the several Underwriters in &lrm;Section&nbsp;2 of this Agreement, and (ii)&nbsp;the completion of the Underwriters&rsquo; distribution
of the Offered Securities<B>,</B> the Company has not distributed and will not distribute any offering material in connection with the
offering and sale of the Offered Securities other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any
free writing prospectus reviewed and consented to by the Representatives, the free writing prospectuses, if any, identified on <U>Schedule
B-2</U> hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>The
Underwriting Agreement</I>.</B></FONT> This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Authorization
of the Offered Securities</I>.</B></FONT> The Shares to be issued and sold by the Company to the Underwriters hereunder have been duly
and validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued, fully
paid and non-assessable and will conform to the descriptions thereof in the Registration Statement, the Time of Sale Prospectus and the
Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights. The Pre-Funded Warrants have been duly
authorized for issuance by the Company and when executed and delivered by the Company pursuant to this Agreement, will be valid and binding
agreements of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited
by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors
or by general equitable principles. The Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the
Pre-Funded Warrants in a number sufficient to meet the current exercise requirements and, when issued and delivered upon exercise of the
Pre-Funded Warrants in accordance therewith, will be duly and validly issued, fully paid and non-assessable and will conform to the descriptions
thereof in the Registration Statement, the Time of Sale Prospectus and the Prospectus. The issuance of Warrant Shares is not subject to
any preemptive or similar rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Applicable Registration or Other Similar Rights</I>.</B></FONT> No person or entity has the right to require registration of shares of
common stock or other securities of the Company or any of its subsidiaries because of the filing or effectiveness of the Registration
Statement or otherwise, except for persons and entities who have expressly waived such right in writing or who have been given timely
and proper written notice and have failed to exercise such right within the time or times required under the terms and conditions of such
right. Except as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, there are no persons with registration
rights or similar rights to have any securities registered by the Company or any of its subsidiaries under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Material Adverse Change</I>.</B></FONT> Neither the Company nor any of its subsidiaries has sustained, since the date of the latest audited
financial statements included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus,
(i)&nbsp;any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by
insurance, or from any labor dispute or action, order or decree of any court or governmental or regulatory authority, otherwise than as
set forth or contemplated in the Registration Statement, the Time of Sale Prospectus and the Prospectus; (ii)&nbsp;any change in the capital
stock (other than the issuance of shares of common stock upon exercise of stock options and warrants described as outstanding in, and
the grant of options and awards under existing equity incentive plans described in, the Registration statement, the Time of Sale Prospectus
and the Prospectus) or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared,
set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse changes, or any development
involving a prospective material adverse change, in or affecting the business, properties, assets, general affairs, management, financial
position, prospects, stockholders&rsquo; equity or results of operations of the Company and its subsidiaries taken as a whole, otherwise
than as set forth or contemplated in the Registration Statement, the Time of Sale Prospectus and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Independent
Accountants</I>.</B></FONT> Ernst&nbsp;&amp; Young LLP, who has certified certain financial statements and related schedules of the Company
and its subsidiaries included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus
is an independent registered public accounting firm with respect to the Company and its subsidiaries within the meaning of Article&nbsp;2-01
of Regulation S-X and the Public Company Accounting Oversight Board (United States).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Financial
Statements</I>.</B></FONT> The financial statements, together with the related notes, included or incorporated by reference in the Time
of Sale Prospectus, the Prospectus and in the Registration Statement fairly present, in all material respects, the financial position
and the results of operations and changes in financial position of the Company and its consolidated subsidiaries at the respective dates
or for the respective periods therein specified. Such statements and related notes have been prepared in accordance with the generally
accepted accounting principles in the United States (&ldquo;<B>GAAP</B>&rdquo;) applied on a consistent basis throughout the periods involved
except as may be set forth in the related notes included in the Registration Statement, the Time of Sale Prospectus and the Prospectus.
The financial statements, together with the related notes, included or incorporated by reference in the Time of Sale Prospectus and the
Prospectus comply in all material respects with Regulation S-X. No other financial statements or supporting schedules or exhibits are
required by Regulation S-X to be described, included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus
or the Prospectus. The summary and selected financial data included or incorporated by reference in the Time of Sale Prospectus, the Prospectus
and the Registration Statement fairly present, in all material respects, the information shown therein as at the respective dates and
for the respective periods specified and are derived from the consolidated financial statements set forth or incorporated by reference
in the Registration Statement, the Time of Sale Prospectus and the Prospectus and other financial information. The interactive data in
eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus
and the Prospectus fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s
rules&nbsp;and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Company&rsquo;s
Accounting System</I>.</B></FONT> The Company and each of its subsidiaries maintains a system of &ldquo;internal control over financial
reporting&rdquo; (as such term is defined in Rule&nbsp;13a-15(f)&nbsp;of the General Rules&nbsp;and Regulations under the Exchange Act
(the &ldquo;<B>Exchange Act Rules</B>&rdquo;)) that complies with the requirements of the Exchange Act and has been designed by their
respective principal executive and principal financial officers, or under their supervision, to provide reasonable assurances that (i)&nbsp;transactions
are executed in accordance with management&rsquo;s general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary
to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (iii)&nbsp;access to
assets is permitted only in accordance with management&rsquo;s general or specific authorization; (iv)&nbsp;the recorded accountability
for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences and
(v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement
fairly presents the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto. The Company&rsquo;s internal control over financial
reporting is effective. Except as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus, since the end
of the Company&rsquo;s most recent audited fiscal year, there has been (A)&nbsp;no material weakness in the Company&rsquo;s internal control
over financial reporting (whether or not remediated) and (B)&nbsp;no change in the Company&rsquo;s internal control over financial reporting
that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Disclosure
Controls and Procedures</I>.</B></FONT> The Company and its subsidiaries maintain disclosure controls and procedures (as such is defined
in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act Rules) that comply with the requirements of the Exchange Act; such disclosure controls
and procedures have been designed to ensure that information required to be disclosed by the Company and its subsidiaries in reports that
they file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s
rules&nbsp;and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the
Company&rsquo;s management to allow timely decisions regarding disclosures. The Company and its subsidiaries have conducted evaluations
of the effectiveness of their disclosure controls as required by Rule&nbsp;13a-15 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Incorporation
and Good Standing of the Company and Its Subsidiaries</I>.</B></FONT> The Company and each of its subsidiaries have been duly organized
and are validly existing as corporations or other legal entities in good standing (or the foreign equivalent thereof) under the laws of
their respective jurisdictions of organization. The Company and each of its subsidiaries are duly qualified to do business and are in
good standing as foreign corporations or other legal entities in each jurisdiction in which their respective ownership or lease of property
or the conduct of their respective businesses requires such qualification and have all power and authority (corporate or other) necessary
to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to so qualify
or have such power or authority would not (i)&nbsp;have, singularly or in the aggregate, a material adverse effect on the business, properties,
management, financial position, stockholders&rsquo; equity, results of operations or prospects of the Company and its subsidiaries taken
as a whole, or (ii)&nbsp;impair in any material respect the ability of the Company to perform its obligations under this Agreement or
to consummate any transactions contemplated by this Agreement, the Time of Sale Prospectus or the Prospectus (any such effect as described
in clauses (i)&nbsp;or (ii), a &ldquo;<B>Material Adverse Change</B>&rdquo;). The Company does not own or control, directly or indirectly,
any interest in any corporation, association or other entity other than (i)&nbsp;the subsidiaries listed in Exhibit&nbsp;21.1 to the Company&rsquo;s
annual report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2024, filed with the Commission on February&nbsp;28, 2025,
(ii)&nbsp;Praxis Medicines International Holdings LLC, and (iii)&nbsp;Praxis Precision Medicines India Private Limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Capitalization
and Other Capital Stock Matters</I>.</B></FONT> The Company has an authorized capitalization as set forth under the heading &ldquo;Capitalization&rdquo;
in the Time of Sale Prospectus, and all of the issued shares of capital stock of the Company, have been duly and validly authorized and
issued, are fully paid and non-assessable, have been issued in compliance with federal and state securities laws, and conform to the description
thereof contained in the Time of Sale Prospectus and the Prospectus. All of the Company&rsquo;s options, warrants and other rights to
purchase or exchange any securities for shares of the Company&rsquo;s capital stock have been duly authorized and validly issued and were
issued in compliance with federal and state securities laws. None of the outstanding shares of common stock were issued in violation of
any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. As of the
date set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, there were no authorized or outstanding
shares of capital stock, options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt
securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than
those described above or accurately described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. Since such
date, the Company has not issued any securities other than common stock issued pursuant to the exercise of warrants or upon the exercise
of stock options or other awards outstanding under the Company&rsquo;s stock option plans, options or other securities granted or issued
pursuant to the Company&rsquo;s existing equity compensation plans or other plans, and the issuance of common stock pursuant to employee
stock purchase plans. The description of the Company&rsquo;s stock option, stock bonus and other stock plans or arrangements, and the
options or other rights granted thereunder, as described in the Time of Sale Prospectus and the Prospectus, accurately and fairly present
the information required to be shown with respect to such plans, arrangements, options and rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Capitalization
of Subsidiaries</I>.</B></FONT> All the outstanding shares of capital stock (if any) of each subsidiary of the Company have been duly
authorized and validly issued, are fully paid and nonassessable and, except to the extent set forth in the Time of Sale Prospectus or
the Prospectus, are owned by the Company directly or indirectly through one or more wholly-owned subsidiaries, free and clear of any claim,
lien, encumbrance, security interest, restriction upon voting or transfer or any other claim of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Stock
Exchange Listing</I>.</B></FONT> The Shares and Warrant Shares have been approved for listing subject to notice of issuance on the Nasdaq
Global Select Market. A registration statement has been filed on Form&nbsp;8-A pursuant to Section&nbsp;12 of the Exchange Act, which
registration statement complies in all material respects with the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Conflicts</I>.</B></FONT> The execution, delivery and performance of this Agreement by the Company, the issue and sale of the Offered
Securities by the Company, the issuance of the Warrant Shares by the Company upon exercise of the Pre-Funded Warrants and the consummation
of the transactions contemplated hereby will not (with or without notice or lapse of time or both) (i)&nbsp;conflict with or result in
a breach or violation of any of the terms or provisions of, constitute a default or a Debt Repayment Triggering Event (as defined below)
under, or result in the creation or imposition of any lien, encumbrance, security interest, claim or charge upon any property or assets
of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument
to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any
of the property or assets of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of
the charter or by-laws (or analogous governing instruments, as applicable) of the Company or any of its subsidiaries or (iii)&nbsp;result
in the violation of any law, statute, rule, regulation, judgment, order or decree of any court or governmental or regulatory agency or
body, domestic or foreign, having jurisdiction over the Company or any of its subsidiaries or any of their properties or assets except,
in the case of clauses (i)&nbsp;and (iii)&nbsp;above, for any such conflict, breach, violation or default that would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Change. A &ldquo;<B>Debt Repayment Triggering Event</B>&rdquo;
means any event or condition that gives, or with the giving of notice or lapse of time would give the holder of any note, debenture or
other evidence of indebtedness (or any person acting on such holder&rsquo;s behalf) the right to require the repurchase, redemption or
repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Compliance
with Laws.</I></B></FONT> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or by-laws (or analogous
governing instrument, as applicable), (ii)&nbsp;in default in any respect, and no event has occurred which, with notice or lapse of time
or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture,
mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it is bound or to which
any of its property or assets is subject or (iii)&nbsp;in violation in any respect of any law, ordinance, governmental rule, regulation
or court order, decree or judgment to which it or its property or assets may be subject (including, without limitation, those administered
by the United States Food and Drug Administration of the U.S. Department of Health and Human Services (the &ldquo;<B>FDA</B>&rdquo;) or
by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA)
except, in the case of clauses (ii)&nbsp;and (iii)&nbsp;above, for any such violation or default that would not, singularly or in the
aggregate, have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Material Actions or Proceedings</I>.</B></FONT> Except as set forth in the Time of Sale Prospectus, there is no legal or governmental
proceeding to which the Company or any of its subsidiaries is a party or of which any property or assets of the Company or any of its
subsidiaries is the subject, including any proceeding before the FDA or comparable federal, state, local or foreign governmental bodies
(it being understood that the interaction between the Company and the FDA and such comparable governmental bodies relating to the clinical
development and product approval process, if any, shall not be deemed proceedings for purposes of this representation), which is required
to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus and is not described therein, or which, singularly
or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material
Adverse Change; and no such proceedings are threatened or, to the Company&rsquo;s knowledge after reasonable investigation and due diligence
inquiry (&ldquo;<B>Knowledge</B>&rdquo;), contemplated by governmental or regulatory authorities or threatened by others. The Company
is in compliance with all applicable federal, state, local and foreign laws, regulations, orders and decrees governing its business, as
described in the Time of Sale Prospectus and the Prospectus, as prescribed by the FDA, or any other federal, state or foreign agencies
or bodies engaged in the regulation of pharmaceuticals or biohazardous substances or materials, except where noncompliance would not,
singly or in the aggregate, have a Material Adverse Change. All preclinical and clinical studies conducted by or on behalf of the Company
to support approval for commercialization of the Company&rsquo;s products have been conducted by the Company, or to the Company&rsquo;s
Knowledge by third parties, in compliance with all applicable federal, state or foreign laws, rules, orders and regulations, except for
such failure or failures to be in compliance as could not reasonably be expected to have, singly or in the aggregate, a Material Adverse
Change. Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent
decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the
Company, any of its subsidiaries nor, to the Company&rsquo;s Knowledge, any of their respective employees, officers, directors, or agents
has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or is subject
to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment,
suspension, or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Intellectual
Property Rights</I>. </B></FONT>The Company and its subsidiaries own or possess the valid right to use all (i)&nbsp;patents, patent applications,
trademarks, trademark registrations, service marks, service mark registrations,&nbsp;Internet domain name registrations, copyrights, copyright
registrations, licenses, trade secret rights (&ldquo;<B>Intellectual Property Rights</B>&rdquo;) and (ii)&nbsp;inventions, software, works
of authorships, trademarks, service marks, trade names, databases, formulae, know how,&nbsp;Internet domain names and other intellectual
property (including trade secrets and other unpatented and/or unpatentable proprietary confidential information, systems, or procedures)
(collectively, &ldquo;<B>Intellectual Property Assets</B>&rdquo;) necessary to conduct their respective businesses as currently conducted,
and as proposed to be conducted and described in the Time of Sale Prospectus and the Prospectus. The Company and its subsidiaries have
not received any opinion from their legal counsel concluding that any activities of their respective businesses infringe, misappropriate,
or otherwise violate, valid and enforceable Intellectual Property Rights of any other person, and except as set forth in the Time of Sale
Prospectus, have not received written notice of any challenge, which is to their Knowledge still pending, by any other person to the rights
of the Company and its subsidiaries with respect to any Intellectual Property Rights or Intellectual Property Assets owned or used by
the Company or its subsidiaries. To the Company&rsquo;s Knowledge, the Company and its subsidiaries&rsquo; respective businesses as now
conducted do not give rise to any infringement of, any misappropriation of, or other violation of, any valid and enforceable Intellectual
Property Rights of any other person. All licenses for the use of the Intellectual Property Rights described in the Time of Sale Prospectus
and the Prospectus are valid, binding upon, and enforceable by or against the parties thereto in accordance to its terms. The Company
has complied in all material respects with, and is not in breach nor has received any asserted or threatened claim of breach of any Intellectual
Property license, and the Company has no Knowledge of any breach or anticipated breach by any other person to any Intellectual Property
license. Except as described in the Time of Sale Prospectus, no claim has been made against the Company alleging the infringement by the
Company of any patent, trademark, service mark, trade name, copyright, trade secret, license in or other intellectual property right or
franchise right of any person. The Company has taken all reasonable steps to protect, maintain and safeguard its Intellectual Property
Rights, including the execution of appropriate nondisclosure and confidentiality agreements. The consummation of the transactions contemplated
by this Agreement will not result in the loss or impairment of or payment of any additional amounts with respect to, nor require the consent
of any other person in respect of, the Company&rsquo;s right to own, use, or hold for use any of the Intellectual Property Rights as owned,
used or held for use in the conduct of the business as currently conducted. With respect to the use of the software in the Company&rsquo;s
business as it is currently conducted, the Company has not experienced any material defects in such software including any material error
or omission in the processing of any transactions other than defects which have been corrected, and to the Company&rsquo;s Knowledge,
no such software contains any device or feature designed to disrupt, disable, or otherwise impair the functioning of any software or is
subject to the terms of any &ldquo;open source&rdquo; or other similar license that provides for the source code of the software to be
publicly distributed or dedicated to the public.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>All
Necessary Permits,&nbsp;etc</I>.</B></FONT> The Company and each of its subsidiaries possess all licenses, certificates, authorizations
and permits issued by, and have made all declarations and filings with, the appropriate local, state, federal or foreign governmental
or regulatory agencies or bodies (including, without limitation, those administered by the FDA or by any foreign, federal, state or local
governmental or regulatory authority performing functions similar to those performed by the FDA) that are necessary for the ownership,
lease or operation of their respective properties or the conduct of their respective businesses as described in the Time of Sale Prospectus
and the Prospectus (collectively, the &ldquo;<B>Governmental Permits</B>&rdquo;) except where any failures to possess or make the same
would not, singularly or in the aggregate, have a Material Adverse Change. The Company and its subsidiaries are in compliance with all
such Governmental Permits; all such Governmental Permits are valid and in full force and effect, except where the invalidity or failure
to be in full force and effect would not, singularly or in the aggregate, have a Material Adverse Change. Neither the Company nor any
subsidiary has received written notification of any revocation, modification, suspension, termination or invalidation (or proceedings
related thereto) of any such Governmental Permit and the Company has no reason to believe that any such Governmental Permit will not be
renewed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Title
to Properties</I>.</B></FONT> The Company and each of its subsidiaries have good and marketable title in and (in the case of real property)
to, or have valid and marketable rights to lease or otherwise use, all items of real or personal property which are material to the business
of the Company and its subsidiaries taken as a whole, in each case free and clear of all liens, encumbrances, security interests, claims
and defects that (i)&nbsp;do not, singularly or in the aggregate, materially affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the Company or any of its subsidiaries or (ii)&nbsp;could not reasonably
be expected, singularly or in the aggregate, to have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Tax
Law Compliance</I>.</B></FONT> The Company and its subsidiaries each (i)&nbsp;have timely filed all necessary federal, state, local and
foreign tax returns, and all such returns were true, complete and correct, (ii)&nbsp;have paid all federal, state, local and foreign taxes,
for which it is liable, including, without limitation, all sales and use taxes and all taxes which the Company or any of its subsidiaries
is obligated to withhold from amounts owing to employees, creditors and third parties, and (iii)&nbsp;do not have any tax deficiency or
claims outstanding or assessed or, to its Knowledge, proposed against any of them, except those, in each of the cases described in clauses
(i), (ii)&nbsp;and (iii)&nbsp;above, that would not, singularly or in the aggregate, have a Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(x)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Insurance</I>.</B></FONT>
The Company and each of its subsidiaries carry, or are covered by, insurance in such amounts and covering such risks as is adequate for
the conduct of their respective businesses and the value of their respective properties. Neither the Company nor any of its subsidiaries
has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain
similar coverage from similar insurers as may be necessary to continue its business at a cost that would not have a Material Adverse Change.
Neither the Company nor any of its subsidiaries has received written notice from any insurer, agent of such insurer or the broker of the
Company or any of its subsidiaries that any material capital improvements or any other material expenditures (other than premium payments)
are required or necessary to be made in order to continue such insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(y)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Compliance
with Environmental Laws</I>.</B></FONT> The Company and its subsidiaries are in compliance with all foreign, federal, state and local
rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection
of health and safety or the environment which are applicable to their businesses (&ldquo;<B>Environmental Laws</B>&rdquo;). The Company
has no Knowledge of any storage, generation, transportation, handling, treatment, disposal, discharge, emission, or other release of any
kind of toxic or other wastes or other hazardous substances by, due to, or caused by the Company or any of its subsidiaries (or any other
entity for whose acts or omissions the Company or any of its subsidiaries is or may otherwise be liable) upon any of the property now
or previously owned or leased by the Company or any of its subsidiaries, or upon any other property, in violation of any law, statute,
ordinance, rule, regulation, order, judgment, decree or permit or which would, under any law, statute, ordinance, rule&nbsp;(including
rule&nbsp;of common law), regulation, order, judgment, decree or permit, give rise to any liability; and there has been no disposal, discharge,
emission or other release of any kind onto such property or into the environment surrounding such property of any toxic or other wastes
or other hazardous substances with respect to which the Company or any of its subsidiaries has knowledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(z)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>ERISA
Compliance</I>.</B></FONT> No &ldquo;prohibited transaction&rdquo; (as defined in Section&nbsp;406 of the Employee Retirement Income Security
Act of 1974, as amended, including the regulations and published interpretations thereunder (&ldquo;<B>ERISA</B>&rdquo;), or Section&nbsp;4975
of the Internal Revenue Code of 1986, as amended from time to time (the &ldquo;<B>Code</B>&rdquo;)) or &ldquo;accumulated funding deficiency&rdquo;
(as defined in Section&nbsp;302 of ERISA) or any of the events set forth in Section&nbsp;4043 (b)&nbsp;of ERISA (other than events with
respect to which the thirty (30)-day notice requirement under Section&nbsp;4043 of ERISA has been waived) has occurred or could reasonably
be expected to occur with respect to any employee benefit plan of the Company or any of its subsidiaries which could, singularly or in
the aggregate, reasonably be expected to have a Material Adverse Change. Each employee benefit plan of the Company or any of its subsidiaries
is in compliance in all material respects with applicable law, including ERISA and the Code. The Company and its subsidiaries have not
incurred and could not reasonably be expected to incur liability under Title IV of ERISA with respect to the termination of, or withdrawal
from, any pension plan (as defined in ERISA). Each pension plan for which the Company or any of its subsidiaries would have any liability
that is intended to be qualified under Section&nbsp;401(a)&nbsp;of the Code is so qualified, and nothing has occurred, whether by action
or by failure to act, which could, singularly or in the aggregate, cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(aa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Company
Not an &ldquo;Investment Company.&rdquo;</I></B></FONT> Neither the Company nor any of its subsidiaries, is or after giving effect to
the offering of the Offered Securities and, upon exercise of the Pre-Funded Warrants, the issuance of Warrant Shares, and the application
of the proceeds thereof as described in the Time of Sale Prospectus and the Prospectus, will be required to register as an &ldquo;investment
company&rdquo; or an entity &ldquo;controlled&rdquo; by an &ldquo;investment company&rdquo; within the meaning of the Investment Company
Act of 1940, as amended, and the rules&nbsp;and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(bb)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Price Stabilization or Manipulation</I>.</B></FONT> Neither the Company nor, to the Company&rsquo;s Knowledge, any of its officers, directors
or affiliates has taken or will take, directly or indirectly, any action designed or intended to stabilize or manipulate the price of
any security of the Company, or which caused or resulted in, or which might in the future reasonably be expected to cause or result in,
stabilization or manipulation of the price of any security of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(cc)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Related-Party
Transactions</I>.</B></FONT> No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries on the
one hand, and the directors, officers, stockholders (or analogous interest holders), customers or suppliers of the Company or any of its
affiliates on the other hand, which is required to be described in the Time of Sale Prospectus and the Prospectus and which is not so
described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(dd)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>FINRA
Matters</I>.</B></FONT> Neither the Company nor any of its affiliates (within the meaning of FINRA Rule&nbsp;5121(f)(1)) directly or indirectly
controls, is controlled by, or is under common control with, or is an associated person (within the meaning of Article&nbsp;I, Section&nbsp;1(ee)
of the By-laws of FINRA) of, any member firm of FINRA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(ee)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Parties
to Lock-Up Agreements</I>.</B></FONT> The Company has furnished to the Underwriters a letter agreement in the form attached hereto as
<U>Exhibit&nbsp;B</U> (the &ldquo;<B>Lock-up Agreement</B>&rdquo;) from each of the persons listed on <U>Exhibit&nbsp;C</U>. Such <U>Exhibit&nbsp;C</U>
lists under an appropriate caption the directors and officers of the Company. If any additional persons shall become directors or officers
(as defined in Rule&nbsp;16a-1(f)&nbsp;under the Exchange Act) of the Company prior to the end of the Company Lock-up Period (as defined
below), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a director or officer
of the Company, to execute and deliver to the Representatives a Lock-up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(ff)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Statistical
and Market-Related Data</I>.</B></FONT> The statistical and market related data included or incorporated by reference in the Registration
Statement, the Time of Sale Prospectus and the Prospectus are based on or derived from sources that the Company believes to be reliable
and accurate, and such data agree with the sources from which they are derived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(gg)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Sarbanes-Oxley
Act.</I></B></FONT> There is and has been no failure on the part of the company or, to the Company&rsquo;s Knowledge, any of the Company&rsquo;s
officers or directors, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules&nbsp;and
regulations promulgated in connection therewith, including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(hh)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Unlawful Contributions or Other Payments</I>.</B></FONT> Neither the Company nor any of its subsidiaries nor, to the Company&rsquo;s Knowledge,
any directory, officer, employee, agent, affiliate or other person acting on behalf of the Company or any subsidiary, has (i)&nbsp;used
any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity (or taken
any act in furtherance thereof), (ii)&nbsp;made any direct or indirect unlawful payment to foreign or domestic government officials or
employees, political parties or campaigns, political party officials, or candidates for political office from corporate funds, (iii)&nbsp;violated
or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any applicable anti-corruption laws,
rules, or regulation of any other jurisdiction in which the Company or any subsidiary conducts business, or (iv)&nbsp;made any other unlawful
bribe, rebate, payoff, influence payment, kickback, or other unlawful payment to any person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Anti-Corruption
and Anti-Bribery Laws</I>.</B></FONT> Neither the Company nor any of its subsidiaries nor any director, officer, or employee of the Company
or any of its subsidiaries, nor to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company
or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i)&nbsp;used
any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made
or taken any act in furtherance of an offer, promise, or authorization of any direct or indirect unlawful payment or benefit to any foreign
or domestic government official or employee, including of any government-owned or controlled entity or public international organization,
or any political party, party official, or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of
the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &ldquo;<B>FCPA</B>&rdquo;), the UK Bribery Act 2010, or any other applicable
anti-bribery or anti-corruption law; or (iv)&nbsp;made, offered, authorized, requested, or taken an act in furtherance of any unlawful
bribe, rebate, payoff, influence payment, kickback or other unlawful payment or benefit . The Company and its subsidiaries and, to the
knowledge of the Company, the Company&rsquo;s affiliates have conducted their respective businesses in compliance with the FCPA and have
instituted and maintain policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued
compliance therewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(jj)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Money
Laundering Laws</I>.</B></FONT> The operations of the Company and its subsidiaries are and have been conducted at all times in compliance
with all applicable financial recordkeeping and reporting requirements, including those of the U.S. Bank Secrecy Act, as amended by Title
III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA
PATRIOT Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business,
the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced
by any governmental agency (collectively, the &ldquo;<B>Anti-Money Laundering Laws</B>&rdquo;), and no action, suit or proceeding by or
before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect
to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>(kk)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Sanctions</I>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Neither
the Company nor any of its subsidiaries, nor any director, officer or employee thereof, nor, to the Company&rsquo;s Knowledge, any agent,
affiliate, representative or other person acting on behalf of the Company or any of its subsidiaries, is an individual or entity (&ldquo;<B>Person</B>&rdquo;)
that is, or is owned or controlled by a Person that is: (i)&nbsp;the subject of any sanctions administered or enforced by the U.S. Department
of Treasury&rsquo;s Office of Foreign Assets Control, the United Nations Security Council, the European Union, His Majesty&rsquo;s Treasury,
or other relevant sanctions authority (collectively, &ldquo;<B>Sanctions</B>&rdquo;), nor (ii)&nbsp;located, organized or resident in
a country or territory that is the subject of a U.S. government embargo (including, without limitation, the so-called Donetsk People&rsquo;s
Republic, the so-called Luhansk People&rsquo;s Republic, the Crimea Region of Ukraine, the non-government controlled areas of the Zaporizhzhia
and Kherson Regions, Cuba,&nbsp;Iran, North Korea and Syria).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds
to any subsidiary, joint venture partner or other Person: (i)&nbsp;to fund or facilitate any activities or business of or with any Person
that, at the time of such funding or facilitation, is the subject of Sanctions, or in any country or territory that, at the time of such
funding or facilitation, is the subject of a U.S. government embargo; or (ii)&nbsp;in any other manner that will result in a violation
of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor, investor or otherwise).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;For
the past ten (10)&nbsp;years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will
not engage in, any direct or indirect dealings or transactions with any Person that at the time of the dealing or transaction is or was
the subject of Sanctions or any country or territory that, at the time of the dealing or transaction is or was the subject of a U.S. government
embargo.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"><FONT STYLE="font-size: 10pt">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
the Company nor any of its subsidiaries is a &ldquo;covered foreign person&rdquo;, as that term is defined in 31 C.F.R. &sect; 850.209.
Neither the Company nor any of its subsidiaries currently engages, or has plans to engage, directly or indirectly, in a &ldquo;covered
activity&rdquo;, as that term is defined in in 31 C.F.R. &sect; 850.208 (&ldquo;<B>Covered Activity</B>&rdquo;). The Company does not
have any joint ventures that engages in or plans to engage in any Covered Activity. The Company also does not, directly or indirectly,
hold a board seat on, have a voting or equity interest in, or have any contractual power to direct or cause the direction of the management
or policies of any person or persons that engages or plans to engage in any Covered Activity.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(ll)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Brokers</I>.</B></FONT>
Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this
Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or the Underwriters for a brokerage commission,
finder&rsquo;s fee or like payment in connection with the offering and sale of the Offered Securities or any transaction contemplated
by this Agreement, the Registration Statement, the Time of Sale Prospectus or the Prospectus.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(mm)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Forward-Looking
Statements.</I></B></FONT> No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E
of the Exchange Act) contained in either the Time of Sale Prospectus or the Prospectus has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(nn)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Outstanding Loans or Other Extensions of Credit</I></B></FONT>. The Company does not have any outstanding extension of credit, in the
form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions
of credit as are expressly permitted by Section&nbsp;13(k)&nbsp;of the Exchange Act.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(oo)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Cybersecurity</I></B></FONT>.
(i)&nbsp;To the Company&rsquo;s Knowledge, (x)&nbsp;there has been no security breach or attack or other compromise of or relating to
any of the Company&rsquo;s and its subsidiaries&rsquo; information technology and computer systems, networks, hardware, software, data
(including the data of their respective customers, employees, suppliers, vendors and any third party data maintained by or on behalf of
them), equipment or technology (&ldquo;<B>IT Systems and Data</B>&rdquo;) and (y)&nbsp;the Company and its subsidiaries have not been
notified of, and have no knowledge of any event or condition that would reasonably be expected to result in any security breach, attack
or compromise to their IT Systems and Data, (ii)&nbsp;the Company and its subsidiaries have complied, and are presently in compliance
with, all applicable laws, statutes or any judgment, order, rule&nbsp;or regulation of any court or arbitrator or governmental or regulatory
authority and all industry guidelines, standards, internal policies and contractual obligations relating to the privacy and security of
IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification
and (iii)&nbsp;the Company and its subsidiaries have implemented backup and disaster recovery technology consistent with industry standards
and practice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(pp)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Compliance
with Data Privacy Laws</I></B></FONT>. The Company and its subsidiaries are, and at all prior times were, in material compliance with
all applicable data privacy and security laws and regulations, including, in each case, to the extent applicable, the Health Insurance
Portability and Accountability Act (&ldquo;<B>HIPAA</B>&rdquo;), as amended by the Health Information Technology for Economic and Clinical
Health Act (the &ldquo;<B>HITECH Act</B>&rdquo;) (42 U.S.C. Section&nbsp;17921 et seq.), and the European Union General Data Protection
Regulation (&ldquo;<B>GDPR</B>&rdquo;) (EU 2016/679) (collectively, &ldquo;<B>Privacy Laws</B>&rdquo;). The Company and its subsidiaries
have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies
and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling and analysis of Personal Data
(the &ldquo;<B>Policies</B>&rdquo;). The Company provides accurate notice of its Policies to those data subjects whose Personal Data is
subject to the Policies. The Policies provide accurate and sufficient notice of the Company&rsquo;s then-current privacy practices relating
to its subject matter and such Policies do not contain any material omissions of the Company&rsquo;s then-current privacy practices. &ldquo;<B>Personal
Data</B>&rdquo; means (i)&nbsp;a natural persons&rsquo; name, street address, telephone number, email address, photograph, social security
number, bank information, or customer or account number; (ii)&nbsp;any information which would qualify as &ldquo;personally identifying
information&rdquo; under the Federal Trade Commission Act, as amended; (iii)&nbsp;Protected Health Information as defined by HIPAA; (iv)&nbsp;&ldquo;personal
data&rdquo; as defined by GDPR; and (v)&nbsp;any other piece of information that allows the identification of such natural person, or
his or her family, or permits the collection or analysis of any data related to an identified person&rsquo;s health or sexual orientation.
To the Company&rsquo;s Knowledge, none of such disclosures made or contained in any of the Policies have been inaccurate, misleading,
deceptive or in violation of any Privacy Laws or Policies in any material respect. To the Company&rsquo;s Knowledge, the execution, delivery
and performance of this Agreement or any other agreement referred to in this Agreement will not result in a breach of any Privacy Laws
or Policies. Neither the Company nor any of its subsidiaries, (i)&nbsp;has received notice of any actual or potential liability under
or relating to, or actual or potential violation of, any of the Privacy Laws, and has no Knowledge of any event or condition that would
reasonably be expected to result in any such notice; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation,
remediation or other corrective action pursuant to any Privacy Law; or (iii)&nbsp;is a party to any order, decree, or agreement that imposed
any obligation or liability under any Privacy Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(qq)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Clinical
Data and Regulatory Compliance.</I></B></FONT> The studies, tests and preclinical or clinical trials conducted by or on behalf of the
Company that are described in the Time of Sale Prospectus and the Prospectus (the &ldquo;<B>Company Studies and Trials</B>&rdquo;) were
and, if still pending, are being, conducted in all material respects in accordance with experimental protocols, procedures and controls,
including all applicable laws and regulations; the descriptions of the results of the Company Studies and Trials contained in the Time
of Sale Prospectus and Prospectus are accurate in all material respects; the Company has no Knowledge of any other studies or trials not
described in the Time of Sale Prospectus and the Prospectus, the results of which are inconsistent with or call in question the results
described or referred to in the Time of Sale Prospectus and the Prospectus; and the Company has not received any written notices from
or had any other correspondence with the FDA or any foreign, state or local governmental body exercising comparable authority requiring
the termination, suspension or material modification of any Company Studies or Trials for which termination, suspension or material modification
would reasonably be expected to have a Material Adverse Change and, to the Company&rsquo;s Knowledge, there are no reasonable grounds
for the same. In using or disclosing patient information received by the Company, if any, in connection with the Company Studies and Trials,
the Company has complied in all material respects with all applicable laws and regulatory rules&nbsp;or requirements, including, without
limitation, the Health Insurance Portability and Accountability Act of 1996 and the rules&nbsp;and regulations thereunder. To the Company&rsquo;s
Knowledge, none of the Company Studies and Trials involved any investigator who has been disqualified as a clinical investigator or has
been found by the FDA or a comparable foreign regulatory authority to have engaged in scientific misconduct or violations of good clinical
practices. To the Company&rsquo;s Knowledge, the manufacturing facilities and operations of its suppliers are operated in compliance in
all material respects with all applicable statutes, rules, and regulations of the FDA and comparable regulatory agencies outside of the
United States to which the Company is subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(rr)</B></FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<B><I>Compliance
with Health Care Laws</I></B>. The Company and its subsidiaries are, and at all times during the past three (3)&nbsp;years have been,
in compliance with all Health Care Laws, except as would not cause a Material Adverse Change to the Company. For purposes of this Agreement,
 &ldquo;Health Care Laws&rdquo; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), the Public
Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal,
state, local and foreign health care fraud and abuse laws, including, without limitation, the Anti-Kickback Statute (42 U.S.C. Section&nbsp;1320a-7b(b)),
the Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal false statements law (42 U.S.C. Section&nbsp;1320a-7b(a)),
18 U.S.C. Sections 286 and 287, the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability
Act of 1996 (&ldquo;HIPAA&rdquo;) (42 U.S.C. Section&nbsp;1320d et seq.), the civil monetary penalties law (42 U.S.C. Section&nbsp;1320a-7a),
the exclusion law (42 U.S.C. Section&nbsp;1320a-7), the Physician Payments Sunshine Act (42 U.S.C. Section&nbsp;1320-7h), and applicable
laws governing government funded or sponsored healthcare programs; (iii)&nbsp;HIPAA, as amended by the Health Information Technology for
Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.); and (iv)&nbsp;all other similar local, state, federal, national,
supranational and foreign laws, relating to the regulation of the Company or its subsidiaries, and (vii)&nbsp;the directives and regulations
promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither the Company nor any of its subsidiaries has
received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from
any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation
of any Health Care Laws nor, to the Company&rsquo;s Knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action threatened. During the past three (3)&nbsp;years, the Company and its subsidiaries have filed, maintained
or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent
submission). Neither the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements,
consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, during
the past three (3)&nbsp;years, neither the Company, any of its subsidiaries nor any of their respective employees, officers, directors,
or, to the Company&rsquo;s knowledge, agents has been excluded, suspended or debarred from participation in any U.S. federal health care
program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding,
or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(tt)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Dividend
Restrictions</I>.</B></FONT> Except as described in the Time of Sale Prospectus and the Prospectus, no subsidiary of the Company is currently
prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends
to the Company, from making any other distribution on such subsidiary&rsquo;s capital stock, from repaying to the Company any loans or
advances to such subsidiary from the Company or from transferring any of such subsidiary&rsquo;s properties or assets to the Company or
any other subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(uu)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Consents Required</I>.</B></FONT> Except for the registration of the Offered Securities under the Securities Act and applicable state
securities laws, and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by FINRA
and the Nasdaq Global Select Market in connection with the purchase and distribution of the Offered Securities by the Underwriters and
the listing of the Shares and Warrant Shares on the Nasdaq Global Select Market, no consent, approval, authorization or order of, or filing,
qualification or registration (each an &ldquo;<B>Authorization</B>&rdquo;) with, any court, governmental or regulatory agency or body,
foreign or domestic, which has not been made, obtained or taken and is not in full force and effect, is required for the execution, delivery
and performance of this Agreement by the Company, the issuance and sale of the Offered Securities, the issuance of Warrant Shares upon
the exercise of the Pre-Funded Warrants or the consummation of the transactions contemplated hereby; and no event has occurred that allows
or results in, or after notice or lapse of time or both would allow or result in, revocation, suspension, termination or invalidation
of any such Authorization or any other impairment of the rights of the holder or maker of any such Authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(vv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Labor Dispute</I>.</B></FONT> There is (A)&nbsp;no significant unfair labor practice complaint pending against the Company, or any of
its subsidiaries, nor to the Company&rsquo;s Knowledge, threatened against it or any of its subsidiaries, before the National Labor Relations
Board, any state or local labor relation board or any foreign labor relations board, and no significant grievance or significant arbitration
proceeding arising out of or under any collective bargaining agreement is so pending against the Company or any of its subsidiaries, or,
to the Company&rsquo;s Knowledge, threatened against it and (B)&nbsp;no labor disturbance by or dispute with, employees of the Company
or any of its subsidiaries exists or, to the Company&rsquo;s Knowledge, is contemplated or threatened, and the Company is not aware of
any existing or imminent labor disturbance by the employees of any of its or its subsidiaries&rsquo; principal suppliers, manufacturers,
customers or contractors, that could reasonably be expected, singularly or in the aggregate, to have a Material Adverse Change. The Company
is not aware that any key employee or significant group of employees of the Company or any subsidiary plans to terminate employment with
the Company or any such subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(ww)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Minute
Books</I>.</B></FONT> The minute books of the Company and each of its subsidiaries have been made available to the Underwriters and counsel
for the Underwriters, and such books (i)&nbsp;contain a complete summary of all meetings and actions of the board of directors (including
each board committee) and stockholders of the Company (or analogous governing bodies and interest holders, as applicable), and each of
its subsidiaries since the time of its respective incorporation or organization through the date of the latest meeting and action, and
(ii)&nbsp;accurately in all material respects reflect all transactions referred to in such minutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(xx)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Margin
Rules</I>.</B></FONT> The application of the proceeds received by the Company from the issuance, sale and delivery of the Offered Securities
as described in the Time of Sale Prospectus and the Prospectus will not violate Regulation T, U or X of the Board of Governors of the
Federal Reserve system or any other regulation of such Board of Governors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(yy)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>PFIC</I>.</B></FONT>
The Company is not a Passive Foreign Investment Company (&ldquo;<B>PFIC</B>&rdquo;) within the meaning of Section&nbsp;1296 of the United
States Internal Revenue Code of 1966, and the Company is not likely to become a PFIC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(zz)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Certification
Regarding Beneficial Owners</I>.</B></FONT> The Company has delivered to the Representatives a properly completed and executed Certification
Regarding Beneficial Owners of Legal Entity Customers, and, if required, copies of identifying documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(aaa)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Acquisitions or Dispositions</I>.</B></FONT> Except as are described in the Registration Statement, the Time of Sale Prospectus and the
Prospectus, there are no contracts, letters of intent, term sheets, agreement, arrangements or understandings with respect to the direct
or indirect acquisition or disposition by the Company of material interests in real or personal property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any certificate signed by any officer of the Company
or any of its subsidiaries and delivered to any Underwriter or to counsel for the Underwriters in connection with the offering, or the
purchase and sale, of the Offered Securities shall be deemed a representation and warranty by the Company to each Underwriter as to the
matters covered thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has a reasonable basis for making each
of the representations set forth in this Section&nbsp;1. The Company acknowledges that the Underwriters and, for purposes of the opinions
to be delivered pursuant to &lrm;Section&nbsp;6 hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy
and truthfulness of the foregoing representations and hereby consents to such reliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Purchase,
Sale and Delivery of the Offered Securities</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>The
Firm Securities</I>.</B></FONT> Upon the terms herein set forth, the Company agrees to issue and sell to the several Underwriters the
number of Firm Shares and Pre-Funded Warrants set forth opposite the name of such Underwriter on <U>Schedule A</U> hereto at a price per
Share of $147.58 and a price per Pre-Funded Warrant of $147.5799. On the basis of the representations, warranties and agreements herein
contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase
from the Company the respective numbers of Firm Shares and Pre-Funded Warrants set forth opposite their names on <U>Schedule A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>The
First Closing Date</I>.</B></FONT> Delivery of certificates for the Firm Securities to be purchased by the Underwriters and payment therefor
shall be made at the offices of Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C., One Financial Center, Boston, Massachusetts
02111 (or such other place as may be agreed to by the Company and the Representatives) at 10:00 a.m.&nbsp;New York City time, on October&nbsp;20,
2025, or such other time and date not later than 2:30 p.m.&nbsp;New York City time, on October&nbsp;20, 2025 as the Representatives shall
designate by notice to the Company (the time and date of such closing are called the &ldquo;<B>First Closing Date</B>&rdquo;). The Company
hereby acknowledges that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally
scheduled include, but are not limited to, any determination by the Company or the Representatives to recirculate to the public copies
of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Section&nbsp;11 of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>The
Optional Shares; Option Closing Date</I>.</B></FONT> In addition, on the basis of the representations, warranties and agreements herein
contained, and upon the terms but subject to the conditions herein set forth, the Company hereby grants an option to the several Underwriters
to purchase, severally and not jointly, up to an aggregate of 501,592 Optional Shares from the Company at the purchase price per share
to be paid by the Underwriters for the Firm Shares, less an amount per share equal to any dividend or distribution declared by the Company
and payable on the Firm Shares but not payable on Optional Shares. The option granted hereunder may be exercised at any time and from
time to time in whole or in part upon notice by the Representatives to the Company, which notice may be given at any time within 30 days
from the date of this Agreement. Such notice shall set forth (i)&nbsp;the aggregate number of Optional Shares as to which the Underwriters
are exercising the option and (ii)&nbsp;the time, date and place at which certificates for the Optional Shares will be delivered (which
time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous
with the First Closing Date, the term &ldquo;<B>First Closing Date</B>&rdquo; shall refer to the time and date of delivery of certificates
for the Firm Securities and such Optional Shares). Any such time and date of delivery, if subsequent to the First Closing Date, is called
an &ldquo;<B>Option Closing Date</B>,&rdquo; and shall be determined by the Representatives and shall not be earlier than two or later
than five full business days after delivery of such notice of exercise. If any Optional Shares are to be purchased, each Underwriter agrees,
severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the
Representatives may determine) that bears the same proportion to the total number of Optional Shares to be purchased as the number of
Firm Securities set forth on <U>Schedule A</U> opposite the name of such Underwriter bears to the total number of Firm Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Public
Offering of the Offered Securities</I>.</B></FONT> The Representatives hereby advise the Company that the Underwriters intend to offer
for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus,
their respective portions of the Offered Securities as soon after this Agreement has been executed as the Representatives, in their sole
judgment, have determined is advisable and practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Payment
for the Offered Securities</I>.</B></FONT> (i)&nbsp;Payment for the Offered Securities shall be made at the First Closing Date (and, if
applicable, at each Option Closing Date) by wire transfer of immediately available funds to the order of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;It
is understood that the Representatives have been authorized, for their own account and the accounts of the several Underwriters, to accept
delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters have
agreed to purchase. Each of TD Cowen, Piper, and Guggenheim, individually and not as the Representatives of the Underwriters, may (but
shall not be obligated to) make payment for any Offered Securities to be purchased by any Underwriter whose funds shall not have been
received by the Representatives by the First Closing Date or the applicable Option Closing Date, as the case may be, for the account of
such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Delivery
of the Offered Securities</I>.</B></FONT> The Company shall deliver, or cause to be delivered to the Representatives for the accounts
of the several Underwriters the Firm Shares at the First Closing Date, against release of a wire transfer of immediately available funds
for the amount of the purchase price therefor. The Pre-Funded Warrants shall be delivered to the purchasers of the Pre-Funded Warrants
in definitive form, registered in such names and in such denominations as the purchasers of the Pre-Funded Warrants shall request in writing
not later than the First Closing Date. The Pre-Funded Warrants will be made available for inspection by the Representatives on the business
day prior to the First Closing Date. The Company and the Representatives shall instruct purchasers of the Pre-Funded Warrants to make
payment for the Pre-Funded Warrants on the First Closing Date to the Company by wire transfer in immediately available funds to the account
specified by the Company at a purchase price of $156.9999 per Pre-Funded Warrant, in lieu of payment by the Underwriters for such Pre-Funded
Warrants, and the Company shall deliver such Pre-Funded Warrants to such purchasers on the First Closing Date in definitive form against
such payment, in lieu of the Company&rsquo;s obligation to deliver such Pre-Funded Warrants to the Underwriters; provided that the Company
shall promptly (but in no event later than the First Closing Date) pay $9.42 per such Pre-Funded Warrant to the Underwriters by wire transfer
in immediately available funds to the account specified by the Representatives. In the event that the purchasers of the Pre-Funded Warrants
fail to make payment to the Company for all or part of the Pre-Funded Warrants on the First Closing Date, the Representatives may elect,
by written notice to the Company, to receive shares of Common Stock in lieu of all or a portion of such Pre-Funded Warrants to be delivered
to the Underwriters under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company shall also deliver, or cause to be
delivered to the Representatives for the accounts of the several Underwriters, certificates for the Optional Shares the Underwriters have
agreed to purchase at the First Closing Date or the applicable Option Closing Date, as the case may be, against the release of a wire
transfer of immediately available funds for the amount of the purchase price therefor. If the Representatives so elect, delivery of the
Firm Shares and Optional Shares may be made by credit to the accounts designated by the Representatives through The Depository Trust Company&rsquo;s
full fast transfer or DWAC programs. If the Representatives so elect, the certificates for the Firm Shares and Optional Shares shall be
registered in such names and denominations as it shall have requested at least two full business days prior to the First Closing Date
(or the applicable Option Closing Date, as the case may be) and shall be made available for inspection on the business day preceding the
First Closing Date (or the applicable Option Closing Date, as the case may be) at a location in New York City as the Representatives may
designate. Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the
obligations of the Underwriters. In the event that the Firm Shares and Pre-Funded Warrants (and Optional Shares, if elected by the Representatives)
are not delivered to the Representatives by 2:30 p.m., New York City time, on the First Closing Date (and the Option Closing Date, if
elected by the Representatives), the Company will return (or will instruct its custodian to return) payment of the full purchase price
to the Representatives via same day funds by 4:30 p.m., New York City time. The Company shall remain liable to the Representatives for
the full amount of the purchase price and any costs associated with recovering the purchase price until the full amount has been received
by the Representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>Section&nbsp;3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Additional
Covenants.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Delivery
of Registration Statement, Time of Sale Prospectus and Prospectus.</I></B></FONT> The Company shall furnish to you in New York City, without
charge, prior to 10:00 a.m.&nbsp;New York City time on the business day next succeeding the date of this Agreement and during the period
when a prospectus relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through
compliance with Rule&nbsp;172 under the Securities Act or any similar rule) in connection with sales of the Offered Securities, as many
copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments thereto or to the Registration Statement as you
may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Representatives&rsquo;
Review of Proposed Amendments and Supplements.</I></B></FONT> During the period when a prospectus relating to the Offered Securities is
required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or
any similar rule), the Company (i)&nbsp;will furnish to the Representatives for review, a reasonable period of time prior to the proposed
time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or supplement and
(ii)&nbsp;will not amend or supplement the Registration Statement without the Representatives&rsquo; prior written consent. Prior to amending
or supplementing any preliminary prospectus, the Time of Sale Prospectus or the Prospectus, the Company shall furnish to the Representatives
for review, a reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such
proposed amendment or supplement. The Company shall not file or use any such proposed amendment or supplement without the Representatives&rsquo;
prior written consent. The Company shall file with the Commission within the applicable period specified in Rule&nbsp;424(b)&nbsp;under
the Securities Act any prospectus required to be filed pursuant to such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Free
Writing Prospectuses.</I></B></FONT> The Company shall furnish to the Representatives for review, a reasonable amount of time prior to
the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared
by or on behalf of, used by, or referred to by the Company, and the Company shall not file, use or refer to any proposed free writing
prospectus or any amendment or supplement thereto without the Representatives&rsquo; prior written consent. The Company shall furnish
to each Underwriter, without charge, as many copies of any free writing prospectus prepared by or on behalf of, used by or referred to
by the Company as such Underwriter may reasonably request. If at any time when a prospectus is required by the Securities Act to be delivered
(whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) in connection with sales of
the Offered Securities (but in any event if at any time through and including the First Closing Date) there occurred or occurs an event
or development as a result of which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted
or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a material
fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
prevailing at such time, not misleading, the Company shall promptly amend or supplement such free writing prospectus to eliminate or correct
such conflict so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
prevailing at such time, not misleading, as the case may be; <I>provided, however</I>, that prior to amending or supplementing any such
free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of time prior to the proposed
time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus, and the Company shall not file,
use or refer to any such amended or supplemented free writing prospectus without the Representatives&rsquo; prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Filing
of Underwriter Free Writing Prospectuses.</I></B></FONT> The Company shall not take any action that would result in an Underwriter or
the Company being required to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act a free writing prospectus
prepared by or on behalf of such Underwriter that such Underwriter otherwise would not have been required to file thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Amendments
and Supplements to Time of Sale Prospectus.</I></B></FONT> If the Time of Sale Prospectus is being used to solicit offers to buy the Offered
Securities at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist
as a result of which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include
an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light
of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result
of which the Time of Sale Prospectus conflicts with the information contained in the Registration Statement, or if, in the opinion of
counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company
shall (subject to Section&nbsp;3(b)&nbsp;and Section&nbsp;3(c)&nbsp;hereof) promptly prepare, file with the Commission and furnish, at
its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so
that the statements in the Time of Sale Prospectus as so amended or supplemented will not include an untrue statement of a material fact
or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to
a prospective purchaser, not misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with
the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply
with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Certain
Notifications and Required Actions</I>.</B></FONT> After the date of this Agreement, the Company shall promptly advise the Representatives
in writing of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information from, the Commission; (ii)&nbsp;the
time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any preliminary
prospectus, the Time of Sale Prospectus, any free writing prospectus or the Prospectus; (iii)&nbsp;the time and date that any post-effective
amendment to the Registration Statement becomes effective; and (iv)&nbsp;the issuance by the Commission of any stop order suspending the
effectiveness of the Registration Statement or any post-effective amendment thereto or any amendment or supplement to any preliminary
prospectus, the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of any preliminary prospectus,
the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of any proceedings to remove, suspend or terminate from
listing or quotation the Shares or Warrant Shares from any securities exchange upon which they are listed for trading or included or designated
for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such
stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally,
the Company agrees that it shall comply with all applicable provisions of Rule&nbsp;424(b), Rule&nbsp;433 and Rule&nbsp;430B under the
Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule&nbsp;424(b)&nbsp;or Rule&nbsp;433
were received in a timely manner by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Amendments
and Supplements to the Prospectus and Other Securities Act Matters.</I></B></FONT> If any event shall occur or condition exist as a result
of which it is necessary to amend or supplement the Prospectus so that the Prospectus does not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus
is delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar rule) to a purchaser,
not misleading, or if in the opinion of the Representatives or counsel for the Underwriters it is otherwise necessary to amend or supplement
the Prospectus to comply with applicable law, the Company agrees (subject to Section&nbsp;3 (b)&nbsp;and Section&nbsp;3(c)) hereof to
promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments
or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
when the Prospectus is delivered (whether physically or through compliance with Rule&nbsp;172 under the Securities Act or any similar
rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the
Representatives&rsquo; consent to, nor delivery of, any such amendment or supplement shall constitute a waiver of any of the Company&rsquo;s
obligations under Section&nbsp;3(b)&nbsp;or Section&nbsp;3(c)&nbsp;of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Blue
Sky Compliance</I>.</B></FONT> The Company shall cooperate with the Representatives and counsel for the Underwriters to qualify or register
the Offered Securities for sale under (or obtain exemptions from the application of) the state securities or blue sky laws of those jurisdictions
designated by the Representatives, shall comply with such laws and shall continue such qualifications, registrations and exemptions in
effect so long as required for the distribution of the Offered Securities. The Company shall not be required to qualify as a foreign corporation
or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified.
The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption
relating to) the Offered Securities for offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for
any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company
shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Use
of Proceeds</I>.</B></FONT> The Company shall apply the net proceeds from the sale of the Offered Securities sold by it in the manner
described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement, the Time of Sale Prospectus and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Transfer
Agent</I>.</B></FONT> The Company shall engage and maintain, at its expense, a registrar and transfer agent for the Shares and Warrant
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Earnings
Statement</I>.</B></FONT> The Company will make generally available to its security holders and to the Representatives as soon as practicable
an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter
of the Company commencing after the date of this Agreement that will satisfy the provisions of Section&nbsp;11(a)&nbsp;of the Securities
Act and the rules&nbsp;and regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Continued
Compliance with Securities Laws</I>.</B></FONT> The Company will comply with the Securities Act and the Exchange Act so as to permit the
completion of the distribution of the Offered Securities as contemplated by this Agreement<B>, </B>the Registration Statement, the Time
of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing, the Company will, during the period when a prospectus
relating to the Offered Securities is required by the Securities Act to be delivered (whether physically or through compliance with Rule&nbsp;172
under the Securities Act or any similar rule), file on a timely basis with the Commission and Nasdaq all reports and documents required
to be filed under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Listing</I>.</B></FONT>
The Company will use its best efforts to list, subject to notice of issuance, the Shares and Warrant Shares on Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Company
to Provide Copy of the Prospectus in Form&nbsp;That May&nbsp;be Downloaded from the Internet</I>.</B></FONT> If requested by the Representatives,
the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement,
to the Representatives an &ldquo;<B>electronic Prospectus</B>&rdquo; to be used by the Underwriters in connection with the offering and
sale of the Offered Securities. As used herein, the term &ldquo;<B>electronic Prospectus</B>&rdquo; means a form of Prospectus, and any
amendment or supplement thereto, that meets each of the following conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory
to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to offerees and purchasers
of the Offered Securities; (ii)&nbsp;it shall disclose the same information as the paper Prospectus, except to the extent that graphic
and image material cannot be disseminated electronically, in which case such graphic and image material shall be replaced in the electronic
Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it
shall be in or convertible into a paper format or an electronic format, satisfactory to the Representatives, that will allow investors
to store and have continuously ready access to the Prospectus at any future time, without charge to investors (other than any fee charged
for subscription to the Internet as a whole and for on-line time). The Company hereby confirms that it has included or will include in
the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time it was declared
effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause
to be transmitted promptly, without charge, a paper copy of the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(o)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Agreement
Not to Offer or Sell Additional Shares</I>.</B></FONT> During the period commencing on and including the date hereof and continuing through
and including the 30th day following the date of the Prospectus (such period, as extended as described below, being referred to herein
as the &ldquo;<B>Lock-up Period</B>&rdquo;), the Company will not, without the prior written consent of TD Cowen and Piper (which consent
may be withheld in their sole discretion), directly or indirectly: (i)&nbsp;sell, offer to sell, contract to sell or lend any Shares or
Related Securities (as defined below); (ii)&nbsp;effect any short sale, or establish or increase any &ldquo;put equivalent position&rdquo;
(as defined in Rule&nbsp;16a-1(h)&nbsp;under the Exchange Act) or liquidate or decrease any &ldquo;call equivalent position&rdquo; (as
defined in Rule&nbsp;16a-1(b)&nbsp;under the Exchange Act) of any Shares or Related Securities; (iii)&nbsp;pledge, lend, hypothecate or
grant any security interest in any Shares or Related Securities; (iv)&nbsp;in any other way transfer or dispose of any Shares or Related
Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic
risk of ownership of any Shares or Related Securities, regardless of whether any such transaction is to be settled in securities, in cash
or otherwise; (vi)&nbsp;announce the offering of any Shares or Related Securities; (vii)&nbsp;submit or file any registration statement
under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to
the Offered Securities); (viii)&nbsp;effect a reverse stock split, recapitalization, share consolidation, reclassification or similar
transaction affecting the outstanding Shares; or (ix)&nbsp;publicly announce the intention to do any of the foregoing; <I>provided, however</I>,
that the Company may (A)&nbsp;effect the transactions contemplated hereby, (B)&nbsp;issue Shares or options to purchase Shares, or issue
Shares upon exercise of options, pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus, but only if the holders of such Shares or options agree in writing with the
Underwriters not to sell, offer, dispose of or otherwise transfer any such Shares or options during such Lock-up Period without the prior
written consent of TD Cowen and Piper (which consent may be withheld in their sole discretion), (C)&nbsp;file any registration statement
on Form&nbsp;S-8 or a successor form thereto with respect to the registration of securities to be offered under any employee benefit or
equity incentive plan referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus, and (D)&nbsp;issue shares
of common stock or other securities issued in connection with a transaction that includes a commercial relationship (including joint ventures,
marketing or distribution arrangements, collaboration agreements or intellectual property license agreements) or any acquisition of assets
or acquisition of not less than a majority or controlling portion of the equity of another entity, provided that (x)&nbsp;the aggregate
number of shares issued pursuant to this clause (D)&nbsp;shall not exceed five percent (5%) of the total number of outstanding shares
of common stock immediately following the issuance and sale of the Securities pursuant hereto (but excluding the Warrant Shares) and (y)&nbsp;the
recipient of any such shares of common stock or securities issued pursuant to this clause (D)&nbsp;during the 30-day restricted period
described above shall enter into an agreement substantially in the form of <U>Exhibit&nbsp;B</U>. For purposes of the foregoing, &ldquo;<B>Related
Securities</B>&rdquo; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable
for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into,
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(p)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Future
Reports to the Representatives.</I></B></FONT> During the period of five years hereafter, the Company will furnish to the Representatives,
c/o TD Securities (USA) LLC, at 1 Vanderbilt Avenue, New York, NY 10017, Attention: Head of Equity Capital Markets, c/o Piper, at 350
North 5th Street, Suite&nbsp;1000, Minneapolis, MN 55401, Attention: Equity Capital Markets, and c/o Guggenheim Securities, LLC, at 330
Madison Avenue, New York, NY 10017, Attention: Head of Equity Capital Markets, (i)&nbsp;as soon as practicable after the end of each fiscal
year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements
of income, stockholders&rsquo; equity and cash flows for the year then ended and the opinion thereon of the Company&rsquo;s independent
public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy statement, Annual
Report on Form&nbsp;10-K, Quarterly Report on Form&nbsp;10-Q, Current Report on Form&nbsp;8-K or other report filed by the Company with
the Commission, FINRA or any securities exchange; and (iii)&nbsp;as soon as available, copies of any report or communication of the Company
furnished or made available generally to holders of its capital stock; <I>provided, however,</I> that the requirements of this Section&nbsp;3(p)&nbsp;shall
be satisfied to the extent that such reports, statement, communications, financial statements or other documents are available on EDGAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(q)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Investment
Limitation</I>.</B></FONT> The Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered
Securities in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment
Company Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(r)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Stabilization or Manipulation; Compliance with Regulation M</I>.</B></FONT> The Company will not take, and will ensure that no affiliate
of the Company will take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation
of the price of the Offered Securities or any reference security with respect to the Offered Securities, whether to facilitate the sale
or resale of the Offered Securities or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable
provisions of Regulation M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(s)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Enforce
Lock-Up Agreements</I>.</B></FONT> During the Lock-up Period, the Company will enforce all agreements between the Company and any of its
securityholders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Offered Securities or Related Securities
or any of the other actions restricted or prohibited under the terms of the form of Lock-up Agreement. In addition, the Company will direct
the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such &ldquo;lock-up&rdquo;
agreements for the duration of the periods contemplated in such agreements, including, without limitation, &ldquo;lock-up&rdquo; agreements
entered into by the Company&rsquo;s officers and directors pursuant to &lrm;Section&nbsp;6(i)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(t)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Company
to Provide Interim Financial Statements</I>.</B></FONT> Prior to the First Closing Date and each applicable Option Closing Date, the Company
will furnish the Underwriters, as soon as they have been prepared by or are available to the Company, a copy of any unaudited interim
financial statements of the Company for any period subsequent to the period covered by the most recent financial statements appearing
in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(u)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Announcement
Regarding Lock-ups</I>.</B></FONT> The Company agrees to announce the Underwriters&rsquo; intention to release any director or &ldquo;officer&rdquo;
(within the meaning of Rule&nbsp;16a-1(f)&nbsp;under the Exchange Act) of the Company from any of the restrictions imposed by any Lock-Up
Agreement, by issuing, through a major news service, a press release in form and substance satisfactory to the Representatives or, if
consented to by the Representatives, in a registration statement that is publicly filed in connection with a secondary offering of the
Company&rsquo;s shares promptly following the Company&rsquo;s receipt of any notification from the Representatives in which such intention
is indicated, but in any case not later than the close of the third business day prior to the date on which such release or waiver is
to become effective; provided, however, that nothing shall prevent the Representatives, on behalf of the Underwriters, from announcing
the same through a major news service, irrespective of whether the Company has made the required announcement; and <I>provided</I>, <I>further</I>,
that no such announcement shall be made of any release or waiver granted solely to permit a transfer of securities that is not for consideration
and where the transferee has agreed in writing to be bound by the terms of a Lock-Up Agreement in the form set forth as <U>Exhibit&nbsp;B</U>
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Registration
Statement of Warrant Shares</I></B></FONT>. The Company shall, at all times while any Pre-Funded Warrants are outstanding, use its commercially
reasonable best efforts to maintain a registration statement covering the issue and sale of the Warrant Shares upon exercise of the Pre-Funded
Warrants such that the Warrant Shares, when issued, will not be subject to resale restrictions under the Securities Act except to the
extent that the Warrant Shares are owned by affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(w)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Reservation
of Warrant Shares</I>.</B></FONT> The Company shall, at all times while any Pre-Funded Warrants are outstanding, reserve and keep available
out of the aggregate of its authorized but unissued and otherwise unreserved shares of Common Stock, solely for the purpose of enabling
it to issue Warrant Shares upon exercise of such Pre-Funded Warrants, the number of Warrant Shares that are initially issuable and deliverable
upon the exercise of the then-outstanding Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Representatives, on behalf
of the several Underwriters, may, in their sole discretion, waive in writing the performance by the Company of any one or more of the
foregoing covenants or extend the time for their performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Payment
of Expenses.</B></FONT> The Company agrees to pay all costs, fees and expenses incurred in connection with the performance of its obligations
hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to
the issuance and delivery of the Offered Securities (including all printing and engraving costs), (ii)&nbsp;all fees and expenses of the
registrar and transfer agent of the Shares, (iii)&nbsp;all necessary issue, transfer and other stamp taxes in connection with the issuance
and sale of the Offered Securities to the Underwriters, (iv)&nbsp;all fees and expenses of the Company&rsquo;s counsel, independent public
or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing,
filing, shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates
of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf of, used by, or referred
to by the Company, and each preliminary prospectus, and all amendments and supplements thereto, and this Agreement, (vi)&nbsp;all filing
fees, attorneys&rsquo; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or registering (or
obtaining exemptions from the qualification or registration of) all or any part of the Offered Securities for offer and sale under the
state securities or blue sky laws, and, if requested by the Representatives, preparing and printing a &ldquo;Blue Sky Survey&rdquo; or
memorandum and a &ldquo;Canadian wrapper&rdquo;, and any supplements thereto, advising the Underwriters of such qualifications, registrations
and exemptions, (vii)&nbsp;the costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with
the rules&nbsp;and regulations of FINRA related to the Underwriters&rsquo; participation in the offering and distribution of the Offered
Securities, including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters (in an amount not
to exceed $15,000 with respect to this clause (vii)), (viii)&nbsp;the costs and expenses of the Company relating to investor presentations
on any &ldquo;road show&rdquo;, including, without limitation, expenses associated with the preparation or dissemination of any electronic
road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection
with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees
and officers of the Company and any such consultants, and up to 50% of the cost of any aircraft chartered in connection with the road
show, (ix)&nbsp;the fees and expenses associated with listing the Offered Securities on Nasdaq, and (x)&nbsp;all other fees, costs and
expenses of the nature referred to in Item 14 of Part&nbsp;II of the Registration Statement. Except as provided in this Section&nbsp;4
or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters shall pay their own expenses, including the fees and
disbursements of their counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Covenant
of the Underwriters.</B></FONT> Each Underwriter severally and not jointly covenants with the Company not to take any action that would
result in the Company being required to file with the Commission pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act a free writing
prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such actions, be required to be filed by the
Company under Rule&nbsp;433(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Conditions
of the Obligations of the Underwriters.</B></FONT> The respective obligations of the several Underwriters hereunder to purchase and pay
for the Offered Securities as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing
Date, shall be subject to the accuracy of the representations and warranties on the part of the Company set forth in Section&nbsp;1 hereof
as of the date hereof and as of the First Closing Date as though then made and, with respect to the Optional Shares, as of each Option
Closing Date as though then made, to the timely performance by the Company of its covenants and other obligations hereunder, and to each
of the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Comfort
Letter</I>.</B></FONT> On the date hereof, the Representatives shall have received from Ernst&nbsp;&amp; Young LLP, independent registered
public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to
the Representatives, containing statements and information of the type ordinarily included in accountant&rsquo;s &ldquo;comfort letters&rdquo;
to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the audited
and unaudited financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus,
and each free writing prospectus, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Compliance
with Registration Requirements; No Stop Order; No Objection from FINRA. </I></B></FONT>For the period from and after the date of this
Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing
Date, each Option Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Company shall have filed the Prospectus with the Commission (including the information previously omitted from the Registration Statement
pursuant to Rule&nbsp;430B under the Securities Act) in the manner and within the time period required by Rule&nbsp;424(b)&nbsp;under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the Registration Statement shall
be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
a filing has been made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and
arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>No
Material Adverse Change or Ratings Agency Change</I>.</B></FONT> For the period from and after the date of this Agreement and through
and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing
Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
the judgment of the Representatives there shall not have occurred any Material Adverse Change; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;there
shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review
for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company
or any of its subsidiaries by any &ldquo;nationally recognized statistical rating organization&rdquo; as that term is used in Rule&nbsp;15c3-1(c)(2)(vi)(F)&nbsp;under
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Opinion
of Counsel for the Company. </I></B></FONT>On each of the First Closing Date and each Option Closing Date the Representatives shall have
received the opinion and negative assurance letter of Latham&nbsp;&amp; Watkins LLP, counsel for the Company, dated as of such date, in
the form as the Representatives shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Opinion
of IP Counsel for the Company.</I></B></FONT> On each of the First Closing Date and each Option Closing Date, the Representatives shall
have received the opinions of each of McCarter&nbsp;&amp; English, LLP and MH2 Technology Law Group LLP, counsel for the Company with
respect to intellectual property, dated as of such date, in the form as the Representatives shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Opinion
of Counsel for the Underwriters</I>.</B></FONT> On each of the First Closing Date and each Option Closing Date the Representatives shall
have received the opinion and negative assurance letter of Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C., counsel for the
Underwriters in connection with the offer and sale of the Offered Securities, in form and substance satisfactory to the Underwriters,
dated as of such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Officers&rsquo;
Certificate</I>.</B></FONT> On each of the First Closing Date and each Option Closing Date, the Representatives shall have received a
certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated
as of such date, to the effect set forth in &lrm;Section&nbsp;6(b)(ii)&nbsp;hereof and further to the effect that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;for
the period from and including the date of this Agreement through and including such date, there has not occurred any Material Adverse
Change;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
representations, warranties and covenants of the Company set forth in Section&nbsp;1 of this Agreement are true and correct with the same
force and effect as though expressly made on and as of such date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;the
Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed or satisfied hereunder
at or prior to such date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Bring-down
Comfort Letter</I>.</B></FONT> On each of the First Closing Date and each Option Closing Date the Representatives shall have received
from Ernst&nbsp;&amp; Young LLP, independent registered public accountants for the Company, a letter dated such date, in form and substance
satisfactory to the Representatives, which letter shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant
to &lrm;Section&nbsp;6(a)&nbsp;of this Agreement, except that the specified date referred to therein for the carrying out of procedures
shall be no more than three business days prior to the First Closing Date or the applicable Option Closing Date, as the case may be; and
(ii)&nbsp;cover certain financial information contained in the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Lock-Up
Agreements.</I></B></FONT> On or prior to the date hereof, the Company shall have furnished to the Representatives an agreement in the
form of <U>Exhibit&nbsp;B</U> hereto from each of the persons listed on <U>Exhibit&nbsp;C</U> hereto, and each such agreement shall be
in full force and effect on each of the First Closing Date and each Option Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Pre-Funded
Warrants.</I></B></FONT> On or prior to the date hereof, the Company shall have furnished to the Representatives electronic copies of
the Pre-Funded Warrants executed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Reserved.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Additional
Documents</I>.</B></FONT> On or before each of the First Closing Date and each Option Closing Date, the Representatives and counsel for
the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling
them to pass upon the issuance and sale of the Offered Securities as contemplated herein, or in order to evidence the accuracy of any
of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings
taken by the Company in connection with the issuance and sale of the Offered Securities as contemplated herein and in connection with
the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for
the Underwriters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If any condition specified in this &lrm;Section&nbsp;6
is not satisfied when and as required to be satisfied (unless waived by the Representatives), this Agreement may be terminated by the
Representatives by notice from the Representatives to the Company at any time on or prior to the First Closing Date and, with respect
to the Optional Shares, at any time on or prior to the applicable Option Closing Date, which termination shall be without liability on
the part of any party to any other party, except that &lrm;Section&nbsp;4, &lrm;Section&nbsp;7, &lrm;Section&nbsp;9 and &lrm;Section&nbsp;10
of this Agreement shall at all times be effective and shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Reimbursement
of Underwriters&rsquo; Expenses</B></FONT>. If this Agreement is terminated by the Representatives pursuant to Section&nbsp;6, Section&nbsp;11
or Section&nbsp;12 of this Agreement, or if the sale to the Underwriters of the Offered Securities on the First Closing Date is not consummated
because of any refusal, inability or failure on the part of the Company to perform any agreement herein or to comply with any provision
hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters as have terminated this Agreement
with respect to themselves), severally, upon demand for all out-of-pocket expenses that shall have been reasonably incurred by the Representatives
and the Underwriters in connection with the proposed purchase and the offering and sale of the Offered Securities, including, but not
limited to, fees and disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Effectiveness
of this Agreement</B></FONT>. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Indemnification</B></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Indemnification
of the Underwriters</I>.</B></FONT> The Company agrees to indemnify and hold harmless each Underwriter, its affiliates, directors, officers,
employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act
against any loss, claim, damage, liability or expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee,
agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation,
or the laws or regulations of foreign jurisdictions where Offered Securities have been offered or sold or at common law or otherwise (including
in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim,
damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto, or the omission
or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading;
or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale
Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;of
the Securities Act, any Marketing Material or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged
omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they
were made, not misleading; or (iii)&nbsp;any act or failure to act or any alleged act or failure to act by any Underwriter in connection
with, or relating in any manner to, the Offered Securities or the offering contemplated hereby, and which is included as part of or referred
to in any loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i)&nbsp;or (ii)&nbsp;above;
and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling person for any and all expenses
(including the fees and disbursements of counsel) as such expenses are incurred by such Underwriter or such affiliate, director, officer,
employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim,
damage, liability, expense or action; <I>provided, however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim,
damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue
statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished
to the Company by the Representatives in writing expressly for use in the Registration Statement, any preliminary prospectus, the Time
of Sale Prospectus, any such free writing prospectus, any Marketing Material or the Prospectus (or any amendment or supplement thereto),
it being understood and agreed that the only such information consists of the information described in &lrm;Section&nbsp;9(b)&nbsp;below.
The indemnity agreement set forth in this &lrm;Section&nbsp;9(a)&nbsp;shall be in addition to any liabilities that the Company may otherwise
have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Indemnification
of the Company, its Directors and Officers</I></B></FONT>. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless
the Company, each of its directors, each of its officers who signed the Registration Statement and each person, if any, who controls the
Company within the meaning of the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred,
to which the Company, or any such director, officer or controlling person may become subject, under the Securities Act, the Exchange Act,
or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such
settlement is effected with the written consent of such Underwriter), insofar as such loss, claim, damage, liability or expense (or actions
in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of
a material fact contained in the Registration Statement, or any amendment thereto, or any omission or alleged omission to state therein
a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement
or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus,
that the Company has used, referred to or filed, or is required to file, pursuant to Rule&nbsp;433 of the Securities Act or the Prospectus
(or any such amendment or supplement) or the omission or alleged omission to state therein a material fact necessary in order to make
the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to
the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement,
such preliminary prospectus, the Time of Sale Prospectus, such free writing prospectus or the Prospectus (or any such amendment or supplement),
in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing
expressly for use therein; and to reimburse the Company, or any such director, officer or controlling person for any and all expenses
(including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer or controlling
person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense
or action. The Company hereby acknowledges that the only information that the Representatives have furnished to the Company expressly
for use in the Registration Statement, any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company
has filed, or is required to file, pursuant to Rule&nbsp;433(d)&nbsp;of the Securities Act or the Prospectus (or any amendment or supplement
to the foregoing) are the statements set forth in paragraphs under the heading &ldquo;Price Stabilization, Short Positions and Penalty
Bids&rdquo; under the caption &ldquo;Underwriting&rdquo; in the Preliminary Prospectus Supplement and the Final Prospectus Supplement.
The indemnity agreement set forth in this &lrm;Section&nbsp;9(b)&nbsp;shall be in addition to any liabilities that each Underwriter may
otherwise have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Notifications
and Other Indemnification Procedures</I>.</B></FONT> Promptly after receipt by an indemnified party under this &lrm;Section&nbsp;9 of
notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against an indemnifying
party under this &lrm;Section&nbsp;9, notify the indemnifying party in writing of the commencement thereof, but the omission to so notify
the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party to the extent
the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying
party from any liability that it may have otherwise than on account of this indemnity agreement. In case any such action is brought against
any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party
will be entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified,
by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such indemnified party, to assume
the defense thereof with counsel reasonably satisfactory to such indemnified party; <I>provided, however</I>, that if the defendants in
any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably concluded
that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such
action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to
those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume
such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt
of notice from the indemnifying party to such indemnified party of such indemnifying party&rsquo;s election to so assume the defense of
such action and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under
this &lrm;Section&nbsp;9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense
thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence
(it being understood, however, that the indemnifying party shall not be liable for the fees and expenses of more than one separate counsel
(together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any
local counsel) for the indemnified parties shall be selected by the Representatives (in the case of counsel for the indemnified parties
referred to in Section&nbsp;9(a)&nbsp;above) or by the Company (in the case of counsel for the indemnified parties referred to in &lrm;Section&nbsp;9(b)&nbsp;above))
or (ii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified
party within a reasonable time after notice of commencement of the action or (iii)&nbsp;the indemnifying party has authorized in writing
the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses
of counsel shall be at the expense of the indemnifying party and shall be paid as they are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<I>Settlements</I>.</B></FONT>
The indemnifying party under this &lrm;Section&nbsp;9 shall not be liable for any settlement of any proceeding effected without its written
consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify
the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding
the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party
for fees and expenses of counsel as contemplated by &lrm;Section&nbsp;9(c)&nbsp;hereof, the indemnifying party shall be liable for any
settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after
receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified
party in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent
of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit
or proceeding in respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder
by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified party from
all liability on claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability
or a failure to act by or on behalf of such indemnified party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Contribution</B></FONT>.
If the indemnification provided for in Section&nbsp;9 of this Agreement is for any reason held to be unavailable to or otherwise insufficient
to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each
indemnifying party shall contribute to the aggregate amount paid or payable by such indemnified party, as incurred, as a result of any
losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative
benefits received by the Company, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Securities
pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i)&nbsp;above but also the relative fault
of the Company, on the one hand, and the Underwriters, on the other hand, in connection with the statements or omissions which resulted
in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits
received by the Company, on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Offered Securities
pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the Offered
Securities pursuant to this Agreement (before deducting expenses) received by the Company, and the total underwriting discounts and commissions
received by the Underwriters, in each case as set forth on the front cover page&nbsp;of the Prospectus, bear to the aggregate initial
public offering price of the Offered Securities as set forth on such cover. The relative fault of the Company, on the one hand, and the
Underwriters, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement
of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one
hand, or the Underwriters, on the other hand, and the parties&rsquo; relative intent, knowledge, access to information and opportunity
to correct or prevent such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The amount paid or payable by a party as a result
of the losses, claims, damages, liabilities and expenses referred to above shall be deemed to include, subject to the limitations set
forth in &lrm;Section&nbsp;9(c)&nbsp;of this Agreement, any legal or other fees or expenses reasonably incurred by such party in connection
with investigating or defending any action or claim. The provisions set forth in &lrm;Section&nbsp;9(c)&nbsp;of this Agreement with respect
to notice of commencement of any action shall apply if a claim for contribution is to be made under this &lrm;Section&nbsp;10; <I>provided,
however,</I> that no additional notice shall be required with respect to any action for which notice has been given under &lrm;Section&nbsp;9(c)&nbsp;of
this Agreement for purposes of indemnification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company and the Underwriters agree that it
would not be just and equitable if contribution pursuant to this &lrm;Section&nbsp;10 were determined by pro rata allocation (even if
the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the
equitable considerations referred to in this &lrm;Section&nbsp;10.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the provisions of this &lrm;Section&nbsp;10,
no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter
in connection with the Offered Securities underwritten by it and distributed to the public. No person guilty of fraudulent misrepresentation
(within the meaning of Section&nbsp;11(f)&nbsp;of the Securities Act) shall be entitled to contribution from any person who was not guilty
of such fraudulent misrepresentation. The Underwriters&rsquo; obligations to contribute pursuant to this &lrm;Section&nbsp;10 are several,
and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on <U>Schedule
A</U>. For purposes of this &lrm;Section&nbsp;10, each affiliate, director, officer, employee and agent of an Underwriter and each person,
if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to contribution
as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person,
if any, who controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution
as the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Default
of One or More of the Several Underwriters</B></FONT><I>.</I> If, on the First Closing Date or any Option Closing Date any one or more
of the several Underwriters shall fail or refuse to purchase Offered Securities that it or they have agreed to purchase hereunder on such
date, and the aggregate number of Offered Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to
purchase does not exceed 10% of the aggregate number of the Offered Securities to be purchased on such date, the Representatives may make
arrangements satisfactory to the Company for the purchase of such Offered Securities by other persons, including any of the Underwriters,
but if no such arrangements are made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions
that the number of Firm Securities set forth opposite their respective names on <U>Schedule A</U> bears to the aggregate number of Firm
Securities set forth opposite the names of all such non-defaulting Underwriters, or in such other proportions as may be specified by the
Representatives with the consent of the non-defaulting Underwriters, to purchase the Offered Securities which such defaulting Underwriter
or Underwriters agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one
or more of the Underwriters shall fail or refuse to purchase Offered Securities and the aggregate number of Offered Securities with respect
to which such default occurs exceeds 10% of the aggregate number of Offered Securities to be purchased on such date, and arrangements
satisfactory to the Representatives and the Company for the purchase of such Offered Securities are not made within 48 hours after such
default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section&nbsp;4,
Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 of this Agreement shall at all times be effective and shall survive such termination.
In any such case either the Representatives or the Company shall have the right to postpone the First Closing Date or the applicable Option
Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration
Statement and the Prospectus or any other documents or arrangements may be effected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As used in this Agreement, the term &ldquo;<B>Underwriter</B>&rdquo;
shall be deemed to include any person substituted for a defaulting Underwriter under this &lrm;Section&nbsp;11. Any action taken under
this &lrm;Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under
this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Termination
of this Agreement</B></FONT><I>.</I> Prior to the purchase of the Firm Securities by the Underwriters on the First Closing Date, this
Agreement may be terminated by the Representatives by notice given to the Company if at any time: (i)&nbsp;trading or quotation in any
of the Company&rsquo;s securities shall have been suspended or limited by the Commission or by Nasdaq, or trading in securities generally
on either Nasdaq or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established
on any of such stock exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, Massachusetts or New
York authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any crisis
or calamity, or any change in the United States or international financial markets, or any substantial change or development involving
a prospective substantial change in United States&rsquo; or international political, financial or economic conditions, as in the judgment
of the Representatives is material and adverse and makes it impracticable to market the Offered Securities in the manner and on the terms
described in the Time of Sale Prospectus or the Prospectus or to enforce contracts for the sale of securities; (iv)&nbsp;in the judgment
of the Representatives there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike,
fire, flood, earthquake, accident or other calamity of such character as in the judgment of the Representatives may interfere materially
with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination
pursuant to this Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company to any Underwriter, except that the Company
shall be obligated to reimburse the expenses of the Representatives and the Underwriters pursuant to Section&nbsp;4 or Section&nbsp;7
hereof or (b)&nbsp;any Underwriter to the Company; <I>provided, however,</I> that the provisions of Section&nbsp;9 and Section&nbsp;10
of this Agreement shall at all times be effective and shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;No
Advisory or Fiduciary Relationship. </B></FONT>The Company acknowledges and agrees that (a)&nbsp;the purchase and sale of the Offered
Securities pursuant to this Agreement, including the determination of the public offering price of the Offered Securities and any related
discounts and commissions, is an arm&rsquo;s-length commercial transaction between the Company, on the one hand, and the several Underwriters,
on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the process leading to such transaction, each Underwriter
is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, creditors, employees
or any other party, (c)&nbsp;no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company
with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised
or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company with respect to the offering
contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates
may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e)&nbsp;the Underwriters
have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has
consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Representations
and Indemnities to Survive Delivery</B></FONT><I>.</I> The respective indemnities, agreements, representations, warranties and other statements
of the Company, of its officers and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force
and effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or any of its or their partners, officers
or directors or any controlling person, as the case may be, and, anything herein to the contrary notwithstanding, will survive delivery
of and payment for the Offered Securities sold hereunder and any termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notices</B></FONT>.
All communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto
as follows:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Representatives:</FONT></TD>
    <TD STYLE="width: 65%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TD Securities (USA) LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1 Vanderbilt Avenue</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10017</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Head of Equity Capital Markets; General Counsel</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Facsimile: 646-562-1249</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CIBLegal@tdsecurities.com</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Piper Sandler&nbsp;&amp; Co.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">350 North 5th Street, Suite&nbsp;1000</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Minneapolis, MN 55401</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Equity Capital Markets; General Counsel</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Facsimile: (612) 303-1070</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LegalCapMarkets@psc.com</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guggenheim Securities, LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">330 Madison Avenue</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10017</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Head of Equity Capital Markets</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy to:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">One Financial Center </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boston, MA 02111 </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: John T. Rudy; Nishant Dharia</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If to the Company:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Praxis Precision Medicines,&nbsp;Inc.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99 High Street, 30<SUP>th</SUP></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif">Floor</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boston, MA 02110</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention: Chief Financial Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">with a copy to:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Latham&nbsp;&amp; Watkins LLP </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">200 Clarendon Street </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 36.25pt">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, MA 02116</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Attention: Peter N. Handrinos; Wesley C. Holmes; Jennifer Yoon</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any party hereto may change the address for receipt of communications
by giving written notice to the others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Successors</B></FONT><I>.</I>
This Agreement will inure to the benefit of and be binding upon the parties hereto, including any substitute Underwriters pursuant to
Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred
to in Section&nbsp;9 and Section&nbsp;10 hereof, and in each case their respective successors, and no other person will have any right
or obligation hereunder. The term &ldquo;<B>successors</B>&rdquo; shall not include any purchaser of the Offered Securities as such from
any of the Underwriters merely by reason of such purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Partial
Unenforceability</B></FONT>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement shall not affect
the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement
is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor
changes) as are necessary to make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><B>Section&nbsp;18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Recognition
of the U.S. Special Resolution Regimes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT>In
the event that any Underwriter that is a Covered Entity (as defined below) becomes subject to a proceeding under a U.S. Special Resolution
Regime (as defined below), the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement,
will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and
any such interest and obligation, were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt"><B>(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT>In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate (as defined below) of such Underwriter becomes subject
to a proceeding under a U.S. Special Resolution Regime, Default Rights (as defined below) under this Agreement that may be exercised against
such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special
Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of this Agreement, (A)&nbsp;&ldquo;<B>BHC Act Affiliate</B>&rdquo;
has the meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k);
(B)&nbsp;&ldquo;<B>Covered Entity</B>&rdquo; means any of the following: (i)&nbsp;a &ldquo;covered entity&rdquo; as that term is defined
in, and interpreted in accordance with, 12 C.F.R. &sect; 252.82(b); (ii)&nbsp;a &ldquo;covered bank&rdquo; as that term is defined in,
and interpreted in accordance with, 12 C.F.R. &sect; 47.3(b); or (iii)&nbsp;a &ldquo;covered FSI&rdquo; as that term is defined in, and
interpreted in accordance with, 12 C.F.R. &sect; 382.2(b); (C)&nbsp;&ldquo;<B>Default Right</B>&rdquo; has the meaning assigned to that
term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable; and (D)&nbsp;&ldquo;<B>U.S.
Special Resolution Regime</B>&rdquo; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated thereunder
and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Governing
Law Provisions</B></FONT><I>.</I> This Agreement shall be governed by and construed in accordance with the internal laws of the State
of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising out of or based
upon this Agreement or the transactions contemplated hereby (&ldquo;<B>Related Proceedings</B>&rdquo;) may be instituted in the federal
courts of the United States of America located in the Borough of Manhattan in the City of New York or the courts of the State of New York
in each case located in the Borough of Manhattan in the City of New York (collectively, the &ldquo;<B>Specified Courts</B>&rdquo;), and
each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment
of any such court (a &ldquo;<B>Related Judgment</B>&rdquo;), as to which such jurisdiction is non-exclusive) of such courts in any such
suit, action or proceeding. Service of any process, summons, notice or document by mail to such party&rsquo;s address set forth above
shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and
unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably
and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in
any such court has been brought in an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-size: 10pt"><B>Section&nbsp;20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;General
Provisions.</B></FONT> This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written
or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement
may be executed in two or more counterparts, each one of which shall be an original, with the same effect as if the signatures thereto
and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto,
and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit.
The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Electronic signatures complying with the New York
Electronic Signatures and Records Act (N.Y. State Tech. &sect;&sect; 301-309), as amended from time to time, or other applicable law will
be deemed original signatures for purposes of this Agreement. Transmission by telecopy, electronic mail or other transmission method of
an executed counterpart of this Agreement will constitute due and sufficient delivery of such counterpart.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each of the parties hereto acknowledges that it
is a sophisticated business person who was adequately represented by counsel during negotiations regarding the provisions hereof, including,
without limitation, the indemnification provisions of &lrm;Section&nbsp;9 and the contribution provisions of &lrm;Section&nbsp;10 hereof,
and is fully informed regarding said provisions. Each of the parties hereto further acknowledges that the provisions of &lrm;Section&nbsp;9
and &lrm;Section&nbsp;10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs
and its business in order to assure that adequate disclosure has been made in the Registration Statement, any preliminary prospectus,
the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as
contemplated by the Securities Act and the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the foregoing is in accordance with your understanding
of our agreement, kindly sign and return to the Company the enclosed copies hereof, whereupon this instrument, along with all counterparts
hereof, shall become a binding agreement in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRAXIS PRECISION MEDICINES,&nbsp;INC.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Timothy Kelly</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Timothy Kelly</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing Underwriting Agreement is hereby
confirmed and accepted by the Representatives in New York, New York as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TD SECURITIES (USA) LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PIPER SANDLER&nbsp;&amp; CO.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>GUGGENHEIM SECURITIES, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Acting individually and as Representatives</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">of the several Underwriters named in</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">the attached <U>Schedule A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>TD Securities (USA) LLC</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Mariel Healy</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Mariel Healy</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Director</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PIPER SANDLER&nbsp;&amp; CO.</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul Scansaroli</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Paul Scansaroli</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Director</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GUGGENHEIM SECURITIES, LLC</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Ronald Gerber</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Ronald Gerber</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Senior Managing Director</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Schedule A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Underwriters</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR> Firm Shares <BR> to be <BR> Purchased</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of <BR> Pre-Funded <BR> Warrants <BR> to be Purchased</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 61%; font: 10pt Times New Roman, Times, Serif; text-align: left">TD Securities (USA) LLC</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font: 10pt Times New Roman, Times, Serif; text-align: right">937,899</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font: 10pt Times New Roman, Times, Serif; text-align: right">98,726</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Piper Sandler&nbsp;&amp; Co.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">937,899</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">98,726</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Guggenheim Securities, LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">574,842</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">60,510</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Truist Securities,&nbsp;Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">332,802</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">35,032</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Oppenheimer&nbsp;&amp; Co. Inc.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">121,019</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,738</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">H.C. Wainwright&nbsp;&amp; Co., LLC</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">121,019</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,738</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Total</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">3,025,480</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: bold 10pt Times New Roman, Times, Serif; text-align: right">318,470</TD><TD STYLE="padding-bottom: 2.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Schedule B-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Pricing Terms</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. The Company is selling 3,025,480 Firm Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. The Company is selling Pre-Funded Warrants to purchase up to 318,470
shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. The Company has granted an option to the Underwriters, severally
and not jointly, to purchase up to 501,592 Optional Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. The public offering price per share for the Shares shall be $157.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. The public offering price per Pre-Funded Warrant shall be $156.9999.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. The exercise price per Pre-Funded Warrant shall be $0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Schedule B-2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Free Writing Prospectuses Included in the
Time of Sale Prospectus</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form&nbsp;of Pre-Funded Warrant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Praxis Precision Medicines,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRAXIS PRECISION MEDICINES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF PRE-FUNDED WARRANT TO PURCHASE
COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number of Shares: [ ] (subject to adjustment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant No.&nbsp;[ ]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Original&nbsp;Issue&nbsp;Date:&nbsp;October&nbsp;20, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Praxis Precision Medicines,&nbsp;Inc.,</FONT>
a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), hereby certifies that, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, [&nbsp;&nbsp;&nbsp;&nbsp;] or its registered assigns (the &ldquo;<B>Holder</B>&rdquo;),
is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [&nbsp;&nbsp;&nbsp;&nbsp;] shares of
common stock, $0.0001 par value per share (the &ldquo;<B>Common Stock</B>&rdquo;), of the Company (each such share, a &ldquo;<B>Warrant
Share</B>&rdquo; and all such shares, the &ldquo;<B>Warrant Shares</B>&rdquo;) at an exercise price per share equal to $0.0001 per share
(as adjusted from time to time as provided in <U>Section&nbsp;9</U> herein, the &ldquo;<B>Exercise Price</B>&rdquo;), upon surrender of
this Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof,
the &ldquo;<B>Warrant</B>&rdquo;) at any time and from time to time on or after the date hereof (the &ldquo;<B>Original Issue Date</B>&rdquo;),
subject to the following terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. <I>Definitions</I>. For purposes of this Warrant, the following
terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;&ldquo;<B>Affiliate</B>&rdquo; means
any Person directly or indirectly controlled by, controlling or under common control with, a Holder, but only for so long as such control
shall continue. For purposes of this definition, &ldquo;control&rdquo; (including, with correlative meanings, &ldquo;controlled by&rdquo;,
 &ldquo;controlling&rdquo; and &ldquo;under common control with&rdquo;) means, with respect to a Person, possession, direct or indirect,
of (a)&nbsp;the power to direct or cause direction of the management and policies of such Person (whether through ownership of securities
or partnership or other ownership interests, by contract or otherwise), or (b)&nbsp;at least 50% of the voting securities (whether directly
or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;&ldquo;<B>Attribution Parties</B>&rdquo;
means, collectively, the following Persons and entities: (i)&nbsp;any direct or indirect Affiliates of the Holder, (ii)&nbsp;any Person
acting or who could be deemed to be acting as a Section&nbsp;13(d)&nbsp;&ldquo;group&rdquo; together with the Holder or any Attribution
Parties and (iii)&nbsp;any other Persons whose beneficial ownership of the Company&rsquo;s Common Stock would or could be aggregated with
the Holder&rsquo;s and/or any other Attribution Parties for purposes of Section&nbsp;13(d)&nbsp;or Section&nbsp;16 of the Exchange Act.
For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;&ldquo;<B>Commission</B>&rdquo; means
the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)&nbsp;&ldquo;<B>Closing Sale Price</B>&rdquo;
means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported
by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate
the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial
Markets, or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin
board for such security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot be calculated for a security on a
particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as
mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such
security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of
Directors&rsquo; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately
adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(e)&nbsp;&ldquo;<B>Exchange Act</B>&rdquo; means
the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f)&nbsp;&ldquo;<B>Group</B>&rdquo; shall have
the meaning ascribed to it in Section&nbsp;13(d)&nbsp;of the Exchange Act, and all related rules, regulations and jurisprudence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in">(f)&nbsp;&ldquo;<B>Person</B>&rdquo; means an
individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other
entity and a government or any department or agency thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(g)&nbsp;&ldquo;<B>Principal Trading Market</B>&rdquo;
means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading,
which, as of the Original Issue Date, shall be the Nasdaq Global Select Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(h)&nbsp;&ldquo;<B>Registration Statement</B>&rdquo;
means the Company&rsquo;s Registration Statement on Form&nbsp;S-3ASR (File No.&nbsp;333-284016), which was automatically effective when
filed on December&nbsp;23, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(i)&nbsp;&ldquo;<B>Securities Act</B>&rdquo; means
the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(j)&nbsp;&ldquo;<B>Standard Settlement Period</B>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, for the Principal Trading Market with respect to the Common
Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Issuance Date was &ldquo;T+1.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(k)&nbsp;&ldquo;<B>Trading Day</B>&rdquo; means
any weekday on which the Principal Trading Market is normally open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(l)&nbsp;&ldquo;<B>Transfer Agent</B>&rdquo; means
Computershare Trust Company, N.A., the Company&rsquo;s transfer agent and registrar for the Common Stock, and any successor appointed
in such capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. <I>Issuance of Securities; Registration of Warrants</I>. The Warrant,
as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant
Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement
or an exchange meeting the requirements of Section&nbsp;3(a)(9)&nbsp;of the Securities Act as in effect on the Original Issue Date, the
Warrant Shares, are not &ldquo;restricted securities&rdquo; under Rule&nbsp;144 promulgated under the Securities Act. The Company shall
register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<B>Warrant Register</B>&rdquo;),
in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is
permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice
to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. <I>Registration of Transfers</I>. Subject to compliance with all
applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this
Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such
registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &ldquo;<B>New
Warrant</B>&rdquo;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing
the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New
Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of
the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue
and deliver at the Company&rsquo;s own expense any New Warrant under this <U>Section&nbsp;3</U>. Until due presentment for registration
of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be
affected by any notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. <I>Exercise of Warrants</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;All or any part of this Warrant shall
be exercisable by the registered Holder in any manner permitted by this Warrant (including <U>Section&nbsp;11</U>) at any time and from
time to time on or after the Original Issue Date, and such rights shall not expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;The Holder may exercise this Warrant
by delivering to the Company (i)&nbsp;an exercise notice, in the form attached as <U>Schedule 1</U> hereto (the &ldquo;<B>Exercise Notice</B>&rdquo;),
completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being
exercised (which may take the form of a &ldquo;cashless exercise&rdquo; if so indicated in the Exercise Notice pursuant to <U>Section&nbsp;10</U>
below), and the date on which the last of such items is delivered to the Company (as determined in accordance with the notice provisions
hereof) is an <B>&ldquo;Exercise Date</B>.&rdquo; The Holder shall not be required to deliver the original Warrant in order to effect
an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant
and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. <I>Delivery of Warrant Shares</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;Upon exercise of this Warrant, the Company
shall promptly (but in no event later than the number of Trading Days comprising the Standard Settlement Period following the Exercise
Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock specified by the Holder in the Exercise
Notice and to which the Holder is entitled pursuant to such exercise (the &ldquo;<B>Exercise Shares</B>&rdquo;) to the Holder&rsquo;s
or its designee&rsquo;s balance account with The Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;) through its Deposit Withdrawal At
Custodian system, or if the Transfer Agent is then a participant in the DTC Fast Automated Securities Transfer Program (the &ldquo;<B>FAST
Program</B>&rdquo;) and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to
or the resale of such Warrant Shares by the Holder or (B)&nbsp;the Exercise Shares are eligible for resale by the Holder without volume
or manner-of-sale restrictions pursuant to Rule&nbsp;144 promulgated under the Securities Act (assuming cashless exercise of this Warrant).
If the Transfer Agent is not a member of the FAST Program or if (A)&nbsp;and (B)&nbsp;above are not true, the Transfer Agent will either
(i)&nbsp;record the Exercise Shares in the name of the Holder or its designee on the certificates reflecting the Exercise Shares with
an appropriate legend regarding restriction on transferability, which shall be issued and dispatched by overnight courier to the address
as specified in the Exercise Notice, and on the Company&rsquo;s share register or (ii)&nbsp;issue such Exercise Shares in the name of
the Holder or its designee in restricted book-entry form in the Company&rsquo;s share register. The Holder, or any natural person or legal
entity (each, a &ldquo;<B>Person</B>&rdquo;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the
holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&rsquo;s
DTC account, the date of the book entry positions or the date of delivery of the certificates evidencing such Exercise Shares, as the
case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;If the Company fails to deliver to the
Holder or its designee Exercise Shares in the manner required pursuant to <U>Section&nbsp;5(a)</U>&nbsp;within the Standard Settlement
Period following the Exercise Date and the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<B>Buy-In</B>&rdquo;)
but did not receive within the Standard Settlement Period, then the Company shall, within two (2)&nbsp;Trading Days after the Holder&rsquo;s
request and in the Holder&rsquo;s sole discretion, either (1)&nbsp;pay in cash to the Holder an amount equal to the Holder&rsquo;s total
purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company&rsquo;s
obligation to issue and deliver such Exercise Shares shall terminate or (2)&nbsp;promptly honor its obligation to deliver to the Holder
or its designee the Exercise Shares pursuant to <U>Section&nbsp;5(a)</U>&nbsp;and pay cash to the Holder in an amount equal to the excess
(if any) of Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased
in the Buy-In, less the product of (A)&nbsp;the number of shares of Common Stock purchased in the Buy-In, times (B)&nbsp;the Closing Sale
Price of a share of Common Stock on the Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;To the extent permitted by law and subject
to <U>Section&nbsp;5(b)</U>, the Company&rsquo;s obligations to issue and deliver Warrant Shares in accordance with and subject to the
terms hereof (including the limitations set forth in <U>Section&nbsp;11</U> below) are absolute and unconditional, irrespective of any
action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any
judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or
any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation
of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the
Company to the Holder in connection with the issuance of Warrant Shares. Subject to <U>Section&nbsp;5(b)</U>, nothing herein shall limit
the Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a
decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common
Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. <I>Charges, Taxes and Expenses</I>. Issuance and delivery for shares
of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent
fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of
which taxes and expenses shall be paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay
any tax that may be payable in respect of any transfer involved in the registration of any Warrant Shares or the Warrants in a name other
than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result
of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost,
stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in
lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction (in such case) and, in each case, a customary and reasonable contractual indemnity, if requested by the
Company. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant
to the Company as a condition precedent to the Company&rsquo;s obligation to issue the New Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8. <I>Reservation of Warrant Shares</I>. The Company covenants that
it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued
and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as
herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free
from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and
restrictions of <U>Section&nbsp;9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance
and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully
paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock
may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange
or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior
written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant
Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this <U>Section&nbsp;9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;<U>Stock Dividends and Splits</U>. If
the Company, at any time while this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution
on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the
Original Issue Date or as amended, that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock
into a larger number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of shares
of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company,
then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common
Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding
immediately after such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after
the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such
record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed
accordingly as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph
as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii)&nbsp;of this paragraph shall
become effective immediately after the effective date of such subdivision or combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;<U>Pro Rata Distributions</U>. If, on
or after the Original Issue Date, the Company shall declare or make any dividend or other pro rata distribution of its assets (or rights
to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property, options, evidence of indebtedness or any other assets by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction, but, for the avoidance of doubt,
excluding any distribution of shares of Common Stock subject to <U>Section&nbsp;9(a)</U>, any distribution of Purchase Rights (as defined
below) subject to <U>Section&nbsp;9(c)</U>&nbsp;and any Fundamental Transaction (as defined below) subject to <U>Section&nbsp;9(d))</U>
(a &ldquo;<B>Distribution</B>&rdquo;) then, in each such case, the Holder shall be entitled to participate in such Distribution to the
same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation,
the Maximum Percentage (as defined below)) immediately before the date on which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such
Distribution (provided, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution
to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and
beneficial ownership) to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage,
at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution
or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;<U>Purchase Rights</U>. If at any time
on or after the Original Issue Date, the Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock,
warrants, securities or other property, in each case pro rata to the record holders of any class of Common Stock (the &ldquo;<B>Purchase
Rights</B>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase
Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum
Percentage) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no
such record is taken, the date as of which the record holders of Common Stock are to be determined for the grant, issuance or sale of
such Purchase Rights (provided, that to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result
in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of such Common Stock as a result of such Purchase
Right (and beneficial ownership) to such extent) and such Purchase Right to such extent shall be held in abeyance for the benefit of the
Holder until such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum
Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial
Purchase Right or on any subsequent Purchase Right to be held similarly in abeyance) to the same extent as if there had been no such limitation).
As used in this <U>Section&nbsp;9(c)</U>, (i)&nbsp;&ldquo;<B>Options</B>&rdquo; means any rights, warrants or options to subscribe for
or purchase shares of Common Stock or Convertible Securities and (ii)&nbsp;&ldquo;<B>Convertible Securities</B>&rdquo; mean any stock
or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)&nbsp;<U>Fundamental Transactions</U>. If,
at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or consolidation of the Company with or into another
Person, in which the Company is not the surviving entity or in which the stockholders of the Company immediately prior to such merger
or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger
or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one or a series
of related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders
of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such
other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person
whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction
in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting
power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any reclassification of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or
property (other than as a result of a subdivision or combination of shares of Common Stock covered by <U>Section&nbsp;9(a)</U>&nbsp;above)
(in any such case, a &ldquo;<B>Fundamental Transaction</B>&rdquo;), then following such Fundamental Transaction the Holder shall have
the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled
to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the
holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise
contained herein (the &ldquo;<B>Alternate Consideration</B>&rdquo;). The Company shall not effect any Fundamental Transaction in which
the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate
Consideration is solely cash and the Company provides for the simultaneous &ldquo;cashless exercise&rdquo; of this Warrant pursuant to
<U>Section&nbsp;10</U> below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving
entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate
Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under
this Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction
type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)&nbsp;<U>Number of Warrant Shares</U>. Simultaneously
with any adjustment to the Exercise Price pursuant to <U>Section&nbsp;9</U>, the number of Warrant Shares that may be purchased upon exercise
of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder
for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior
to such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(e)&nbsp;<U>Calculations</U>. All calculations
under this <U>Section&nbsp;9</U> shall be made to the nearest one-tenth of one cent or the nearest share, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f)&nbsp;<U>Notice of Adjustments</U>. Upon the
occurrence of each adjustment pursuant to this <U>Section&nbsp;9</U>, the Company at its expense will, at the written request of the Holder,
promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth
such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities
issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail
the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate
to the Holder and to the Company&rsquo;s transfer agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(g)&nbsp;<U>Notice of Corporate Events</U>. If,
while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other distribution of cash, securities or other property
in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital
stock of the Company or any subsidiary, (ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder
approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs
of the Company, then the Company shall deliver to the Holder a notice of such transaction at least ten (10)&nbsp;days prior to the applicable
record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction;
provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action
required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters
into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <U>Section&nbsp;9(c)</U>,
other than a Fundamental Transaction under clause (iii)&nbsp;of <U>Section&nbsp;9(c)</U>, the Company shall deliver to the Holder a notice
of such Fundamental Transaction at least thirty (30)&nbsp;days prior to the date such Fundamental Transaction is consummated. Holder agrees
to maintain any information disclosed pursuant to this <U>Section&nbsp;9(g)</U>&nbsp;in confidence until such information is publicly
available, and shall comply with applicable law with respect to trading in the Company&rsquo;s securities following receipt any such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10. <I>Payment of Exercise Price</I>. Notwithstanding anything contained
herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a &ldquo;cashless
exercise&rdquo;, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected
pursuant to Section&nbsp;3(a)(9)&nbsp;of the Securities Act, as determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">X = Y [(A-B)/A]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;X&rdquo; equals the number of Warrant Shares
to be issued to the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;Y&rdquo; equals the total number of Warrant
Shares with respect to which this Warrant is then being exercised;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;A&rdquo; equals the Closing Sale Prices
of the shares of Common Stock (as reported by Bloomberg Financial Markets) as of the Trading Day on the date immediately preceding the
Exercise Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;B&rdquo; equals the Exercise Price then
in effect for the applicable Warrant Shares at the time of such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of Rule&nbsp;144 promulgated under the Securities Act,
it is intended, understood and acknowledged that the Warrant Shares issued in a &ldquo;cashless exercise&rdquo; transaction shall be deemed
to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this
Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of
such exercise). In the event that the Registration Statement or another registration statement registering the issuance of Warrant Shares
is, for any reason, not effective at the time of exercise of this Warrant, then the Warrant may only be exercised through a cashless exercise,
as set forth in this <U>Section&nbsp;10</U>. Except as set forth in <U>Section&nbsp;5(b)</U>&nbsp;(Buy-In remedy) and <U>Section&nbsp;12</U>
(payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be settled in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11. <I>Limitations on Exercise</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;Notwithstanding anything to the contrary
contained herein, the Company shall not effect the exercise of any portion of this Warrant, and the Holder of the Warrant shall not have
the right to exercise any portion of the Warrant, and any such exercise shall be null and void ab initio and treated as if the exercise
had not been made, to the extent that immediately prior to or following such exercise, the Holder, together with the Attribution Parties,
beneficially owns or would beneficially own as determined in accordance with Section&nbsp;13(d)&nbsp;of the s Exchange Act and the rules&nbsp;promulgated
thereunder, in excess of [4.99%][9.99%] (the &ldquo;<B>Maximum Percentage</B>&rdquo;) of the Common Stock that would be issued and outstanding
following such exercise. For purposes of calculating beneficial ownership for determining whether the Maximum Percentage is or will be
exceeded, the aggregate number of shares of Common Stock held and/or beneficially owned by the Holder together with the Attribution Parties,
shall include the number of shares of Common Stock held and/or beneficially owned by the Holder together with the Attribution Parties
plus the number of shares of Common Stock issuable upon exercise of the relevant Warrant with respect to which the determination is being
made but shall exclude the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, unexercised
Warrant held and/or beneficially owned by the Holder or the Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or unconverted portion of any other securities of the Company held and/or beneficially owned by such Holder or any Attribution Party (including,
without limitation, any convertible notes, convertible stock or warrants) that are subject to a limitation on conversion or exercise analogous
to the limitation contained herein. For purposes of this Paragraph 11(a), beneficial ownership of the Holder or the Attribution Parties
shall, except as set forth in the immediately preceding sentence, be calculated and determined in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;promulgated thereunder. For purposes of the Warrant, in determining the number of outstanding shares
of Common Stock, a Holder of the Warrant may rely on the number of outstanding shares of Common Stock as reflected in (1)&nbsp;the Company&rsquo;s
most recent Form&nbsp;10-K, Form&nbsp;10-Q, Current Report on Form&nbsp;8-K or other public filing with the Securities and Exchange Commission,
as the case may be, (2)&nbsp;a more recent public announcement by the Company or (3)&nbsp;any other notice by the Company or the Company&rsquo;s
transfer agent setting forth the number of shares of Common Stock outstanding (such issued and outstanding shares, the &ldquo;<B>Reported
Outstanding Share Number</B>&rdquo;). For any reason at any time, upon the written or oral request of the Holder, the Company shall within
one (1)&nbsp;Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then
outstanding. The Holder shall disclose to the Company the number of shares of Common Stock that it, together with the Attribution Parties
holds and/or beneficially owns and has the right to acquire through the exercise of derivative securities and any limitations on exercise
or conversion analogous to the limitation contained herein contemporaneously or immediately prior to submitting an Exercise Notice for
the relevant Warrant. If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares
of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i)&nbsp;notify the Holder in writing of the number
of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder&rsquo;s, together
with the Attribution Parties&rsquo;, beneficial ownership, as determined pursuant to this <U>Section&nbsp;11(a)</U>, to exceed the Maximum
Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice
(the number of shares by which such purchase is reduced, the &ldquo;<B>Reduction Shares</B>&rdquo;) and (ii)&nbsp;as soon as reasonably
practicable, the Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by the Holder and the Attribution Parties since the date as of which the Reported Outstanding Share Number was
reported. In the event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the Holder, together with
the Attribution Parties, being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding
shares of Common Stock (as determined under Section&nbsp;13(d)&nbsp;of the Exchange Act), the number of shares so issued by which the
Holder&rsquo;s, together with the Attribution Parties&rsquo;, aggregate beneficial ownership exceeds the Maximum Percentage (the &ldquo;<B>Excess
Shares</B>&rdquo;) shall be deemed null and void and shall be cancelled ab initio, and the Holder and/or the Attribution Parties shall
not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares
has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. By
written notice to the Company, a Holder of the Warrant may from time to time increase or decrease the Maximum Percentage to any other
percentage not in excess of 19.99% specified in such notice; provided that any increase in the Maximum Percentage will not be effective
until the sixty-first (61st) day after such notice is delivered to the Company and shall not negatively affect any partial exercise effected
prior to such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;This <U>Section&nbsp;11</U> shall not
restrict the number of shares of Common Stock which a Holder or the Attribution Parties may receive or beneficially own in order to determine
the amount of securities or other consideration that such Holder or the Attribution Parties may receive in the event of a Fundamental
Transaction as contemplated in <U>Section&nbsp;9(c)</U>&nbsp;of this Warrant. For purposes of clarity, the shares of Common Stock issuable
pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder or
the Attribution Parties for any purpose including for purposes of Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;promulgated
thereunder or Section&nbsp;16 of the Exchange Act Rule&nbsp;16a-1(a)(1)&nbsp;promulgated thereunder. No prior inability to exercise this
Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any
subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this <U>Section&nbsp;11(a)</U>&nbsp;to the extent necessary to correct this paragraph or any
portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this <U>Section&nbsp;11(a)</U>&nbsp;or
to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph
may not be waived and shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will
be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number
of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market
value (based on the Closing Sale Price) for any such fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13. <I>Notices</I>. Any and all notices or other communications or
deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective
on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered confirmed e-mail at the e-mail address
specified in the books and records of the Transfer Agent prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next
Trading Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail at the e-mail address specified
in the books and records of the Transfer Agent on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any
Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying
next business day delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14. <I>Warrant Agent</I>. The Company shall initially serve as warrant
agent under this Warrant. Upon thirty (30)&nbsp;days&rsquo; notice to the Holder, the Company may appoint a new warrant agent. Any corporation
into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company
or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all
of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act.
Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage
prepaid) to the Holder at the Holder&rsquo;s last address as shown on the Warrant Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">15. <I>Miscellaneous</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;<U>No Rights as a Stockholder</U>. Except
as otherwise set forth in this Warrant, the Holder, solely in such Person&rsquo;s capacity as a holder of this Warrant, shall not be entitled
to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose (except to the extent the Holder
is required to be deemed a holder of the Warrant Shares for tax purposes under applicable tax law), nor shall anything contained in this
Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity as the Holder of this Warrant, any of the rights
of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue
of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive
dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled
to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities
on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;<U>Authorized Shares</U>. (i)&nbsp;Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may
be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company will (a)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such
exercise immediately prior to such increase in par value, (b)&nbsp;take all such action as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (c)&nbsp;use
commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof as may be necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ii)&nbsp;Before taking any action which would result in an adjustment
in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations
or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;<U>Successors and Assigns</U>. Subject
to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company
without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding
on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence,
nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy
or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors
and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)&nbsp;<U>Amendment and Waiver</U>. Except as
otherwise provided herein, the provisions of the Warrants may be amended and the Company may take any action herein prohibited, or omit
to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(e)&nbsp;<U>Acceptance</U>. Receipt of this Warrant
by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f)&nbsp;<U>Governing Law; Jurisdiction</U>. ALL
QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND
ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE
COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF
NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED
HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES,
AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH
COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN
ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF
DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT
SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY
MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(g)&nbsp;<U>Headings</U>. The headings herein
are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(h)&nbsp;<U>Severability</U>. In case any one
or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining
terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt
in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so
agreeing, shall incorporate such substitute provision in this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">IN WITNESS WHEREOF, the Company has caused this
Warrant to be duly executed by its authorized officer as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD COLSPAN="2"><B>PRAXIS PRECISION MEDICINES,&nbsp;INC.</B> <B>&nbsp;</B></TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
<TD STYLE="width: 5%">&nbsp;</TD>
<TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF EXERCISE NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[To be executed by the Holder to purchase shares
of Common Stock under the Warrant]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;The undersigned is the Holder of Warrant No.&nbsp;__ (the
 &ldquo;<B>Warrant</B>&rdquo;) issued by Praxis Precision Medicines,&nbsp;Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;).
Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2)&nbsp;The undersigned hereby exercises its right to purchase Warrant
Shares pursuant to the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3)&nbsp;The Holder intends that payment of the Exercise Price shall
be made as (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Exercise </FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Cashless Exercise&rdquo; under Section</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;10 of the Warrant </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">(4)&nbsp;If the Holder has elected a Cash Exercise, the Holder shall
pay the sum of $__ in immediately available funds to the Company in accordance with the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(5)&nbsp;Pursuant to this Exercise Notice, the Company shall deliver
to the Holder Warrant Shares determined in accordance with the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(6)&nbsp;By its delivery of this Exercise Notice, the undersigned represents
and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the
number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d)&nbsp;of the Securities Exchange Act of 1934, as
amended) permitted to be owned under Section&nbsp;11(a)&nbsp;of the Warrant to which this notice relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt; width: 42%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name&nbsp;of&nbsp;Holder:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Signature must conform in all respects to name
of Holder as specified on the face of the Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form&nbsp;of Lock-Up Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Praxis Precision Medicines,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[see attached]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form&nbsp;of Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">October&nbsp;16, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">TD Securities (USA) LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Piper Sandler&nbsp;&amp; Co.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guggenheim Securities, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">As representatives of the underwriters named</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">in Schedule A to the Underwriting Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">referred to below</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in">c/o</TD>
<TD STYLE="text-align: justify">TD Securities (USA) LLC</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">1 Vanderbilt Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">New York, NY 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">c/o</FONT></TD><TD STYLE="text-align: justify">Piper Sandler&nbsp;&amp; Co.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">350 North 5th Street, Suite&nbsp;1000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Minneapolis, MN 55401</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: justify; width: 0.25in">c/o</TD>
                                                                                    <TD STYLE="text-align: justify">Guggenheim Securities, LLC</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">330 Madison Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">New York, NY 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Sirs and Madams:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">As an inducement to the underwriters
(the &ldquo;<B><I>Underwriters</I></B>&rdquo;) to execute an underwriting agreement (the &ldquo;<B><I>Underwriting Agreement</I></B>&rdquo;)
providing for a public offering (the &ldquo;<B><I>Offering</I></B>&rdquo;) of securities, including shares of common stock (the &ldquo;<B><I>Common
Stock</I></B>&rdquo;) and/or pre-funded warrants to purchase Common Stock, of Praxis Precision Medicines,&nbsp;Inc. and any successor
(by merger or otherwise) thereto (the &ldquo;<B><I>Company</I></B>&rdquo;), the undersigned hereby agrees that without, in each case,
the prior written consent of TD Securities (USA) LLC and Piper Sandler&nbsp;&amp; Co. (collectively, with Guggenheim Securities, LLC,
the &ldquo;<B><I>Representatives</I></B>&rdquo;) during the period specified in the second succeeding paragraph (the &ldquo;<B><I>Lock-Up
Period</I></B>&rdquo;), the undersigned will not: (1)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell
any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, make any
short sale or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into,
exercisable or exchangeable for or that represent the right to receive Common Stock (including without limitation, Common Stock which
may be deemed to be beneficially owned by the undersigned in accordance with the rules&nbsp;and regulations of the Securities and Exchange
Commission and securities which may be issued upon exercise of a stock option or warrant) whether now owned or hereafter acquired (the
 &ldquo;<B><I>Undersigned&rsquo;s Securities</I></B>&rdquo;); (2)&nbsp;enter into any swap or other agreement that transfers, in whole
or in part, any of the economic consequences of ownership of the Undersigned&rsquo;s Securities, whether any such transaction described
in clause (1)&nbsp;or (2)&nbsp;above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise; (3)&nbsp;make
any demand for or exercise any right with respect to, the registration of any Common Stock or any security convertible into or exercisable
or exchangeable for Common Stock; or (4)&nbsp;publicly disclose the intention to do any of the foregoing.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned agrees that
the foregoing restrictions preclude the undersigned from engaging in any hedging or other transaction which is designed to or which reasonably
could be expected to lead to or result in a sale or disposition of the Undersigned&rsquo;s Securities even if such Securities would be
disposed of by someone other than the undersigned. Such prohibited hedging or other transactions would include without limitation any
short sale or any purchase, sale or grant of any right (including without limitation any put or call option) with respect to any of the
Undersigned&rsquo;s Securities or with respect to any security that includes, relates to, or derives any significant part of its value
from the Undersigned&rsquo;s Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Lock-Up Period will commence
on the date of this Agreement and continue and include the date 30 days after the date of the final prospectus used to sell securities
of the Company in the Offering pursuant to the Underwriting Agreement.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Notwithstanding
the foregoing, the undersigned may transfer the Undersigned&rsquo;s Securities (i)&nbsp;as a <I>bona fide</I> gift or gifts, (ii)&nbsp;to
any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, (iii)&nbsp;if the undersigned
is a corporation, partnership, limited liability company, trust or other business entity (1)&nbsp;to another corporation, partnership,
limited liability company, trust or other business entity that is a direct or indirect affiliate (as defined in Rule&nbsp;405 promulgated
under the Securities Act of 1933, as amended) of the undersigned, (2)&nbsp;in distributions of shares of Common Stock or any security
convertible into or exercisable for Common Stock to limited partners, limited liability company members or stockholders of the undersigned,
or (3)&nbsp;in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&rsquo;s
capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially
all of the undersigned&rsquo;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this Agreement,
(iv)&nbsp;if the undersigned is a trust, to the beneficiaries of such trust, (v)&nbsp;by testate succession or intestate succession or
pursuant to a court order or order of a regulatory agency, (vi)&nbsp;acquired in the Offering or in open market transactions after completion
of the Offering; </FONT>provided that no filing under Section&nbsp;16(a)&nbsp;of the Securities Exchange Act of 1934, as amended (the
 &ldquo;<B><I>Exchange Act</I></B>&rdquo;) reporting a reduction in beneficial ownership of shares of Common Stock shall be required or
shall be voluntarily made during the Lock-Up Period, (vii)&nbsp;to the Company pursuant to agreements under which the Company has the
option to repurchase such shares or securities upon termination of the undersigned, (viii)&nbsp;solely in connection with the surrender
or forfeiture to the Company of shares of Common Stock in partial or full settlement of any withholding tax obligation of the undersigned
accruing upon the exercise or vesting of any equity award granted pursuant to the Company&rsquo;s equity incentive plans, and (ix)&nbsp;pursuant
to a bona fide third-party tender offer, merger, consolidation or other similar transaction made to all holders of Common Stock involving
a change of control of the Company (including, without limitation, the entry into any lock-up, voting or similar agreement pursuant to
which the undersigned may agree to transfer, sell, tender or otherwise dispose of Common Stock or other such securities in favor of any
such transaction, or vote any securities in favor of such transaction); <I>provided that</I> all of the Common Stock subject to this Agreement
that is not so transferred, sold, tendered or otherwise disposed of remain subject to this Agreement; and <I>provided further</I> that
in the event that the tender offer, merger, consolidation or other such transaction is not completed, the Common Stock owned by the undersigned
shall remain subject to the restrictions contained in this Agreement. For purposes of this agreement, &ldquo;change of control&rdquo;
shall mean the consummation of (1)&nbsp;any bona fide third-party tender offer approved by the board of directors of the Company, for
any and all of the Company&rsquo;s outstanding voting securities or (2)&nbsp;any merger, consolidation or other similar transaction, in
one transaction or a series of related transactions, in each case, approved by the board of directors of the Company and the result of
which is that any &ldquo;person&rdquo; (as defined in Section&nbsp;13(d)(3)&nbsp;of the Exchange Act), or group of persons, other than
the Company, becomes the beneficial owner (as defined in Rules&nbsp;13d-3 and 13d-5 of the Exchange Act) of 75% of the outstanding voting
securities of the Company; <I>provided that</I>, for the avoidance of doubt, the Offering shall not constitute a change of control; <I>provided,</I>
in the case of clauses (iii)(1)&nbsp;and (2), and (iv), that such transfer shall not involve a disposition for value, and in the case
of clauses, (i)-(v), (x)&nbsp;the transferee agrees in writing with the Underwriters to be bound by the terms of this Lock-Up Agreement,
unless prohibited by an order of court, and (y)&nbsp;no public announcement or filing is voluntarily made regarding such transfer during
the Lock-Up Period and if the undersigned is required to file a report under Section&nbsp;16(a)&nbsp;of the Exchange Act, reporting a
reduction in beneficial ownership of shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common
Stock during the Lock-Up Period, the undersigned shall include a statement in such report describing the reason for such reduction. For
purposes of this Agreement, &ldquo;immediate family&rdquo; shall mean any relationship by blood, marriage or adoption, not more remote
than first cousin. Furthermore, the foregoing restrictions in the first paragraph shall not apply to the sale of shares of Common Stock
pursuant to a written plan, existing as of the date hereof (which, for clarity, shall not be amended during the Lock-Up Period) and provided
to the Representatives as of the date hereof, meeting the requirements of Rule&nbsp;10b5-1(c)&nbsp;under the Exchange Act, if then permitted
by the Company and applicable law; <I>provided that</I> any filing made under the Exchange Act in connection therewith shall state that
such sales were made pursuant to a written plan meeting the requirements of Rule&nbsp;10b5-1(c)&nbsp;under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">In
addition, the foregoing restrictions in the first paragraph shall not apply to (i)&nbsp;the exercise of stock options granted pursuant
to the Company&rsquo;s equity incentive plans </FONT>(which exercises may be effected on a cashless basis to the extent the instruments
representing such options permit exercises on a cashless basis); <I>provided</I> that it shall apply to any of the Undersigned&rsquo;s
Securities issued upon such exercise, or (ii)&nbsp;the establishment of any contract, instruction or plan (a &ldquo;<B><I>Plan</I></B>&rdquo;)
that satisfies all of the requirements of Rule&nbsp;10b5-1(c)(1)(i)(B)&nbsp;under the Exchange Act; <I>provided</I> that no sales of the
Undersigned&rsquo;s Securities shall be made pursuant to such a Plan prior to the expiration of the Lock-Up Period (as such may have been
extended pursuant to the provisions hereof), and such a Plan may only be established if there is no voluntary public announcement of the
establishment or existence of the Plan and there is no voluntary filing with the Securities and Exchange Commission or other regulatory
authority in respect of the Plan or transactions thereunder or contemplated thereby; <I>provided that </I>any public announcement or filing
shall be permitted to the extent required under the Exchange Act and shall include a statement to the effect that no transfers will be
made under the Plan during the Lock-Up Period.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned also agrees
and consents to the entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar against the transfer of
the Undersigned&rsquo;s Securities or Common Stock held by the undersigned&rsquo;s immediate family, if any, except in compliance with
the foregoing restrictions. In furtherance of the foregoing, the Company and its transfer agent and registrar are hereby further authorized
to decline to make any transfer of shares of Common Stock if such transfer would constitute a violation or breach of this Agreement.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned hereby represents
and warrants that it has full power and authority to enter into this Agreement and that this Agreement has been duly authorized (if the
undersigned is not a natural person), executed and delivered by the undersigned and is a valid and binding agreement of the undersigned.
All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors,
assigns, heirs or personal representatives of the undersigned.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned understands
that the undersigned shall be released from all obligations under this Agreement if (i)&nbsp;the Company notifies the Underwriters that
it does not intend to proceed with the Offering, (ii)&nbsp;the Underwriting Agreement does not become effective, or if the Underwriting
Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery
of the Common Stock to be sold thereunder, or (iii)&nbsp;the Offering is not completed by October&nbsp;31, 2025.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned understands
that the Underwriters are entering into the Underwriting Agreement and proceeding with the Offering in reliance upon this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Agreement shall be governed
by, and construed in accordance with, the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="2" STYLE="text-align: justify">Very truly yours,</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="2" STYLE="text-align: center">Printed Name of Holder</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"></TD><TD STYLE="text-align: justify; width: 3%">By:</TD>
         <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD COLSPAN="2" STYLE="text-align: center">Signature</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: 0">Printed Name of Person Signing</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">(and indicate capacity of person signing if</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt">signing as custodian,
trustee, or on behalf<BR>
</FONT>of an entity)</P>

</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 490.5pt"><B>Exhibit&nbsp;C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Directors and Officers<BR>
<U>Signing Lock-up Agreement</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Directors</U></B></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dean Mitchell</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeffrey Chodakewitz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Merit Cudkowicz</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jill DeSimone</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Norden</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William Young</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>Officers</U></B></FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Marcio Souza</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Timothy Kelly</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Alex Nemiroff</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lauren Mastrocola</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>tm2528989d1_ex4-1.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRAXIS PRECISION MEDICINES,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF PRE-FUNDED WARRANT TO PURCHASE
COMMON STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number of Shares: [ ] (subject to adjustment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrant No.&nbsp;[ ]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Original&nbsp;Issue&nbsp;Date:&nbsp;October&nbsp;20, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Praxis Precision Medicines,&nbsp;Inc., a Delaware corporation (the
 &ldquo;<B>Company</B>&rdquo;), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, [&nbsp;&nbsp;&nbsp;&nbsp;] or its registered assigns (the &ldquo;<B>Holder</B>&rdquo;), is entitled, subject to the terms
set forth below, to purchase from the Company up to a total of [&nbsp;&nbsp;&nbsp;&nbsp;] shares of common stock, $0.0001 par value per
share (the &ldquo;<B>Common Stock</B>&rdquo;), of the Company (each such share, a &ldquo;<B>Warrant Share</B>&rdquo; and all such shares,
the &ldquo;<B>Warrant Shares</B>&rdquo;) at an exercise price per share equal to $0.0001 per share (as adjusted from time to time as provided
in <U>Section&nbsp;9</U> herein, the &ldquo;<B>Exercise Price</B>&rdquo;), upon surrender of this Warrant to Purchase Common Stock (including
any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &ldquo;<B>Warrant</B>&rdquo;) at any time
and from time to time on or after the date hereof (the &ldquo;<B>Original Issue Date</B>&rdquo;), subject to the following terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">1. <I>Definitions</I>. For purposes of this Warrant, the following
terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;&ldquo;<B>Affiliate</B>&rdquo; means
any Person directly or indirectly controlled by, controlling or under common control with, a Holder, but only for so long as such control
shall continue. For purposes of this definition, &ldquo;control&rdquo; (including, with correlative meanings, &ldquo;controlled by&rdquo;,
 &ldquo;controlling&rdquo; and &ldquo;under common control with&rdquo;) means, with respect to a Person, possession, direct or indirect,
of (a)&nbsp;the power to direct or cause direction of the management and policies of such Person (whether through ownership of securities
or partnership or other ownership interests, by contract or otherwise), or (b)&nbsp;at least 50% of the voting securities (whether directly
or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;&ldquo;<B>Attribution Parties</B>&rdquo;
means, collectively, the following Persons and entities: (i)&nbsp;any direct or indirect Affiliates of the Holder, (ii)&nbsp;any Person
acting or who could be deemed to be acting as a Section&nbsp;13(d)&nbsp;&ldquo;group&rdquo; together with the Holder or any Attribution
Parties and (iii)&nbsp;any other Persons whose beneficial ownership of the Company&rsquo;s Common Stock would or could be aggregated with
the Holder&rsquo;s and/or any other Attribution Parties for purposes of Section&nbsp;13(d)&nbsp;or Section&nbsp;16 of the Exchange Act.
For clarity, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;&ldquo;<B>Commission</B>&rdquo; means
the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)&nbsp;&ldquo;<B>Closing Sale Price</B>&rdquo;
means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported
by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate
the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial
Markets, or if the foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin
board for such security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot be calculated for a security on a
particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as
mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such
security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of
Directors&rsquo; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately
adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(e)&nbsp;&ldquo;<B>Exchange Act</B>&rdquo; means
the Securities Exchange Act of 1934, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f)&nbsp;&ldquo;<B>Group</B>&rdquo; shall have
the meaning ascribed to it in Section&nbsp;13(d)&nbsp;of the Exchange Act, and all related rules, regulations and jurisprudence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f)&nbsp;&ldquo;<B>Person</B>&rdquo; means an
individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other
entity and a government or any department or agency thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(g)&nbsp;&ldquo;<B>Principal Trading Market</B>&rdquo;
means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for trading,
which, as of the Original Issue Date, shall be the Nasdaq Global Select Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(h)&nbsp;&ldquo;<B>Registration Statement</B>&rdquo;
means the Company&rsquo;s Registration Statement on Form&nbsp;S-3ASR (File No.&nbsp;333-284016), which was automatically effective when
filed on December&nbsp;23, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(i)&nbsp;&ldquo;<B>Securities Act</B>&rdquo; means
the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(j)&nbsp;&ldquo;<B>Standard Settlement Period</B>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, for the Principal Trading Market with respect to the Common
Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Issuance Date was &ldquo;T+1.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(k)&nbsp;&ldquo;<B>Trading Day</B>&rdquo; means
any weekday on which the Principal Trading Market is normally open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(l)&nbsp;&ldquo;<B>Transfer Agent</B>&rdquo; means
Computershare Trust Company, N.A., the Company&rsquo;s transfer agent and registrar for the Common Stock, and any successor appointed
in such capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">2. <I>Issuance of Securities; Registration of Warrants</I>. The Warrant,
as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant
Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement
or an exchange meeting the requirements of Section&nbsp;3(a)(9)&nbsp;of the Securities Act as in effect on the Original Issue Date, the
Warrant Shares, are not &ldquo;restricted securities&rdquo; under Rule&nbsp;144 promulgated under the Securities Act. The Company shall
register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<B>Warrant Register</B>&rdquo;),
in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is
permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute
owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice
to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">3. <I>Registration of Transfers</I>. Subject to compliance with all
applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this
Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon any such
registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &ldquo;<B>New
Warrant</B>&rdquo;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing
the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New
Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in respect of
the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue
and deliver at the Company&rsquo;s own expense any New Warrant under this <U>Section&nbsp;3</U>. Until due presentment for registration
of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be
affected by any notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">4. <I>Exercise of Warrants</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;All or any part of this Warrant shall
be exercisable by the registered Holder in any manner permitted by this Warrant (including <U>Section&nbsp;11</U>) at any time and from
time to time on or after the Original Issue Date, and such rights shall not expire.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;The Holder may exercise this Warrant
by delivering to the Company (i)&nbsp;an exercise notice, in the form attached as <U>Schedule 1</U> hereto (the &ldquo;<B>Exercise Notice</B>&rdquo;),
completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being
exercised (which may take the form of a &ldquo;cashless exercise&rdquo; if so indicated in the Exercise Notice pursuant to <U>Section&nbsp;10</U>
below), and the date on which the last of such items is delivered to the Company (as determined in accordance with the notice provisions
hereof) is an <B>&ldquo;Exercise Date</B>.&rdquo; The Holder shall not be required to deliver the original Warrant in order to effect
an exercise hereunder. Execution and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant
and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">5. <I>Delivery of Warrant Shares</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;Upon exercise of this Warrant, the Company
shall promptly (but in no event later than the number of Trading Days comprising the Standard Settlement Period following the Exercise
Date), upon the request of the Holder, credit such aggregate number of shares of Common Stock specified by the Holder in the Exercise
Notice and to which the Holder is entitled pursuant to such exercise (the &ldquo;<B>Exercise Shares</B>&rdquo;) to the Holder&rsquo;s
or its designee&rsquo;s balance account with The Depository Trust Company (&ldquo;<B>DTC</B>&rdquo;) through its Deposit Withdrawal At
Custodian system, or if the Transfer Agent is then a participant in the DTC Fast Automated Securities Transfer Program (the &ldquo;<B>FAST
Program</B>&rdquo;) and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to
or the resale of such Warrant Shares by the Holder or (B)&nbsp;the Exercise Shares are eligible for resale by the Holder without volume
or manner-of-sale restrictions pursuant to Rule&nbsp;144 promulgated under the Securities Act (assuming cashless exercise of this Warrant).
If the Transfer Agent is not a member of the FAST Program or if (A)&nbsp;and (B)&nbsp;above are not true, the Transfer Agent will either
(i)&nbsp;record the Exercise Shares in the name of the Holder or its designee on the certificates reflecting the Exercise Shares with
an appropriate legend regarding restriction on transferability, which shall be issued and dispatched by overnight courier to the address
as specified in the Exercise Notice, and on the Company&rsquo;s share register or (ii)&nbsp;issue such Exercise Shares in the name of
the Holder or its designee in restricted book-entry form in the Company&rsquo;s share register. The Holder, or any natural person or legal
entity (each, a &ldquo;<B>Person</B>&rdquo;) so designated by the Holder to receive Warrant Shares, shall be deemed to have become the
holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&rsquo;s
DTC account, the date of the book entry positions or the date of delivery of the certificates evidencing such Exercise Shares, as the
case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;If the Company fails to deliver to the
Holder or its designee Exercise Shares in the manner required pursuant to <U>Section&nbsp;5(a)</U>&nbsp;within the Standard Settlement
Period following the Exercise Date and the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<B>Buy-In</B>&rdquo;)
but did not receive within the Standard Settlement Period, then the Company shall, within two (2)&nbsp;Trading Days after the Holder&rsquo;s
request and in the Holder&rsquo;s sole discretion, either (1)&nbsp;pay in cash to the Holder an amount equal to the Holder&rsquo;s total
purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company&rsquo;s
obligation to issue and deliver such Exercise Shares shall terminate or (2)&nbsp;promptly honor its obligation to deliver to the Holder
or its designee the Exercise Shares pursuant to <U>Section&nbsp;5(a)</U>&nbsp;and pay cash to the Holder in an amount equal to the excess
(if any) of Holder&rsquo;s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased
in the Buy-In, less the product of (A)&nbsp;the number of shares of Common Stock purchased in the Buy-In, times (B)&nbsp;the Closing Sale
Price of a share of Common Stock on the Exercise Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;To the extent permitted by law and subject
to <U>Section&nbsp;5(b)</U>, the Company&rsquo;s obligations to issue and deliver Warrant Shares in accordance with and subject to the
terms hereof (including the limitations set forth in <U>Section&nbsp;11</U> below) are absolute and unconditional, irrespective of any
action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any
judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or
any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation
of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such obligation of the
Company to the Holder in connection with the issuance of Warrant Shares. Subject to <U>Section&nbsp;5(b)</U>, nothing herein shall limit
the Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a
decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common
Stock upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">6. <I>Charges, Taxes and Expenses</I>. Issuance and delivery for shares
of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent
fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of
which taxes and expenses shall be paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay
any tax that may be payable in respect of any transfer involved in the registration of any Warrant Shares or the Warrants in a name other
than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result
of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost,
stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in
lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of
such loss, theft or destruction (in such case) and, in each case, a customary and reasonable contractual indemnity, if requested by the
Company. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant
to the Company as a condition precedent to the Company&rsquo;s obligation to issue the New Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8. <I>Reservation of Warrant Shares</I>. The Company covenants that
it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued
and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as
herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free
from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and
restrictions of <U>Section&nbsp;9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance
and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully
paid and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock
may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange
or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior
written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant
Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this <U>Section&nbsp;9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;<U>Stock Dividends and Splits</U>. If
the Company, at any time while this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution
on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the
Original Issue Date or as amended, that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock
into a larger number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of shares
of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company,
then in each such case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common
Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding
immediately after such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after
the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such
record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed
accordingly as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph
as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii)&nbsp;of this paragraph shall
become effective immediately after the effective date of such subdivision or combination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;<U>Pro Rata Distributions</U>. If, on
or after the Original Issue Date, the Company shall declare or make any dividend or other pro rata distribution of its assets (or rights
to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation,
any distribution of cash, stock or other securities, property, options, evidence of indebtedness or any other assets by way of a dividend,
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction, but, for the avoidance of doubt,
excluding any distribution of shares of Common Stock subject to <U>Section&nbsp;9(a)</U>, any distribution of Purchase Rights (as defined
below) subject to <U>Section&nbsp;9(c)</U>&nbsp;and any Fundamental Transaction (as defined below) subject to <U>Section&nbsp;9(d))</U>
(a &ldquo;<B>Distribution</B>&rdquo;) then, in each such case, the Holder shall be entitled to participate in such Distribution to the
same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation,
the Maximum Percentage (as defined below)) immediately before the date on which a record is taken for such Distribution, or, if no such
record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such
Distribution (provided, that to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder
and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution
to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and
beneficial ownership) to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until
such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage,
at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution
or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;<U>Purchase Rights</U>. If at any time
on or after the Original Issue Date, the Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock,
warrants, securities or other property, in each case pro rata to the record holders of any class of Common Stock (the &ldquo;<B>Purchase
Rights</B>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase
Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum
Percentage) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no
such record is taken, the date as of which the record holders of Common Stock are to be determined for the grant, issuance or sale of
such Purchase Rights (provided, that to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result
in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of such Common Stock as a result of such Purchase
Right (and beneficial ownership) to such extent) and such Purchase Right to such extent shall be held in abeyance for the benefit of the
Holder until such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum
Percentage, at which time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial
Purchase Right or on any subsequent Purchase Right to be held similarly in abeyance) to the same extent as if there had been no such limitation).
As used in this <U>Section&nbsp;9(c)</U>, (i)&nbsp;&ldquo;<B>Options</B>&rdquo; means any rights, warrants or options to subscribe for
or purchase shares of Common Stock or Convertible Securities and (ii)&nbsp;&ldquo;<B>Convertible Securities</B>&rdquo; mean any stock
or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)&nbsp;<U>Fundamental Transactions</U>. If,
at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or consolidation of the Company with or into another
Person, in which the Company is not the surviving entity or in which the stockholders of the Company immediately prior to such merger
or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger
or consolidation, (ii)&nbsp;the Company effects any sale to another Person of all or substantially all of its assets in one or a series
of related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders
of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such
other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person
whereby such other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction
in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting
power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any reclassification of the Common Stock or any
compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or
property (other than as a result of a subdivision or combination of shares of Common Stock covered by <U>Section&nbsp;9(a)</U>&nbsp;above)
(in any such case, a &ldquo;<B>Fundamental Transaction</B>&rdquo;), then following such Fundamental Transaction the Holder shall have
the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled
to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the
holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise
contained herein (the &ldquo;<B>Alternate Consideration</B>&rdquo;). The Company shall not effect any Fundamental Transaction in which
the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate
Consideration is solely cash and the Company provides for the simultaneous &ldquo;cashless exercise&rdquo; of this Warrant pursuant to
<U>Section&nbsp;10</U> below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving
entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate
Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under
this Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction
type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)&nbsp;<U>Number of Warrant Shares</U>. Simultaneously
with any adjustment to the Exercise Price pursuant to <U>Section&nbsp;9</U>, the number of Warrant Shares that may be purchased upon exercise
of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder
for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior
to such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(e)&nbsp;<U>Calculations</U>. All calculations
under this <U>Section&nbsp;9</U> shall be made to the nearest one-tenth of one cent or the nearest share, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f)&nbsp;<U>Notice of Adjustments</U>. Upon the
occurrence of each adjustment pursuant to this <U>Section&nbsp;9</U>, the Company at its expense will, at the written request of the Holder,
promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth
such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities
issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail
the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate
to the Holder and to the Company&rsquo;s transfer agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(g)&nbsp;<U>Notice of Corporate Events</U>. If,
while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other distribution of cash, securities or other property
in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital
stock of the Company or any subsidiary, (ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder
approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs
of the Company, then the Company shall deliver to the Holder a notice of such transaction at least ten (10)&nbsp;days prior to the applicable
record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction;
provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action
required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters
into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <U>Section&nbsp;9(c)</U>,
other than a Fundamental Transaction under clause (iii)&nbsp;of <U>Section&nbsp;9(c)</U>, the Company shall deliver to the Holder a notice
of such Fundamental Transaction at least thirty (30)&nbsp;days prior to the date such Fundamental Transaction is consummated. Holder agrees
to maintain any information disclosed pursuant to this <U>Section&nbsp;9(g)</U>&nbsp;in confidence until such information is publicly
available, and shall comply with applicable law with respect to trading in the Company&rsquo;s securities following receipt any such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">10. <I>Payment of Exercise Price</I>. Notwithstanding anything contained
herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a &ldquo;cashless
exercise&rdquo;, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected
pursuant to Section&nbsp;3(a)(9)&nbsp;of the Securities Act, as determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">X = Y [(A-B)/A]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;X&rdquo; equals the number of Warrant Shares
to be issued to the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;Y&rdquo; equals the total number of Warrant
Shares with respect to which this Warrant is then being exercised;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;A&rdquo; equals the Closing Sale Prices
of the shares of Common Stock (as reported by Bloomberg Financial Markets) as of the Trading Day on the date immediately preceding the
Exercise Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&ldquo;B&rdquo; equals the Exercise Price then
in effect for the applicable Warrant Shares at the time of such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For purposes of Rule&nbsp;144 promulgated under the Securities Act,
it is intended, understood and acknowledged that the Warrant Shares issued in a &ldquo;cashless exercise&rdquo; transaction shall be deemed
to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this
Warrant was originally issued (provided that the Commission continues to take the position that such treatment is proper at the time of
such exercise). In the event that the Registration Statement or another registration statement registering the issuance of Warrant Shares
is, for any reason, not effective at the time of exercise of this Warrant, then the Warrant may only be exercised through a cashless exercise,
as set forth in this <U>Section&nbsp;10</U>. Except as set forth in <U>Section&nbsp;5(b)</U>&nbsp;(Buy-In remedy) and <U>Section&nbsp;12</U>
(payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be settled in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11. <I>Limitations on Exercise</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;Notwithstanding anything to the contrary
contained herein, the Company shall not effect the exercise of any portion of this Warrant, and the Holder of the Warrant shall not have
the right to exercise any portion of the Warrant, and any such exercise shall be null and void ab initio and treated as if the exercise
had not been made, to the extent that immediately prior to or following such exercise, the Holder, together with the Attribution Parties,
beneficially owns or would beneficially own as determined in accordance with Section&nbsp;13(d)&nbsp;of the s Exchange Act and the rules&nbsp;promulgated
thereunder, in excess of [4.99%][9.99%] (the &ldquo;<B>Maximum Percentage</B>&rdquo;) of the Common Stock that would be issued and outstanding
following such exercise. For purposes of calculating beneficial ownership for determining whether the Maximum Percentage is or will be
exceeded, the aggregate number of shares of Common Stock held and/or beneficially owned by the Holder together with the Attribution Parties,
shall include the number of shares of Common Stock held and/or beneficially owned by the Holder together with the Attribution Parties
plus the number of shares of Common Stock issuable upon exercise of the relevant Warrant with respect to which the determination is being
made but shall exclude the number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, unexercised
Warrant held and/or beneficially owned by the Holder or the Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised
or unconverted portion of any other securities of the Company held and/or beneficially owned by such Holder or any Attribution Party (including,
without limitation, any convertible notes, convertible stock or warrants) that are subject to a limitation on conversion or exercise analogous
to the limitation contained herein. For purposes of this Paragraph 11(a), beneficial ownership of the Holder or the Attribution Parties
shall, except as set forth in the immediately preceding sentence, be calculated and determined in accordance with Section&nbsp;13(d)&nbsp;of
the Exchange Act and the rules&nbsp;promulgated thereunder. For purposes of the Warrant, in determining the number of outstanding shares
of Common Stock, a Holder of the Warrant may rely on the number of outstanding shares of Common Stock as reflected in (1)&nbsp;the Company&rsquo;s
most recent Form&nbsp;10-K, Form&nbsp;10-Q, Current Report on Form&nbsp;8-K or other public filing with the Securities and Exchange Commission,
as the case may be, (2)&nbsp;a more recent public announcement by the Company or (3)&nbsp;any other notice by the Company or the Company&rsquo;s
transfer agent setting forth the number of shares of Common Stock outstanding (such issued and outstanding shares, the &ldquo;<B>Reported
Outstanding Share Number</B>&rdquo;). For any reason at any time, upon the written or oral request of the Holder, the Company shall within
one (1)&nbsp;Business Day confirm orally and in writing or by electronic mail to the Holder the number of shares of Common Stock then
outstanding. The Holder shall disclose to the Company the number of shares of Common Stock that it, together with the Attribution Parties
holds and/or beneficially owns and has the right to acquire through the exercise of derivative securities and any limitations on exercise
or conversion analogous to the limitation contained herein contemporaneously or immediately prior to submitting an Exercise Notice for
the relevant Warrant. If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares
of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i)&nbsp;notify the Holder in writing of the number
of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder&rsquo;s, together
with the Attribution Parties&rsquo;, beneficial ownership, as determined pursuant to this <U>Section&nbsp;11(a)</U>, to exceed the Maximum
Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice
(the number of shares by which such purchase is reduced, the &ldquo;<B>Reduction Shares</B>&rdquo;) and (ii)&nbsp;as soon as reasonably
practicable, the Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. In any case, the number
of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company,
including this Warrant, by the Holder and the Attribution Parties since the date as of which the Reported Outstanding Share Number was
reported. In the event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the Holder, together with
the Attribution Parties, being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding
shares of Common Stock (as determined under Section&nbsp;13(d)&nbsp;of the Exchange Act), the number of shares so issued by which the
Holder&rsquo;s, together with the Attribution Parties&rsquo;, aggregate beneficial ownership exceeds the Maximum Percentage (the &ldquo;<B>Excess
Shares</B>&rdquo;) shall be deemed null and void and shall be cancelled ab initio, and the Holder and/or the Attribution Parties shall
not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares
has been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. By
written notice to the Company, a Holder of the Warrant may from time to time increase or decrease the Maximum Percentage to any other
percentage not in excess of 19.99% specified in such notice; provided that any increase in the Maximum Percentage will not be effective
until the sixty-first (61st) day after such notice is delivered to the Company and shall not negatively affect any partial exercise effected
prior to such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;This <U>Section&nbsp;11</U> shall not
restrict the number of shares of Common Stock which a Holder or the Attribution Parties may receive or beneficially own in order to determine
the amount of securities or other consideration that such Holder or the Attribution Parties may receive in the event of a Fundamental
Transaction as contemplated in <U>Section&nbsp;9(c)</U>&nbsp;of this Warrant. For purposes of clarity, the shares of Common Stock issuable
pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be beneficially owned by the Holder or
the Attribution Parties for any purpose including for purposes of Section&nbsp;13(d)&nbsp;of the Exchange Act and the rules&nbsp;promulgated
thereunder or Section&nbsp;16 of the Exchange Act Rule&nbsp;16a-1(a)(1)&nbsp;promulgated thereunder. No prior inability to exercise this
Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with respect to any
subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this <U>Section&nbsp;11(a)</U>&nbsp;to the extent necessary to correct this paragraph or any
portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this <U>Section&nbsp;11(a)</U>&nbsp;or
to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph
may not be waived and shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will
be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number
of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market
value (based on the Closing Sale Price) for any such fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">13. <I>Notices</I>. Any and all notices or other communications or
deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective
on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered confirmed e-mail at the e-mail address
specified in the books and records of the Transfer Agent prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next
Trading Day after the date of transmission, if such notice or communication is delivered via confirmed e-mail at the e-mail address specified
in the books and records of the Transfer Agent on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any
Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying
next business day delivery, or (iv)&nbsp;upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">14. <I>Warrant Agent</I>. The Company shall initially serve as warrant
agent under this Warrant. Upon thirty (30)&nbsp;days&rsquo; notice to the Holder, the Company may appoint a new warrant agent. Any corporation
into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company
or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all
of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act.
Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage
prepaid) to the Holder at the Holder&rsquo;s last address as shown on the Warrant Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">15. <I>Miscellaneous</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(a)&nbsp;<U>No Rights as a Stockholder</U>. Except
as otherwise set forth in this Warrant, the Holder, solely in such Person&rsquo;s capacity as a holder of this Warrant, shall not be entitled
to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose (except to the extent the Holder
is required to be deemed a holder of the Warrant Shares for tax purposes under applicable tax law), nor shall anything contained in this
Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity as the Holder of this Warrant, any of the rights
of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue
of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive
dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled
to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities
on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(b)&nbsp;<U>Authorized Shares</U>. (i)&nbsp;Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue
or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may
be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality
of the foregoing, the Company will (a)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such
exercise immediately prior to such increase in par value, (b)&nbsp;take all such action as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant, and (c)&nbsp;use
commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction
thereof as may be necessary to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(ii)&nbsp;Before taking any action which would result in an adjustment
in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations
or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(c)&nbsp;<U>Successors and Assigns</U>. Subject
to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company
without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding
on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence,
nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy
or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors
and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(d)&nbsp;<U>Amendment and Waiver</U>. Except as
otherwise provided herein, the provisions of the Warrants may be amended and the Company may take any action herein prohibited, or omit
to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(e)&nbsp;<U>Acceptance</U>. Receipt of this Warrant
by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(f)&nbsp;<U>Governing Law; Jurisdiction</U>. ALL
QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND
ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE
COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF
NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED
HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES,
AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH
COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN
ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF
DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT
SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY
MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(g)&nbsp;<U>Headings</U>. The headings herein
are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">(h)&nbsp;<U>Severability</U>. In case any one
or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining
terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt
in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so
agreeing, shall incorporate such substitute provision in this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">IN WITNESS WHEREOF, the Company has caused this
Warrant to be duly executed by its authorized officer as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
<TD COLSPAN="2"><B>PRAXIS PRECISION MEDICINES,&nbsp;INC.</B> <B>&nbsp;</B></TD></TR>
<TR>
    <TD STYLE="width: 50%">&nbsp;</TD>
<TD STYLE="width: 5%">&nbsp;</TD>
<TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
<TD STYLE="border-bottom: Black 1pt solid; vertical-align: bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
<TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF EXERCISE NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[To be executed by the Holder to purchase shares
of Common Stock under the Warrant]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1)&nbsp;The undersigned is the Holder of Warrant No.&nbsp;__ (the
 &ldquo;<B>Warrant</B>&rdquo;) issued by Praxis Precision Medicines,&nbsp;Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;).
Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(2)&nbsp;The undersigned hereby exercises its right to purchase Warrant
Shares pursuant to the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(3)&nbsp;The Holder intends that payment of the Exercise Price shall
be made as (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 24px; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 24px; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Exercise </FONT></TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="vertical-align: top; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Cashless Exercise&rdquo; under Section&nbsp;10 of the Warrant </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(4)&nbsp;If the Holder has elected a Cash Exercise, the Holder shall
pay the sum of $__ in immediately available funds to the Company in accordance with the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(5)&nbsp;Pursuant to this Exercise Notice, the Company shall deliver
to the Holder Warrant Shares determined in accordance with the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(6)&nbsp;By its delivery of this Exercise Notice, the undersigned represents
and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the
number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d)&nbsp;of the Securities Exchange Act of 1934, as
amended) permitted to be owned under Section&nbsp;11(a)&nbsp;of the Warrant to which this notice relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt; width: 42%">&nbsp;</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name&nbsp;of&nbsp;Holder:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt">&nbsp;</TD>
    <TD STYLE="padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 0.25pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 0.25pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Signature must conform in all respects to name
of Holder as specified on the face of the Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>tm2528989d1_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%">&nbsp;</TD>
    <TD STYLE="width: 30%; font: 10pt Times New Roman, Times, Serif">200 Clarendon Street&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: middle">Boston, Massachusetts 02116&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Tel: +1.617.948.6000 Fax: +1.617.948.6001&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><IMG SRC="tm2528989d1_ex5-1img01.jpg" ALT="">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">www.lw.com<BR>
    <BR>
    FIRM / AFFILIATE OFFICES</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 70%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%">Austin</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%">Milan</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Beijing</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Munich</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Boston</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">New York</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Brussels</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Orange County</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Chicago</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Paris</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dubai</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Riyadh</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">October&nbsp;17, 2025</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">D&uuml;sseldorf</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">San Diego</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Frankfurt</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">San Francisco</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Hamburg</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Seoul</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Hong Kong</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Silicon Valley</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Houston</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Singapore</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">London</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Tel Aviv</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Los Angeles</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Tokyo</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Madrid</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Washington, D.C.</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Praxis Precision Medicines,&nbsp;Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">99 High Street, 30<SUP>th</SUP> Floor&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, MA 02110</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: Registration Statement on Form&nbsp;S-3; up to 3,527,072
shares of Common Stock and pre-funded warrants to purchase up to 318,470 shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the addressee set forth above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have acted as special counsel to Praxis
Precision Medicines,&nbsp;Inc., a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), in connection with the proposed
issuance of up to 3,527,072 shares (the &ldquo;<B><I>Shares</I></B>&rdquo;) of common stock, $0.0001 par value per share (the
&ldquo;<B><I>Common Stock</I></B>&rdquo;), and pre-funded warrants to purchase up to 318,470 shares of Common Stock (the
&ldquo;<B><I>Pre-funded Warrants</I></B>&rdquo;). The Shares and the Pre-funded Warrants are included in a registration statement on
Form&nbsp;S-3 under the Securities Act of 1933, as amended (the &ldquo;<B><I>Act</I></B>&rdquo;), filed with the Securities and
Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) on December&nbsp;23, 2024 (Registration No.&nbsp;333-284016) (as so
filed and as amended, the &ldquo;<B><I>Registration Statement</I></B>&rdquo;), and are being offered pursuant to a base prospectus
dated December&nbsp;23, 2024 (the &ldquo;<B><I>Base Prospectus</I></B>&rdquo;) and a prospectus supplement dated October&nbsp;16,
2025 filed with the Commission pursuant to Rule&nbsp;424(b)&nbsp;under the Act (together with the Base Prospectus, the
&ldquo;<B><I>Prospectus</I></B>&rdquo;). The Shares and the Pre-funded Warrants are being sold pursuant to an underwriting agreement
dated October&nbsp;16, 2025 by and among the Company and TD Securities (USA) LLC, Piper Sandler&nbsp;&amp; Co. and Guggenheim
Securities, LLC, as representatives of the several underwriters named in Schedule A thereto (the &ldquo;<B><I>Underwriting
Agreement</I></B>&rdquo;). This opinion is being furnished in connection with the requirements of Item 601(b)(5)&nbsp;of Regulation
S-K under the Act, and no opinion is expressed herein as to any matter pertaining to the contents of the Registration Statement or
related Prospectus, other than as expressly stated herein with respect to the issue of the Shares, the Pre-funded Warrants and the
Warrant Shares (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">October&nbsp;17,
2025 <BR>
Page&nbsp;2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2528989d1_ex5-1img02.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As such counsel, we have examined such matters
of fact and questions of law as we have considered appropriate for purposes of this letter. With your consent, we have relied upon certificates
and other assurances of officers of the Company and others as to factual matters without having independently verified such factual matters.
We are opining herein as to the General Corporation Law of the State of Delaware (the &ldquo;<B><I>DGCL</I></B>&rdquo;) and in paragraph
2, the internal laws of the State of New York, and we express no opinion with respect to the applicability thereto, or the effect thereon,
of the laws of any other jurisdiction or, in the case of Delaware, any other laws, or as to any matters of municipal law or the laws
of any local agencies within any state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Subject to the foregoing and the other matters
set forth herein, it is our opinion that, as of the date hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>When
the Shares shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the
purchasers, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated
by the Underwriting Agreement, the issue and sale of the Shares will have been duly authorized by all necessary corporate action of the
Company and the Shares will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>When
the Pre-funded Warrants shall have been duly issued by the Company against payment therefor in the circumstances contemplated by the
Underwriting Agreement, the issue and sale of the Pre-funded Warrants will have been duly authorized by all necessary corporate action
of the Company, and the Pre-funded Warrants will be legally valid and binding obligations of the Company, enforceable against the Company
in accordance with their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.<FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>When
the shares of Common Stock initially issuable upon exercise of the Pre-funded Warrants (the &ldquo;<B><I>Warrant Shares</I></B>&rdquo;)
shall have been duly registered on the books of the transfer agent and registrar therefor in the name or on behalf of the Pre-funded
Warrants holders, and have been issued by the Company against payment therefor (not less than par value) in the circumstances contemplated
by the Pre-funded Warrants, the issue of the Warrant Shares will have been duly authorized by all necessary corporate action of the Company
and the Warrant Shares will be validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In rendering the foregoing opinions, we have assumed
that (i)&nbsp;the Company will comply with all applicable notice requirements regarding uncertificated shares provided in the DGCL and
(ii)&nbsp;upon the issue of any of the Warrant Shares, the total number of shares of Common Stock issued and outstanding will not exceed
the total number of shares of Common Stock that the Company is then authorized to issue under its Amended and Restated Certificate of
Incorporation and by the board of directors of the Company in connection with the offering contemplated by the Registration Statement
and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">With your consent, we have assumed (a)&nbsp;that
the Pre-funded Warrants have been duly authorized, executed and delivered by the parties thereto other than the Company, (b)&nbsp;that
the Pre-funded Warrants constitute legally valid and binding obligations of the parties thereto other than the Company, enforceable against
each of them in accordance with their respective terms, and (c)&nbsp;that the status of the Pre-funded Warrants as legally valid and
binding obligations of the Company is not affected by any (i)&nbsp;breaches of, or defaults under, agreements or instruments, (ii)&nbsp;violations
of statutes, rules, regulations or court or governmental orders or (iii)&nbsp;failures to obtain required consents, approvals or authorizations
from, or make required registrations, declarations or filings with, governmental authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal; font-weight: normal">October&nbsp;17,
2025 <BR>
Page&nbsp;3</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2528989d1_ex5-1img03.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our opinions are subject to: (i)&nbsp;the effect
of bankruptcy, insolvency, reorganization, preference, fraudulent transfer, moratorium or other similar laws relating to or affecting
the rights and remedies of creditors; (ii)&nbsp;(a)&nbsp;the effect of general principles of equity, whether considered in a proceeding
in equity or at law (including the possible unavailability of specific performance or injunctive relief), (b)&nbsp;concepts of materiality,
reasonableness, good faith and fair dealing, and (c)&nbsp;the discretion of the court before which a proceeding is brought; and (iii)&nbsp;the
invalidity under certain circumstances under law or court decisions of provisions providing for the indemnification of or contribution
to a party with respect to a liability where such indemnification or contribution is contrary to public policy. We express no opinion
as to (a)&nbsp;any provision for liquidated damages, default interest, late charges, monetary penalties, make-whole premiums or other
economic remedies to the extent such provisions are deemed to constitute a penalty; (b)&nbsp;consents to, or restrictions upon, governing
law, jurisdiction, venue, arbitration, remedies, or judicial relief; (c)&nbsp;any provision requiring the payment of attorneys&rsquo;
fees, where such payment is contrary to law or public policy; (d)&nbsp;other applicable exceptions; and (e)&nbsp;the severability, if
invalid, of provisions to the foregoing effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This opinion is for your benefit in connection
with the Registration Statement and may be relied upon by you and by persons entitled to rely upon it pursuant to the applicable provisions
of the Act. We consent to your filing this opinion as an exhibit to the Company&rsquo;s Current Report on Form&nbsp;8-K dated October&nbsp;17,
2025 and to the reference to our firm in the Prospectus under the heading &ldquo;Legal Matters.&rdquo; In giving such consent, we do
not thereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Act or the rules&nbsp;and
regulations of the Commission thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif">Sincerely,</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">/s/ Latham&nbsp;&amp; Watkins LLP</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>prax-20251016.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaOBSbOdzZR+yYkxtmB8bQk6/yAuoIEPWSxoRv5mQbMC -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:PRAX="http://praxismedicines.com/20251016" elementFormDefault="qualified" targetNamespace="http://praxismedicines.com/20251016">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://praxismedicines.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="prax-20251016_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="prax-20251016_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>prax-20251016_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>prax-20251016_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="prax-20251016.xsd#Cover" roleURI="http://praxismedicines.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://praxismedicines.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>tm2528989d1_ex5-1img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2528989d1_ex5-1img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  < 1<# 2(  A$! Q$!_\0
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MEXABNI+)90EM.UNY<#!8=<8)XYKS+P7KTWA[P;XKL)6)GT623R@3T+$J /\
M@:D_C78?"^P-CX!T\M_K+G=<.?7<QP?^^0*(5')I??\ D&(PL:*FWW27HU?\
MK&OKOBW3/#MY86M\9/,O7V1[-OR\@9;+#CGWK8EG2&)Y&SM12Q^@KP[Q+I\W
MC3Q-XNOHB3'HUJ(H#_MHP) _[YD_,5Z?X$U@^(/!FGWDS;YO+\J8L<DNORDG
MZXS^-$*G-)I_(,3A(TZ,9Q>OVOFKK\#$_P"%R>&2/]5??]\Q_P#Q==#X8\9:
M9XL%R=.6<"WV[_-"_P 6<8VL?0UQ7Q'LK2'Q;X+6*UAC5[[#A(P PWQ]?6O3
MH+2VM=WV>WBBW=?+0+G\J(.;DTWL5B88:-&$J<6G+SVL[=BCI_B*RU+5]2TR
M!91/I[*LQ8#'S9QC!SV[@56M_%^FW?BB;P_ D\EW""9'4*8UP.<D-D=<=.M>
M6WWBI_#7C+QC%:QEM0OYH8+4Y 5&VL-Q)],C_P#57I'@KPC!X5TK86$VH7&'
MN[@\EW] 3V&?Z]Z49N3LOF%?"TZ,.>5]4N5>=DV_1%[6?%%AH6HZ;8W:S&74
M9/*A*!< Y4<Y(_O#IFKVK:I!HVE7&HW(<PVZ;W"8SCVR0*\[^)O_ ".O@?\
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M;6(RI:?90H.P< $'C@5[!11*FI-MO<=+'3I0A"FE[NNJ3N[_ (::'+^ M?\
M^$B\(65XY/GHODSY_OJ "?QX/XUS"_\ )P$G_7A_[(*]/HIN%TDWL91Q$83G
M*,=))JW:YD>*?^11UG_KQF_] -<W\*(T;X=:<612=TO)'_31J[NBFX^]S$*M
M:@Z5MVG?Y6/+M$ 7X]Z^   +$<#_ '8:3XBVMSXK\7:-X6L[A82D;WDTC+N"
M=E)'?H1C_:KU*BI]G[KB;K&M58U4M8QLO5*USQ7QIX-\3VNC'6+[Q*-1;32)
MHT-N$9.1D@Y[<'\*[^_\1Q7/PXN]>M7'SV#2*1_"^W&/P;C\*ZNBFJ?*VUU)
MJ8MU(Q4XKW7?33332R]-SQ9?#BW_ ,!K:54_TJU$EZC#@C#MG_QW^0JU\/\
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K6EVDJO 9%VKYA)8K\N0<D]SUKH:*OE1A[6??^D,C4( H' &**?13,S__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2528989d1_ex5-1img02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2528989d1_ex5-1img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  4 , # 2(  A$! Q$!_\0
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MPTJR_:XT)\P@>6S !BH.<Y .>G8TOB+Q.?#B/-+I-]<VL<8DDN( FQ.2,'+
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@**!MM@$522% )ZD#K2+&BL65%#'J0***!#J*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2528989d1_ex5-1img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2528989d1_ex5-1img03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  4 , # 2(  A$! Q$!_\0
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MPTJR_:XT)\P@>6S !BH.<Y .>G8TOB+Q.?#B/-+I-]<VL<8DDN( FQ.2,'+
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@**!MM@$522% )ZD#K2+&BL65%#'J0***!#J*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Oct. 16, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 16,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PRAXIS PRECISION MEDICINES, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001689548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5195942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">99 High Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">30th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">300-8460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PRAX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2528989d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://praxismedicines.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>prax-20251016.xsd</File>
    <File>prax-20251016_lab.xml</File>
    <File>prax-20251016_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2528989d1_8k.htm">tm2528989d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2528989d1_8k.htm": {
   "nsprefix": "PRAX",
   "nsuri": "http://praxismedicines.com/20251016",
   "dts": {
    "schema": {
     "local": [
      "prax-20251016.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "prax-20251016_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prax-20251016_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2528989d1_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://praxismedicines.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-10-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2528989d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-10-16",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2528989d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://praxismedicines.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-25-100488-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-100488-xbrl.zip
M4$L#!!0    ( %.145MS-FE,+@,  /<+   1    <')A>"TR,#(U,3 Q-BYX
M<V2U5MMRVC 0?>],_T'U:\880Z$)@60(:3K,D":!YM*\=(2]$ VVY$HRF'Y]
M)5^X&5R@K9_DU3EG=[6[LIN7D>^A*7!!&&T9=JEL(* .<PD=MXS'@=D>=+I=
M UU>O'^'U-/\8)KHAH#G-M U<\PN';%S]!7[T$!?@ +'DO%S](2]4%O8#?&
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MV[EC*DE >-A\=620X4AKO;"PV. T_;S-$DHR>"(R5&Y9L%ILLM"0!,2"S1?
M0B%%6NN%A<L-X6LQO?W,V6O^6.9G!=L&J-VRT6FYR8A5&A K7?X 9G0(4C$Z
MI:X?>':'A.(JRR+<4HO4,3:@68.9EBXD8"!S+5I2$LGK+3<L1TN&OF8$Y8\$
M798_0U?/!*_J\?5+(U$D7XA0JW(:8VY#J$OL_%='0,.MWQYI*8, J=<>_#LD
M5032(8ZIN14,\_IY7&%BGI,-^+9#?X@K@H::UQSUZ8.@::!)DZDBK'ER700B
M&>DSFU$]N3V\Q&N('*^,+0:-A7%-$00CH"UH65S_K0 _N?.VJS2)KE*&X:LL
M#8WCC'EM>T:RO(,@( +:KJ 4>840%4HO_?\9TR>^?<ZC_1UG$2'R*:NL&JWZ
MKK\-C';+S)N:U*1I4&A G+W%+T#@H0I4J^-#;<;R>3%//C0NL[FQZ&GQB,4!
MO-WFF9Q!A3'X*GAGD./;"P,:8-QDZ(@("+T!-J$;#D4D*D(_(!6,:M&>SL^R
M0Q9 $G_>WY,'PN5[!TNRRS^+'3UUG&$,B'5]]C:X.>;)7&]@$!"^U2UTJI>A
M>@5H)9\1*ZM O\M*4%&+[??+ZYNNQ2>Q66\2?ZUP1L26_P)02P,$%     @
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M%"+Q?E1$:.;X0( ?6P.)OT&]\?!H1$(^GE/.73Y'!*B75]D#L?^!B=VO\Q6
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M,)AXXC$S7AWDELVPMF2&+T0(UI'Q6;H]IL?6>],R;O;KVH/LL<QUOLZ;,__
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MW;%(,18VQ[=KD>8W9 2N\C&(L$=E^*H  F.%ZPL?A1GS])S7O7G1Q35KZ*<
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M^'J2/^@<\7E6U0VODOAP@3D.LP/=,D=7"75'/6XXHP3I/WB1S$!$7299GDQ
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M%3X].*;(I4:^Y#2,K">:R124 &LD0Y,XFV>]6.CNSM.#!^:A_;,""Z?>9YG
MM3TOKV2U<.%DQ9QXK? SM?],(+G#O7MH[EU@=,/F[<.50(,+Q5H9BKEQ,4*.
MYV*9DP6 PR?Q ,(T,P/$=0+WG(*O;0&[0G$M/]C=G>'1KCEI^U^PASOL$YVH
MS&')1L+7AO-TT:U5!EOD[?FU-V14 ,:#PFM4*LHUH#\ZLYC<H!O8Q9&8Q7#
MMYC\D%<2^B(<\F*+RMY=]D0PZ",'#D]E@@?*66OR![WE^FN8BOR%WNE^CY?0
M_XU,]G*N?Z2[,VP\W^HN\2]')*@$@KIZ<$8.#2^167#X?IY=P%:!SJI@E+S9
ML'=^(\E\(C-1C@!^@K3:YHUAL3^V,1E;&_6VIT;LDANN\.[.+2]Q5Q51O T?
MLTA6,)&QPPW:V)YN4F"\=($.JX?N_6T>J/"$7&NZ6QV3T(? $:G<&!3>NSLN
MMN,C M_>4D0@6AL0L"\.LV*JL?[$8SJV;^Q[]([I9QW%]4IFS:"WM;*'E<S0
MF#%)M^XFD,L\5[\D/2OA7,&:P ?Q+R-65]Q17OC1:;E<.?>L$W(T047KGV#L
MZP6>GJH$(R5ZGC1)]$N"S\!!1"?@TZWJ3+30N[2ILO02$TFK&I;/IEM>//_E
MY)T]85^=L?**SW9Z26?F7,)4-J1;%F!Q@_\#&SBI,S#!JQ6?W2)*PD/H?3A5
MM?J-S*=39,_U#0."Q_EKI),P'Y('+T<+>]%BE@9V"/]1S+*:DM)?S>(?$R2$
M(I<^\WM\^/?_^X<'#Q\_^<S_V#P62% ^Q9*$SRAC]!7@<-?E&=CY<-E+>) B
M,$BA3$LXS(S'@$.4)G"(3&"#Q*D<PIE@34+1:3_QDJ(ES_(2CR$*BI1\+C[I
MR1R>I_X7XT/XF_1.SC_K=W=WUG[9.Y/P@3FHMO*JOG\8I[UD_W:.>/B?GUX1
MK"G/$@K1D_0/]-X[3I:2[OGIFU<_6WP51;Z'M22)OTD*SNPV.0]&:1C)N;LS
MI5$1(*'LZ*._5S5)R*A&.39/I@Q*H;&S6/51MHXFFZ..] GO0+4FN37+]50=
M[NZ\+1$*M8PH80I? (5:N#11F(V0-XZL24;&!G^#CGQ1HH*>IBD^KJ;1<8BL
MK1!4QMB#29IBY*5NLJ9M$%Z!<P W3D=15FZ-)C#MZ*(HKT"3GZ4=?1$+C,/$
M(LCXJ%+X=Y%:P(LL%YA*)O5B'J4[ .9[4;2P<" WRZJ3.#P^.O@'30F_N$J3
M*N+HU/-TFBY<8.[A,07FONU&AX,'!VG"*[SF@:VRN^/''--ZP-[A#%%B=68P
MLC7XT++*SC F#3I[U!8*L4^+5)X.&OT@,<&TRMP:6H.VINT(TJI;7@>,'+,5
M>\VG=F-7$5J"+M;V\M7;=R?PD@*!DR:@].CX^&COZ?[>]_M[S_;WLGT>S.=G
M_[;P!,9\KGX@IK>OJ^@*,2TP'E01K"#PN(]O)-VC-5E9ZP@-^1%QI"**QG>5
M@>2AWV!BD^30 D\@1@1 U^*P:S\.NY,4&>^^\0NVQ[;#ICSX"YOR%6-3-ILC
MD[LR1YYG]13LOK9*N^;&[LZ+A/)'V^:PKM#18@G@[NKFN]D1FHJAY.> 3$N=
M]PM&,E;I#+G)Y-W&I%8XQ3&%=^VEGZ;IDO"#+$,02;S L#\]^)T+W43O#SZ,
M1_55VUOO';,#.0BP:@2%J]IB'9IP*R@A;<%:,X>=)HJ#E'5SX&6KBVGPH!$N
M8Z6X!\FP8"[Q$+MOWT#<&DQ#?T^C68;V5^.?AC](3)Q&WQ9-U:86%@4&H7\+
MVITXTA(VD#QN_%SO R+H9^1/3>1I,XWYX_=A+\!RQ,.,@</D@LT4$T36S^+X
MX*CE:8)F'^7#9!\Z>=*URA0."D]< N'-.E_-9)RV0EOOZS/)B_,&4<>AHQ?L
M[G3>L/'AL=NG^#8W:G>'/K'M/BC&*\JQSE6W8)I58"#!IRF:PU>7 _O>.$'@
M0-S;Q@_G'2@#^\$89T,?.XZVW*_M5W[;=23#Y-HGWJ\CG>\9QZ,^;T&E=N8:
M*UJ%@1R^Y2Z.$Z;MV8+'J&F8*(>)S#C'#RX3#V-6LLQ8HMS1)5"[6-:&E %(
MW*I<K/,X)%J[64;V(L1DN:ZYXK$^>TT061].8!88.NI47.JH79::NB"83(D*
M:L6:0E/4QDU&5\?GP_&E1NU$\[8JLOK<ZR3U:1 9*1%J\3J[Q;SI)_RYSE=.
M=?GC@HH"OTJ' ESS<B8Z1U#Z&HJE\"LYU#;?!K.J,Q,>"&&(C&X:$7F/T>RA
M?Q'6BXZ:1]+C7:H24CQX$BC1Y_TFU03B*05ONE["B?$;$W5NDIJKE9@08WV"
M7&X0Q17P(%-LP0\%GNR>J>/]@CV1F]JNT[NR75_"^=O=^:><;+]E:?TD<B"5
M7A3-*_)9BE ^,&WY,*)X=1YT!_=Q_-VW>^=R&(=3B.2WVDN'QB@)_8S^B[OM
M#)\)*WRO.%"5>T  2(>S#-4)E3A6'@&POC8%[=)A0[*'>:O=M.((,2UXGP,D
M3B]&0I;H2+*KEX[9W<G"*XCG?!0\_'!OMF9IR83D^&;*$ A:1@P)C.?04,=.
MIZ /3:"U%].18_!9,Z61T3AB2=5VIQV[>9-5>LV)DSQ*.&+F2A9 B*/(*V 1
MSI-\CA-AJ4TRA<ZPBKX0&2E&/8O,F\=0\(4C"*X^TMO#_$&T<+ /?\('\W&U
MX3Y0D^B^B5+,TS..NG(NWMT6-L[(]F(TR%@.UAMW7"P\,Z8;8TDF-<50<&](
M%()E4K9GY^+QP=JD-!HY*K8B8@O_S1N3LS*M^_Z/30X'6IZV'.T!>%N#1TO_
M74=^X_@WP]!!AS;:#A)@E5TGI8[8%??GML@Q[MY3\GH]T>H!&R$56.2BG'$
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M5\R"D!U&Y&26Y;RYHAZA5R7,DQ*&+,NP.-&N3W])>'0X3Y0R29-,$AHU1B)
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M310')!KR/S;Q],82J=_="5)*:$7%:W))]3G:QA,\Y%C-3 2H7M:5G/VXXF3
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M-P*>(+L?)'.+']:9C@5PN:&6>\;NCLZ_#U0/)$?WB\$BL[XP6S*ZE/VKHH)
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M7%COS:/0XTF0<LEJ<UR3S&$&B[(MN"F!=X2V.Q>7[ER 62,:E<*"^-T@WVZ
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MI2LX69/=L395W70\I:47?G7%UT<TO<+V)_JJ'<D7C^1([K%_;D,'>EL\C_(
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M--!PBO+P66N/=:IDUXWD,NBZPPK')<+"G%'A5>38X45@%UFD==YW*?L>N-7
M?)-Z>QVC7>"8S,(QI)_9)&W+.?=B;GH79GCA77J8Z1"#U+&K]_=3Q)!_!?P
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M"=N*8S3_E9=-JU[4VB?R9 .E8<S$ZYZ!/D*(6=[^?ID-B:'UIX\_G_6N<UB
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MW!-2Q[G6*':6C/VY6XR5V\N/]($K>XG4V 0-#/!;T^ $^BAC(*(?04AI .\
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MEC_YD/>+'F Z4EJRP[*WL<P2^>I5\DMQY>SSG<V?SCZ>_#R^_NG/\%]IWO/
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MKM1I+3+%JB0O<U%5GYZ9;:WOR!\IYAG6AC+%4_'SRVP\J8TF&U$EG_FMV09
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MF96('?V S02:=55;KKCQO0IV/Z0,''4<5UA=\5B\7\-UOZQ+_R:R]*W[+B<
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M;EV%5=34,/WTA-;>_AF^PTG9 ].:3[ZF->]A6G.W%M;D)KL+[ U0\RN8<N/
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MOLSP'+]A=6O=Y#'&V9C#E.V:  ,_&3['!U,CXL(QX -8ZZZ/@:+ CIQ;U>M
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M3P-D'CTM?N RI+\6K^&S[@ZN^7@@XT\O?GCU"\'8?_[\YO6S_P-02P,$%
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M[_? Y@ -1A5=H)$AA@@Y?3AFF <(E5D=*FE>(@Z-HK0N\VM2-1?T%PZQ07(
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M@.JO&1,;1O#B+&W/LU4O30504RU.&$HL3(AD$?#^"(.,M1T!O2.^K '7G"@
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MR_=O:(7O>A=O>^-Q#TX$P$4O]$[__A[FTM#'M9\.1E?O83I<]/L+7#X\#!,
M""[ZO"S\B8 +O]"_^-X8CFS4XP?@V7'_W=4Y+!N.1[8/#\/8)^]'(S@I_ X&
MW0,@G\,28 \TT+ _NH))-%@L?)'E"4CLV4XO3][C(Z/]D(#4 .X//8#M"#@_
M_MY[,^S#L5Y<TCP]6,]P3*AS@><R&,,H OXAH,'E2;^/"PSI]Y/SWN =K* '
M;\#_>92K_G!T>0&X2N?Z=VL#_FGR%"=O$57@!!WT"7;''MZ.GC> '?PT."&T
MI@6/1OJ:(%QP->K[XSX"&U^@^X(0X25MV3I>NW>]P3G^V8-1KSXJ_ ]^&O3P
MX@Q&<)%A0'@-Z,!X<#: #_@*?D.7=_#F[3@X[9_#PH<?@STZ[?Y/@]/^!:V[
MVU&_[>-J:4&\O0! S;AZ.L0-P$'US\X0QHC% '[8..UPP#1%3I>.B/<EP&%J
M0J1C,$8,?W-Y200$'CL[&YP, %3=3@LH>1YS[>'S6P0'8GIO<&$P6M.LTS[@
M+9&3\\&[@4:P#[V/].^0 ();Q:/0<_%3W0Y<U@LX>P !O#MFR@=TYTL01I $
MET.3$9!Z<',&@#'P.^#FQP?(I:Q^%F]C"O@1_0M#21;RC3!A$&<+[NI 'JDL
MX0XU&?;HDO;)M@1 ,1(U-XF;FN/$JY.]C<Q,)DNG'C7]8!7?A:7X8OL""=J6
M9B$9EY^@/6=L *:DR/:P\89^:F1T"ZAL38SAV5-N?2ZEYT7=DW:UJL\!A0ZJ
MAYU0=5V?!P1J+:3=N1!))"-+J$CUDEC%2?UH9U71^)--6)/U/:U/C,Z8IL%F
M(,O@C((D2I5L)8QX3^Z&4@MTRC]IHF/:#(44C,-HK*RNO% VO>88.P7SDNE7
M5Y+23F()E=%#F 5X&O+]1V( Z#5\-:6>$X]>_S+L QMB,08H>N]-GX3."V1R
MQ+#/^V?CX/B\=_&/>US.?#='Y(_?')$/V1$)K!^DH@N4 CZPF!'6E'HR%,V\
M&!:)I%FG%.D_75?*.%":CBS8='F>3-FY)-22HF(Y< UM=%,N(X7.G#_PFH]!
M@ 7)I7]^/KKJG8 (];='3Q[1YRN0\-3G+Y[T-IE5"WSTR5\T+D_S-(U6)6"=
M^NO1:US!4 U/U<:F4:J(!N#C(X5.XU.]<O@37T-Y&A=]\;='3P$YCU]?#7L_
M@P8 ^NO)8(1",\A[($;""8;\*B@WAYC('L##:K#CUS0@_&?(BS$3JF7)7KY[
M\I=']35XS]S]R'/OF::96\=HA-"KLTM4SLT1'<RC99)N7MQU2/1L"=C(9_KH
M]?'FQ:O'.-KK^M3;"=++P%\:/ZBV^N_][[T#]$6TC-M!O1V4]VXS8PS,^BJ[
M>4S4Z)ZRB=V8_M&3;US_(7%]3SX%SC Z>=L_?0],\8BYPWT50ELW<'8Y?,=S
M@8C=_[D_!';8%XO)0]S2+^-<ZOQK6:HEWK*M;III9R$RVKW6+<ZCF2J7]P9
M0-F^][A)TJ/7.ED>33[<#X0=GHD??JU$Y(O\D-_XK_^BND- /4SE(7G(*3ED
MJB5=%=%G+/]:Q%-6B=_%("MCVHJ2\K+I(1; .8W3Z);"Y:V8.Z_(D<CR3B7*
M;N>$X^M)3&>[!4GYX@#DD*/*RB>8Q7.[%J&N4F1YQY=QE)$AK%95]OYK\G#
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MLJ*^#=2?4]DS/?.3KU_Z52H-8Z<QJ"<%>,%C=R6F,1%X%ZQX<[G3[_./N[.
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M3YMD:X]]=9A@%X0W]J5U3?Y_+8P-_ ;!??I*0?SFP?\!4$L! A0#%     @
M4Y%16W,V:4PN P  ]PL  !$              ( !     '!R87@M,C R-3$P
M,38N>'-D4$L! A0#%     @ 4Y%16R#[UB3]"@  ?X8  !4
M ( !70,  '!R87@M,C R-3$P,39?;&%B+GAM;%!+ 0(4 Q0    ( %.145LP
MXB#-70<  .)7   5              "  8T.  !P<F%X+3(P,C4Q,#$V7W!R
M92YX;6Q02P$"% ,4    " !3D5%;7NI8M5P=  !NJ0  $@
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64$L%!@     '  < S@$  .># 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>tm2528989d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="prax-20251016.xsd" xlink:type="simple"/>
    <context id="AsOf2025-10-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001689548</identifier>
        </entity>
        <period>
            <startDate>2025-10-16</startDate>
            <endDate>2025-10-16</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-10-16" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-10-16" id="Fact000004">0001689548</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-10-16" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-10-16" id="Fact000010">2025-10-16</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-10-16" id="Fact000011">PRAXIS PRECISION MEDICINES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-10-16" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-10-16" id="Fact000013">001-39620</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-10-16" id="Fact000014">47-5195942</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-10-16" id="Fact000015">99 High Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-10-16" id="Fact000016">30th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-10-16" id="Fact000017">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-10-16" id="Fact000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-10-16" id="Fact000019">02110</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-10-16" id="Fact000020">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-10-16" id="Fact000021">300-8460</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-10-16" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-10-16" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-10-16" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-10-16" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-10-16" id="Fact000026">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-10-16" id="Fact000027">PRAX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-10-16" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-10-16" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
